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Abstract 
Merkel cell polyomavirus (MCV) is a causative factor in Merkel cell cancer (MCC).  This 
aggressive skin malignancy is associated with UV-light exposure, ageing or 
immunosuppression, implying immune constraint of MCC development.  We examined 
immune control over MCV in MCC patients by comparing immune parameters with donor 
groups who share risk factors alongside healthy controls. This showed MCC patients had 
frequent and strong MCV antibody responses but no differences in responses to other 
polyomaviruses suggesting no general defect in humoral immunity to these viruses.  MCC 
patients had lower frequencies of B-cells while T-cells from patients with active disease 
proliferated relatively poorly.  Quantifying peripheral T-cell responses to the large- and small-
T-antigens in patient groups and healthy donors by ELISpot showed that like with other 
polyomaviruses, responses were weak.  Novel epitopes were identified by establishing T-
antigen-specific CD4 and CD8 T-cell clones from healthy donors which recognised antigen-
expressing cells.  However MCC tumours and lines were found to have low levels of surface 
HLA Class I and Class II and could poorly process and present epitope to T-cells.  Consistent 
with this, preliminary experiments showed that small-T inhibited epitope presentation 
suggesting that small-T function must be inhibited for efficient T cell targeting of infected 
cells.  
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Chapter 1  
Introduction 
1.1 Merkel Cell Cancer (MCC) 
1.1.1 Merkel cells 
In 1875, Merkel first described small, oval basophilic cells within the skin, predominantly in 
the basal layer of the epidermis [1]. They are present all over the skin but are found in higher 
density in hairless areas, such as the soles and palms [2]. They can be found in distinct 
populations and in certain conditions do undergo hyperplasia which occurs independently of 
epidermal cell proliferation [3]. Initially termed “Tastzellen” (touch cells), they were assumed 
to have a sensory function from being bound to terminal ends of sensory nerves. There is 
some evidence that they are important for light touch determination [4], however, their exact 
function remains unclear, even today. Histologically, these cells are identified by the presence 
of secretory granules and through commonly expressing keratin containing filaments termed 
cytokeratins (CK). Of this family of proteins that form the cytoskeleton of epithelial cells, the 
members most commonly associated with Merkel cells are CK8, CK18, CK19 and CK20 [5, 
6].  Merkel cells can undergo a malignant transformation forming Merkel cell cancer (MCC).   
 
1.1.2 MCC clinical features 
MCC tends to develop as a firm, pink-violet, non-pigmented nodule and it is often difficult to 
diagnosis by clinical examination alone, often being mistaken for a simple cyst [7]. The 
majority of cases are found on sun-exposed skin, particularly the head and face [8]. The 
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median age of diagnosis is 74 (range 8-101) and it is commoner in Caucasians and females [8, 
9]. Definitive diagnosis is established by positive staining for chromogranin, synaptophysin, 
neuron-specific enolase and CD56 (also known as the neural cell adhesion molecule), which 
represent both the epithelial and neuroendocrine antigens present in normal Merkel cells [10, 
11]. Additionally, expression of cytokeratins can aid in diagnosis with CK20 para-nuclear dot 
like staining and seen in 97-100% of MCC [10, 12, 13].  Another cytokeratin, CK19, is 
expressed in 33% of all cases and can be useful in CK20 negative cases [10].  
 
1.1.3 MCC staging, prognosis and treatment 
MCC tends to be an aggressive tumour that grows rapidly and metastasises early. In a large 
retrospective cohort of 5823 MCC patients from the USA, 66% presented with local disease, 
27% with nodal involvement and 7% with metastatic disease [14]. Disease stage classification 
is shown in Table 1.1. 
Table 1.1. MCC disease staging classification. Adapted from [14]. 
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Stages 1 and 2 (Local disease) 
When primary tumour is the only area of disease, treatment is through surgical resection. 
Unless the tumour is very small, adjuvant radiotherapy to the tumour bed would also be 
recommended. This is because recurrence rate can be as high as 30-43% and even patients 
with margin-negative resected disease have a recurrence rate of 8% [15, 16]. There is some 
evidence that radiotherapy reduces rates of local recurrence [17]. The size of primary tumour 
is also important prognostically with tumours less than 2cm (stage 1) having survival rates of 
66-81% compared with 51-67% in tumours greater than 2cm (stage 2) [14, 15].  The thickness 
of the primary tumour has also been identified as having a prognostic impact, where patients 
with tumours over 10 mm thick having a significantly worse five year disease free survival of 
18 % compared with 69 % for patients with tumors less than or equal to 10 mm [18].  Other 
investigators have found that, even thin tumours had the potential to have spread to other 
areas [19],  perhaps explained by the early ability of MCC to invade lympho-vascular vessels, 
with two-thirds of MCC less than 2 cm in diameter showing histological evidence for this 
[20].   
Stage 3 (Regional lymph node involvement) 
Patients with confirmed Stage 3 disease are treated with a combination of surgery and 
radiotherapy with the documented 5 year survival for these patients being 39% [14].  A role 
for adjuvant chemotherapy or radiotherapy in this patient group is not clear with no evidence 
of survival benefit [21]. However, it has the potential to be helpful in well selected cases [15]. 
The number of lymph nodes involved by MCC metastatic spread is a strong predictor of 
overall survival (0 nodes involved, 76% 5-year survival, more than or equal to 6 nodes 
involved, 24% 5 year overall survival) [22].  
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Stage 4 (Metastatic disease) 
At this advanced stage, patients have a very poor outcome with the majority of patients living 
less than 12 months and 5 year survival rate of 18% [14]. Treatment is limited to palliative 
surgery and radiotherapy for particularly symptomatic areas of disease, delivered alongside 
systemic platinum-based chemotherapy. Although the initial response rate to chemotherapy is 
good (60-76%), these effects are not durable and patients tend to progress quickly [23, 24]. 
There are no approved second line treatments. Importantly, due to the mostly elderly patient 
population, cytotoxic chemotherapy can be extremely difficult to tolerate and be associated 
with significant morbidity. 
 
1.1.4 Epidemiology, risk factors and clinical associations 
MCC is rare in the general population but appears to be on the increase [25] with age-
standardised incidence rate per million doubling in ten years from 1.7 in 1993-1997 to 3.5 in 
2003-2007 [26]. 
There is a dramatic increase in incidence of MCC seen over the age of 50 [8]. Although MCC 
is more commonly seen in females, male MCC patients have poorer outcomes, with a 5-year 
relative survival ratio amongst men of 36% (95% confidence interval 20-54%) compared with 
69% (56-82%) in women [27]. There appears to be a relationship between UV radiation 
exposure and MCC [28] with the majority of cases occurring on areas of sun-exposed skin 
(36% occur on the face), disease rates correlating with proximity to the equator [8] and also 
with the side of the body more exposed to the sun during driving [29, 30].  
Immunocompromise is another associated risk factor for MCC, with HIV-positive patients 
having a 13-fold increase in risk of developing MCC compared to the general population [31]. 
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Patients who are on immunosuppressive medication post-organ transplant have at least a ten 
times increased risk relative compared to their peers [32, 33]. Given the rarity of Merkel cell 
cancer, it has been difficult to make associations with other diseases, however, the review of 
large cancer registry datasets has repeatedly shown two interesting points. Firstly, the chance 
of developing a second cancer after diagnosis with MCC is slightly but significantly increased 
[34]. Secondly, a number of cancers, particularly skin (Squamous cell carcinoma, Melanoma) 
or haematological malignancies (Chronic Lymphocytic Leukaemia (CLL), Multiple 
Myeloma, Non-Hodgkin Lymphoma) are associated with higher than expected risk of 
subsequent MCC development [34-36]. One study found a standardised incidence ratio of 
15.7 (3.2-46) of developing MCC after CLL [37]. MCC patients who are immunosuppressed 
have a poorer outcome in terms of MCC specific survival [38, 39]. For example, MCC 
patients who have received solid organ transplants have significantly reduced MCC-specific 
survival compared with immunocompetent patients, independent of disease stage at 
presentation (56.3% versus 95.2% survival at 1 year) [40]. Additionally, CLL patients with 
MCC are 3.8 times more likely to die from MCC compared to MCC patients with no history 
of CLL [35]. In a single centre retrospective study, a low absolute lymphocyte count at 
diagnosis of MCC has been associated with poorer overall survival, an effect which is 
independent of other tumour, patient or treatment factors [41]. 
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1.2 Merkel cell polyomavirus (MCV) 
1.2.1 Discovery of MCV 
The link between immunocompromise and MCC led to the hypothesis that an infectious agent 
may link the two. In 2008, the laboratory of Moore and Chang applied digital transcriptome 
subtraction (DTS) technology on MCC specimens [42]. By creating two cDNA libraries, one 
from a single tumour and the other from pooled tissue from three other patients, 
pyrosequencing of these two libraries generated 382,747 sequences to use as a high fidelity 
data set. Of these sequences, 99.4% aligned to known human RNA, mitochondrial, assembled 
chromosomes or immunoglobulin sequences. Of the remaining sequences, one (DTS 1) from 
the single source cDNA library revealed a transcript highly homologous to African green 
monkey lymphotropic polyomavirus and to human BK polyomavirus T-antigen sequence. 
The second DTS transcript had no homology to deposited polyomavirus sequences. By viral 
genome walking, the complete 5387 base pair (bp) sequence of viral DNA was defined from 
tumour specimen MCV350 and used to create a closed circular form of the genome typical of 
polyomaviruses (see Figure 1.1). Using primers derived from this sequence, a second 5201 bp 
sequence was identified from another tumour MCV339. Of ten tumours tested, viral DNA 
was discovered in 80%, as compared to 16% of skin from control skin samples.  
       
  Chapter 1: Introduction 
7 
 
                                                      
Figure 1.1. A full map of the MCV350 isolate genome identified by viral genome walking following 
discovery of viral DNA sequences (DTS1 and DTS2) within a MCC tumour. The position of early (Large 
and small T-antigens) and late (VP-1, VP-2 and VP-3) genes are shown. Figure adapted from [42].  
 
1.2.2 Introduction to polyomaviruses 
MCV was the fifth polyomavirus to be discovered in humans although other polyomaviruses 
have been detected in many other vertebrate hosts including birds, rodents and cattle [43]. The 
polyomavirus family has a very highly conserved genome sequence (between 50-80% shared 
amino acid), but each virus has a very narrow species and cell specificity [44]. This is likely 
due to both the presence or absence of cell surface receptors that allow cell entry and also the 
presence or absence of cell signalling factors within host that allow viral DNA replication 
[45].  All polyomaviruses consist of non-enveloped, icosahedral virions with small (around 
5000 base pairs) super-coiled double stranded DNA genome which can be divided into three 
sections, encoding early and late genes as well as a non-coding control region.   
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The early genes encode two major proteins through alternative splicing of the same transcript. 
These proteins, Large T-antigen (LT) and Small T-antigen (sT) facilitate viral genome 
replication and transformation by disrupting cell cycle control, the mechanisms of which are 
discussed in sections 1.2.3 and 1.2.4. The late coding region contains a primary transcript 
encoding the structural capsid proteins. The non-coding control region (NCCR) contains the 
viral promoters that mediate both early and late gene transcription and origins of replication.  
 
1.2.3 Large T -antigen (LT) 
LT is a protein expressed early in infection and is essential for viral replication. There are a 
number of well conserved regions throughout the entire polyomavirus family that appear to be 
integral to function (see Figure 1.2). 
 
 
Figure 1.2. Structure of the MCV Large T-antigen (LT) gene showing the position of functional domains 
within both exon 1 (bp196-429) and exon 2 (bp861-3080) of MCV350 genome. CR1, Constant Region 1; 
NLS, Nuclear Localisation Signal; OBD, Origin Binding Domain. Adapted from[44]. 
 
Conserved Region 1 (CR1), DNAJ and Retinoblastoma (RB) binding domains 
The CR1 and DNAJ domains exist within exon 1 of the T-antigen, a region common between 
both LT and sT. The DNAJ domain functions as a molecular chaperone, interacting with a 
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heat shock protein Hsc70 regulating ATPase activity. Early in infection, LT accumulates in 
the cell nucleus, driven by factors including the nuclear localisation signal (NLS) [46]. There, 
ATP generated from the J domain and Hsc70 interaction provides energy to disrupt the 
important Retinoblastoma (RB)-E2F complex [47]. The E2F family are a tightly regulated 
group of transcription factors that when activated allow gene transcription and entry into cell 
cycle [48]. E2Fs are usually held in a repressive complex with a member of the RB family of 
proteins (RB, p106, p130), inhibiting transcription in the quiescent cell. When required, a 
chromatin remodelling factor can bind to RB using an LXCXE domain, releasing these 
factors.  
LT contains a LXCXE RB binding domain that binds and inactivates all three RB proteins 
after disruption of the RBRB-E2F complex, temporarily displace RBRB and releasing 
activated E2F leading to up-regulation of E2F gene targets and the induction of unregulated 
cell entry into S phase. Large T-antigen mutants lacking either a functional LXCXE motif or 
the J domain fail to increase E2F-dependent transcription and do not stimulate proliferation, 
indicating both domains are essential for viral replication [49]. The CR1 domain is so-called 
as it is homologous to a region conserved between the 12S and 13S splice variants of the 
adenovirus E1A viral protein.  Its function has not been as well characterised as the other 
regions although it is also thought to be involved in binding to the RB family of proteins [50, 
51].  
Origin Binding Domain (OBD) 
DNA replication is initiated in polyomaviruses by the binding of LT to the replicative origin, 
found in the non-coding control region (NCCR) located between the early and late genes in 
the viral sequence. The replicative origin contains multiple copies of the pentameric DNA 
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sequence GAGGC, each separated by a one base space to which the LT OBD is able to bind 
[52]. This allows full-length LT molecules to assemble and form a dodecameric structure 
wherein two head-to-head hexameric LT rings encircle the DNA and from this position bi-
directional DNA replication can commence [53, 54]. 
Zinc binding and ATPase Domains 
The zinc binding and ATPase domains form the enzymatic core of T-antigen’s DNA helicase 
activity. The zinc-binding domain is responsible primarily for the formation of T-antigen 
hexamers, the active helicase form which can then be positioned on the OBD as described 
above. The ATPase domain provides the energy needed for helicase activity. For full helicase 
activity, co-ordinated actions of OBD, Zinc binding and ATPase domains are all required 
[55].  
The ATPase domain also contains a site capable of binding P53, an important transcription 
factor which activates pathways associated with tumour suppressor activity. Under normal 
circumstances, P53 levels are low, but in response to stress, DNA damage or active 
oncogenes, the half-life of P53 rises dramatically, leading to its accumulation within the cell 
leading to the up-regulation of genes such as P21 capable of promoting cell cycle arrest, 
inducing apoptosis and thereby preventing further viral replication [56, 57]. The binding of 
polyomavirus LT to P53 can lead to P53 inactivation and thereby inhibit the cellular anti-viral 
protective process [58].  Although full length MCV LT has a putative P53 binding domain 
and is able to modulate this pathway, it has been shown that this does not occur through direct 
interaction [59, 60]. Even the case of SV40, in which P53/LT binding does occur, this is not 
independently sufficient to block P53 function. It is, therefore, likely that other indirect 
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mechanisms perhaps involving sT, the DNAJ and RB binding domains on LT are also 
important in functional suppression of P53 [61, 62]. 
Helicase Domain 
Found at the carboxyl end of LT, the helicase domain is important in allowing viral DNA 
replication by initiating bi-directional double-stranded DNA unwinding once LT has bound to 
the OBD. This domain also recruits cellular proteins involved in DNA synthesis such as DNA 
polymerase thereby enabling viral replication [63]. The T-antigen is unique amongst viruses 
by being able to initiate DNA winding without need for a separate initiator molecule [55].  
Nuclear Localisation Signal (NLS) 
All polyomavirus LT proteins, with the exception of avian polyomavirus, contains a nuclear 
localization signal (RKRK) which results in the typical nuclear LT localisation pattern seen in 
most LT-expressing cells [50]. 
MCV Unique Regions (MUR) 
MCV LT has two unique sequences, starting after the J Domain and separated by the RB 
binding site, known as MUR 1 and 2. Although these regions do not appear essential to LTs 
growth promoting function, they may be important in stabilising the protein and thereby 
allowing high level expression in the cells [64].  The MUR1 contains a binding site for the 
cytosolic human protein Vam6p, resulting in sequestration of this protein into the nucleus. 
This may have a role in regulating MCV replication as inhibition of this binding results in 
enhanced replication through an as yet unknown mechanism potentially involving lysosomal 
trafficking or an impact on pathways such as TGF-β and mTOR [65, 66]. 
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1.2.4 Small T-antigen (sT)  
The Small T-antigen shares the amino-terminal 78 amino acids that encode exon 1 with Large 
T and 57kT containing the DNAJ domain binding sites, but lacks the Large T Origin Binding 
Domain (OBD) that is required for DNA recognition (Figure 1.3). 
Figure 1.3. Small T-antigen (sT) gene structure showing position of functional domains in single exon 
(bp196-756) of MCV350 genome. CR1, Constant Region 1; PP2A, Protein Phosphatase 2A. Adapted from [67]. 
 
The sT does encode for a Protein Phosphatase 2A (PP2A) binding domain (CXCXXC) that is 
spliced out of the other T-antigen variants. PP2A binding by SV40 sT results in inhibition of 
Akt dephosphorylation which causes constitutive activation of this molecule and stimulation 
of numerous cell signalling pathways causing up-regulation of transcription  [68].  
In vitro, infection with sT-deficient SV40 virus results in defective viral replication which is 
reversed if sT DNA is re-introduced into the cell. The binding of sT to PP2A may be 
important here by leading to dephosphorylation of serine residues adjacent to the DNA 
binding domain on LT that increase the binding affinity of LT for the viral DNA-binding site 
with a consequent increase in DNA replication efficiency [69].  Similarly, MCV sT co-
expressed with LT is able to increase viral replication above that seen with LT alone. This 
increase is abrogated if the PP2A binding site of sT is mutated, again indicating that sT 
mediated sequestration of PP2A may be important to efficient replication [52, 65, 67].   
MCV sT is able to stimulate cellular proliferation through the constitutive phosphorylation of 
4E-BP1, a translation initiation factor important downstream of Akt and mTOR in the Akt 
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signalling pathway known to be deregulated in many cancers [70]. Although the mechanism 
for this is unknown, it is not thought to be due to sT binding to PP2A or heat shock proteins, 
both mechanisms utilised by SV40 sT to induce proliferation.  The sT-antigen is also able to 
inhibit an ubiquitin ligase complex, Fbw7, that promotes the degradation of several important 
proto-oncogenic proteins including c-myc and cyclin E by binding to them and consequently 
activating related transcriptional pathways [71]. Alongside this, inhibition of Fbw7 also 
reduces the degradation of MCV LT, leading to increased cellular levels of this protein [71].  
Other than mediating viral replication and cellular proliferation, sT may also have other roles. 
The binding of sT to the protein phosphatase PP2C, leads to high cellular levels of 
unphosphorylated stathmin, a protein thought to be important in destabilising cellular 
microtubules, resulting in cells with a more motile and migratory phenotype [72].  
 
1.2.5 57kT and Alternate frame of the Large T Open reading frame (ALTO) 
The MCV early region mRNA can also splice to form two alternate open reading frames 
producing unique proteins. 57kT is identical to full-length LT but lacks an origin-binding 
domain and seems to share similarity with the 17kT protein found in SV40 and whose 
function remains mostly unknown [42]. The second alternate protein, termed ALTO 
conserves only the region around the RB binding site. This protein shares similarities with the 
Middle T in murine polyomavirus and again its functional role is unknown although it is not 
thought to be essential to viral replication [73]. 
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1.2.6 MCV Late genes 
The MCV late region encodes open reading frames for three capsid proteins by alternative 
splicing, VP-1, VP-2 and VP-3. The capsid is made up primarily of VP1 molecules (around 
90% of the total).  VP-1 and VP-2, when expressed in uninfected cells, self-assemble into a 
55-nm diameter icosahedral viral particles that can be harvested as antigen for serological 
assays [74, 75].  The MCV VP-3 sequence contains aberrations not seen in other 
polyomaviruses and attempts to synthesise this protein have been unsuccessful, suggesting 
VP-3 has no functional role in MCV [74]. 
 
1.2.7 MCV DNA integration within MCC genome 
In the same study that discovered MCV [42] the previously mentioned DTS1 viral transcript 
described was extended using 3’RACE (Rapid amplification of cDNA ends) to three other 
cDNAs. Two of these showed different length fusions of viral DNA with intron 1 of the 
human receptor tyrosine phosphatase type 2 (PTPRG) gene on chromosome 3p14.2. The 
integration of viral DNA into the cellular genome was subsequently confirmed through 
sequencing of PCR products using viral DNA and PTPRG sequences primers [42].  To 
confirm whether viral genome integration was a generalised feature of MCC, southern blot 
analysis was performed on DNA from eight enzymatically digested tumours which were then 
probed with MCV-specific primers. These results showed that five of eight cases tested 
contained MCV DNA, that virus was indeed integrated to the human genome and that the 
integration pattern was identical for all cells within the tumour and also between the primary 
tumour and distant metastases, suggesting viral integration is an early event in cancer 
development [42].  Since the seminal discovery of MCV within the MCC tumour genome, 
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numerous laboratories have confirmed this finding and throughout the world, 64-86% of cases 
express LT and so are defined as MCV positive (MCV+) [76-79]. More recently, assessment 
of sT expression alongside LT, the use of novel LT antibodies and improved PCR techniques 
have shown that up to 97% of cases may be MCV+ [80, 81]. All mutations lead to truncations 
of LT which retain the RBRB protein binding domain whilst deleting the helicase domain and 
P53 binding site within the ATPase domain [82-84].  The loss of the helicase domain makes 
the virus incompetent to replicate proving its presence within the tumour cells is not simply as 
a “passenger” [85]. The mutations can be substitutions, frameshift, missense, insertions or 
deletions and the majority result in a truncation secondary to a stop codon within exon 2. 
There does not appear to be specific sites within the host cell genome that are associated with 
the integration of LT [82, 84].  
The clinical significance of MCV+ compared to MCV negative MCC has been investigated 
retrospectively in a number of studies. These virus positive primary tumours tend to occur on 
the limbs and may be slower to metastasise than virus negative disease [86, 87]. There is 
some discordance in the published literature regarding the effect on disease outcome, with 
some studies finding improvement while others finding no significant difference in overall 
survival [87-91].  
The viral load found within tumours may be a more sensitive predictor of outcome and 
various studies have shown that the numbers of viral copies per cell in MCV+ disease is 
extremely heterogeneous (0.119-42.8) and perhaps this is useful as a clinical biomarker, with 
values over 1 copy/cell (40-60% of MCV+ MCC) appearing to have some clinical benefit [83, 
87, 91].  
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1.2.8 Role of MCV LT in MCC oncogenesis 
The oncogenic effects of MCV LT-antigen have been demonstrated in vitro as it has with 
other polyomaviruses.  In MCC, the LT protein is truncated by mutation to leave the constant 
region 1 (CR1), J domain and RB binding regions (see Figure 1.4) [85]. While these domains 
play a role in oncogenesis, it is likely that transformation occurs in concert with cellular 
mutations and with the support of other factors, such as cellular heat shock protein 70 (hsc70) 
as inhibition of this protein is able to limit proliferation and survival in LT expressing 
MCV+MCC cell lines [64, 92]. 
 
                           
Figure 1.4. The sites of truncation mutations seen in a variety of published MCC tumours. All mutations 
occur in the region between the RB binding domain and the helicase domain. Adapted from [85] 
 
Large T-antigen expression is essential for the growth of MCV+ MCC cell lines and this is 
dependent on ability of LT to bind to RB [93].  Knockdown of Large T with shRNA in these 
same cell lines used in a xenograft model leads to tumour regression [93, 94]. The truncation 
of the LT appears to be an essential part of cancer development as transfection of truncated 
LT into a MCV negative MCC cell line, unlike wild type LT, 57KT or Small T, results in a 
cell type that has a defective response to UV light with decreased levels of DNA repair and 
cell cycle arrest [95].  
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Truncated LT is more effective at growth promotion than its full length counterpart perhaps as 
the 100 residues of the C-terminal portion of LT that are lost as part of the truncation have 
been shown to have growth inhibitory function [60]. This may be due to the fact that the LT 
helicase domain initiates a DNA damage response that leads to p53 phosphorylation and 
activation of downstream p53 target genes and consequent inhibition of cell proliferation, a 
function that is lost after the oncogenic truncation [96, 97]. 
Alongside this, truncated LT binds RB with a stronger affinity than the full length protein and 
is also able to relocalise RB to the cytoplasm, which may also increase its tumourigenic 
potential [59]. In tumours, high levels of RB expression are mostly limited to MCV+ cases, 
defined either by evidence of MCV DNA in the tumour, or through demonstrable presence of 
Large T-antigen expression [79, 98], although this has been controversial [99]. However, not 
all MCV+ MCC express RB and one study has shown that these patients have significantly 
poorer outcomes [79, 88, 100].  
A truncation mutation affecting the nuclear localization signal can result in more diffuse 
nuclear or cytoplasmic distribution [101], however this motif is not required for the 
accumulation of truncated LT-antigen within the nucleus nor is it required to promote 
proliferation of MCC cells [64]. 
The integration of MCV expressing LT with an intact RB binding domain in MCC leads to 
the of up regulation of transcription of Survivin mRNA by up to  7 fold as compared to virus 
negative cases. This protein, also known as BIRC5a (baculoviral inhibitor of apoptosis repeat-
containing 5), is anti-apoptotic, through its ability to inhibit caspase activation. It is 
commonly up-regulated in cancer and it is an attractive potential therapeutic target due to its 
absence from terminally differentiated cells.  In vitro tests with a small molecule inhibitor of 
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Survivin, YM155, leads to the irreversible, non-apoptotic death of MCV positive cell lines. 
When MCV+ MCC xenograft models are treated with YM155, the effect is cytostatic while 
treatment is given, but tumour growth continues after treatment is withdrawn [102, 103].  
 
1.2.9 Role of MCV sT in MCC oncogenesis 
MCV sT expression is detected in the majority of MCV+ MCC and no truncation mutations 
have been found to impact on its structure or function [70, 104]. sT expression is likely to 
have an effect on cell growth. In vitro, this has been demonstrated by ectopic expression of sT 
in fibroblasts that leads to cellular proliferation [70, 105]. However, the importance of 
continued sT expression in established MCC cells is less clear, with two groups performing 
shRNA knockdown experiments in MCV+ MCC cell lines. Shuda et al found that growth 
inhibition is specific to MCV+ cell lines only and occurs on a similar scale to pan T-antigen 
knockdown [70]. Angermeyer et al found a non-specific growth retardation in both MCV+ 
and MCV- cell lines on sT shRNA knockdown and also that pan-T-antigen knockdown could 
be completely rescued with re-expression of LT alone, suggesting sT is not essential in this 
process [105]. 
The strongest evidence for oncogenesis mediated by sT comes from recently developed 
transgenic mouse models. The postnatal induction of sT using an inducible transgene leads to 
epithelial neoplastic lesions that resemble squamous cell carcinoma. This is accompanied by 
the elevated expression of proteins such as Cyclin E usually targeted for degradation by 
Fbw7, suggesting impairment of this pathway by sT is important to cellular transformation 
[106]. In another transgenic mouse model, induction of sT at an embryonal stage led to the 
proliferation of Merkel cells in the touch domes of late embryos but these normalised post-
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natally. Here, high level of sT expression in mice was universally fatal after a few days while 
low level expression led to some dermal hyperkeratosis but no tumour growth. Tumours did 
develop, however, when p53-null mice were used, suggesting that dysregulation of this 
pathway may be required in order for sT to be oncogenic [107]. 
Lastly, it is important to note that expression levels of MCV sT may be important to the 
oncogenic process as that these can be altered by external factors. MCV sT is likely to have a 
UV-inducible gene promoter which leads to increased mRNA transcription after stimulation 
of MCV-infected skin with UV light and this may be important to MCC given the link 
between the cancer and sunlight exposure [108]. 
 
1.3 Pathogenesis of MCV-negative MCC 
The recurrent finding of a proportion of MCC that do not contain detectable MCV DNA or 
stain positively for LT/sT by immunohistochemistry [109] suggests that there are at least two 
pathogenic pathways. This may be reflected phenotypically, with the suggestion that the 
classical neuroendocrine disease tends to be virally associated (63% of such cases), whereas 
tumours deficient in expression of endocrine markers are virus negative [110]. In Australia, a 
larger proportion of MCCs are MCV negative and this may be due to an inverse relationship 
in MCV positivity and the prevalence of sun damaged skin [111, 112]. Further evidence for 
this relationship has recently become available with the finding that MCV- tumours have a 
significantly higher rate of somatic single nucleotide mutations than MCV+ tumours and a 
high number of these are C>T amino acid substitutions which are a signature of UV-mediated 
mutagenesis [113].  
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The genes most commonly affected by mutation in MCV- MCC are RB1 and P53. In MCV- 
MCC, loss of function RB1 gene mutations are prevalent and may be a driver of oncogenesis 
in these cases [113, 114]. Mutations of P53, leading to a loss of function, are much more 
common in the virus negative subgroup, with between 50 and 100% harbouring mutations in 
this gene [79, 80, 100, 115, 116].  
 
1.4 The polyomavirus family 
The first polyomavirus to be discovered was murine polyomavirus, first described in the 
1950s and which although ubiquitous is able to cause tumours in experimentally infected new 
born or immunosuppressed mice [117]. Much of our knowledge on polyomavirus biology is 
based on Simian Virus 40 (SV40), the first identified primate polyomavirus, discovered in 
1960 within cultures of African green monkey kidney cells used to produce the polio vaccine 
[118]. The finding that this virus is capable of inducing tumours in rodents through expression 
of Large and Small T-antigens, in other experimental models has led to major discoveries of 
important oncogenic pathways as described in section 1.2 [119].  
Until recently, polyomaviruses were split into 3 clades; SV40, avian, and murine; with the 
human viruses BK and JC belonging to the SV40 clade. However due to improved molecular 
techniques, a number of new human polyomaviruses have been discovered leading to a 
reclassification by the International Committee on Taxonomy of Viruses (ICTV) 
recommending the division of the family of Polyomaviridae into three genera: Genus 
Orthopolyomavirus, Genus Wukipolyomavirus  and Genus Avipolyomavirus [120].  
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1.5 Merkel cell polyomavirus (MCV) 
According to the most recent taxonomical classification, MCV is placed in the 
orthopolyomavirus genus (mammalian viruses with high nucleotide similarity) [43]. 
Phylogenetically MCV is most similar to the murine polyomavirus, unlike the other human 
polyomaviruses which are more closely-related to SV40. Although many domains of MCV 
share homology with the other human polyomaviruses, the closest homology is actually with 
the African Green Monkey Lymphotropic virus.  
 
1.5.1 MCV Epidemiology 
Following the initial discovery of MCV in MCC specimens, studies into the prevalence of 
MCV in the wider population were initiated.  A difficulty with this investigation is the fact 
that primary MCV infection appears to be asymptomatic and so data relies on examination of 
serological evidence of infection only. The seroprevalence of MCV in the general adult 
population is high, between 64 and 88% [75, 121] and this finding is consistent throughout 
North America and Europe. Infection appears to start from early childhood and increases 
steadily with age as shown by the prevalence of IgG antibodies against MCV VP-1 capsid 
protein which are present in 9% of 1-4 year olds, increasing to 35% by age 13, [122, 123].  
 
1.5.2 MCV Tropism and Transmission 
MCV appears to be a persistent infection and viral DNA has been isolated from a number of 
sites. Most commonly, it can be found in skin (up to 40% of healthy control subjects) 
suggesting on-going infection here [124]. In these cases, viral load correlates positively with 
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antibody titre [125]. Recent work infecting different skin cell types with MCV pseudovirus 
shows that dermal fibroblasts were the most capable of being infected and so are likely to be a 
host cell for MCV [126].  MCV DNA has been uncommonly found in numerous other sites 
such as respiratory secretions and urine, and digestive tract [127-129]. Lymphotropism has 
been investigated and revealed inconclusive results. Buffy coats from 22% of healthy donors 
have low level expression of MCV DNA (10-100 molecules per 100000 cells) using nested 
PCR amplifying a sequence of Large T-antigen [130]. In a cohort of patients being 
investigated for a coagulopathy, none had detectable levels of MCV in their peripheral blood. 
However, in MCC- HIV+ subjects, viral DNA was isolated in between 9.5%-39.1% [101, 
131].  Furthermore, a small study using peripheral blood from immunocompromised renal 
transplant patients showed the presence of MCV in the peripheral blood and furthermore, for 
DNA to be specifically found within inflammatory monocytes [132]. In MCC patients, viral 
DNA is more readily assessable within the peripheral blood, particularly, when disease is 
active [83]. Whether this is due to presence of circulating tumour cells, viral reactivation or 
actual lymphotropism remains unknown. The exact mode of transmission of MCV remains to 
be elucidated but is likely to involve skin to skin contact, given the apparent tropism, 
continued shedding and common finding of MCV DNA on environmental surfaces [133]. 
However, it is possible that other routes such as faecal-oral, mucosal, or respiratory may also 
be involved. 
 
1.5.3 MCV and other disease associations 
The relationship between MCV infection and other diseases have been investigated. In 
Chronic Lymphocytic Leukaemia (CLL), a haematological malignancy associated with higher 
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than expected numbers of cases of MCC, the search for a role of MCV in pathogenesis has 
been controversial. In one study, 27.1% of CLL cases studied showed evidence of viral DNA 
in purified CD19+ leukaemic cells. Within this group, they also found evidence of LT 
truncation mutations, similar to those found in MCC, in some cases, hypothesising some 
similarity in pathogenesis between MCC and a sub-group of CLL [134]. However, other 
groups have not been able to corroborate these findings. In these studies, MCV DNA was 
found in only 2% of cases and in these only at a low level [135] or found in the T cell rather 
than B cell population [136]. The largest study also investigated tumour cell tissue 
microarrays from 173 cases of lymphoid malignancies, most commonly CLL, for expression 
of LT protein and was unable to detect it in any cases [109]. 
As MCV appears to be most commonly resident in the skin, an association with other skin 
conditions has also been investigated. MCV DNA has been isolated from squamous cell 
carcinoma (11-38% of cases) [78, 137, 138], Actinic keratosis (6-15%) [137, 139, 140], and 
Basal cell carcinoma (0-14%) [137, 139]. Despite cumulative testing of a large number of 
non-MCC cutaneous tumours, expression of the oncoprotein, T-antigen has been seen only 
very sporadically and not always specifically in tumour cells [140-142]. Therefore while it is 
possible that a tiny minority of these cancers are driven by MCV, it is much more likely that it 
is a passenger virus and perhaps tissue sampling at a time of active viral replication may 
account for the rare expression of T-antigen. 
There are also no strong links to MCV mediated oncogenesis in other non-cutaneous cancers 
[110, 143-146].  However there has been a suggestion from the Far East of MCV Large T 
expression in a subset of non-small cell lung cancer that is currently being further investigated 
[147, 148]. 
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1.6 Other human polyomaviruses 
1.6.1 BK and JC polyomaviruses: 
In 1971, BK virus was isolated from the urine of a renal transplant patient with these 
initials[149]. In the same year, the JC virus (again named after the patient suffering from 
Progressive Multifocal Leukoencephalopathy (PML) [150] from whom the virus was first 
isolated) was discovered. Both viruses are often acquired in childhood and are seroprevalent. 
BK infects over 70% of the healthy adult population [151-154] whilst JC infects around 50% 
[151, 152, 154]. Primary infection is asymptomatic, making identification of route of 
transmission difficult. Both viruses, however, are known to reside latently in the urinary tract 
[155], occasionally becoming detectable in the urine of healthy asymptomatic people [151]. 
Both viruses only become pathogenic in times of immunocompromise, probably secondary to 
viral reactivation. BK virus is responsible for a nephropathy and haemorrhagic cystitis in 
renal transplant and stem cell transplant patients respectively [156, 157]. JC virus, although 
present in the renal tract is very infrequently associated with nephropathy. Instead, it is 
associated with a serious neurological condition, progressive multifocal leukoencephalopathy 
(PML) in patients with HIV-AIDs and also patients with Multiple Sclerosis treated with the 
anti-α4-integrin antibody Natalizumab that inhibits lymphocyte trafficking through the blood-
brain barrier [158, 159]. 
Both BK and JC viruses can induce tumour formation in new-born rodents and so are 
putatively oncogenic [160, 161]. Although BK and JC viral DNA has been recovered from a 
wide range of tumour types, the evidence of a role in oncogenesis is currently controversial, 
made particularly difficult by the high seroprevalence of both viruses throughout the general 
population. 
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1.6.2 KI and WU polyomaviruses 
The 3rd and 4th human polyomaviruses were discovered in 2007 [162, 163]. Although isolated 
from different areas of the world, KI (Karolinska Institut) and WU (Washington University) 
were both found using similar techniques, isolated from respiratory secretions of children 
suffering with respiratory tract infections.  By concentrating virus using filtration and ultra- 
centrifugation, then performing nuclease digestion and PCR using random primers, residual 
nucleic acid was amplified and the products cloned and subjected to high throughput DNA 
sequencing and analysed bioinformatically.  Both viral genomes bear some homology to BK, 
JC and SV40, though they lack Middle T and agnoprotein regions, thus forming their own 
phylogenetic branch within the virus family. 
Although, both viruses seem to reside in the lung and were discovered in patients with 
respiratory symptoms, it is not known whether either is pathogenic. In a study comparing 
adults with and without respiratory symptoms, the number with evidence of viral DNA in the 
nasal aspirates was low and not significantly different between the groups [164]. 
Seroprevalence studies show that most (55-98%) of the healthy adult population have been 
exposed [152, 154]. No formal link has been made with either of these viruses and cancer. 
 
1.6.3 Human polyomavirus 6 and 7 (HPyV6 and HPyV7) 
In 2010, while looking for presence of MCV DNA in skin swabs from healthy volunteers, 
using rolling circle DNA amplification, Schowalter et al, discovered two novel double-
stranded circular genome sequences [124]. These share close homology with the late regions 
of KI and WU viruses but very divergent early regions, resulting in sharing a common 
phylogenetic branch but separate clade. Seroprevalence of both is high, with 69-83.4% and 
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35%-63.6% of healthy people having evidence of HPyV6 and HpyV7 VP-1 antibodies 
respectively [124, 165]. While HPyV6 DNA is found in 30% of swabs taken from normal 
skin, HPyV7 appears less frequent (20%) [166-169]. Again, neither virus has any clear 
pathogenic association although HPyV6 has been found in the majority of epithelial 
proliferations in skin of patients treated with BRAF inhibitors [170] as well as the CSF of a 
HIV+ patient with leukoencephalopathy [171]. HPyV7 has been found in two cases of pruritic 
epidermal hyperplasia in patients who had undergone lung transplantation [172]. Neither virus 
has been associated with any skin malignancy including MCC [173, 174]. 
 
1.6.4 Trichodysplasia Spinulosa polyomavirus (TSV) 
Trichodysplasia Spinulosa (TS), a skin condition associated with immunocompromise 
associated with friable follicular spinous process formation. In 1999, electron microscopy of 
thin tissue sections from a patient revealed the presence of intracellular small icosahedral viral 
particles [175]. In 2010, using DNA extracted from a spinous process from a patient and 
performing rolling circle amplification, another novel DNA sequence was discovered [176]. 
Although encoding LT, sT and VP1, 2 and 3 like the other recently discovered 
polyomaviruses, phylogenetically this was more closely related to Borneo Orang-utan 
polyomavirus and has been classed as such. It is seroprevalent with 70%-80% of healthy 
adults showing detectable TSV VP-1 seroresponse [165, 177-179]. It is rarely detected within 
the skin or hair follicles, with a 4% DNA detection rate in immunosuppressed patients not 
suffering with TS and <1% of skin of healthy donors [169, 176]. It is not known to have a role 
in any other disease processes.   
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1.6.5 Human polyomavirus 9 (HPyV9) 
This was detected in the serum of a renal transplant patient as part of a general screen for 
novel polyomaviruses capable of causing opportunistic infections in immunocompromised 
populations by screening DNA extracted from various tissues and performing PCR with 
primers targeting well conserved regions of the VP-1 gene. 84 of 514 samples contained 
polyomavirus and after sequencing, 1 of these did not belong to a previously identified virus 
and was named HPyV9 [180]. This virus was noteworthy for its close relationship to 
Lymphotropic polyomavirus (LPV) found in African green monkeys as this may explain why 
around 30% of adult human sera contain antibodies to LPV. The seroprevalence of HPyV9 in 
healthy adults is roughly 10–40% [165, 178, 181]. Alongside serum, HPyV9 has also 
infrequently found to reside in skin. There are no current links of HPyV9 with disease. 
 
1.6.6 Human polyomavirus 10 (also known as MW or MX) 
Isolated from a healthy stool sample of a 15 month old child from Malawi, through 
purification of virus-like particles and shotgun pyrosequencing, this virus was identified as 
part of a global gut microbiome survey. This sequence was then used to develop primers to 
screen stool from a sample of American children, with a detection rate of 2.3% from 514 
samples [182]. This virus was originally termed Malawi (MW) polyomavirus. 
Concurrently, polyomaviruses isolated from a stool sample in Mexico (originally named MX) 
[183] and from chondyloma specimens from a patient with Warts with Hypoglobulinaemia, 
Infections, and Myeloathexis (WHIM) syndrome (originally termed HPyV10) [184], although 
originally thought to be novel, were seen to have 95-99% similarity between to MW virus 
making them likely to be strains of the same virus. This virus has an extremely high 
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seroprevalence (>99%) in healthy adults but no known pathogenic associations [181]. It has 
also been rarely detected from skin swabs of healthy donors at a frequency of 3.5% [169].  
 
1.6.7 Human polyomavirus 11 (HPyV11, also known as St Louis polyomavirus) 
This polyomavirus was isolated from stool samples in Malawi, Gambia and the USA [185]. 
Although sharing an ancestral recombinant origin with MW virus, it is distinct in its ability to 
form a unique T-antigen splice variant, termed 229T, alongside the usual Large and Small T-
antigens. Very little is known about this virus and the role of 229T. The seroprevalence of this 
virus is thought to be approximately 70% of healthy adults [186]. 
 
1.6.8 Human polyomavirus 12 (HPyV12) 
Most recently, this virus was isolated from resected liver tissue and was subsequently found 
in other GI tract organs such as the caecum as well as in stool samples. The seroprevalence is 
23% in healthy adults [187]. Again, there are no known associations with this virus and any 
diseases. 
 
1.7 Viral Immunity 
Viruses are small pathogenic intracellular organisms that utilise cell machinery hijacked from 
infected host cells in order to replicate. The nature and length of infection is dependent on the 
virus in question. Some viruses, such as influenza A, cause acute lytic infections that impact 
seriously on the normal physiology of the host cell leading to cell death, the release of 
infectious virions and the forward transmission of infection to other cells and other hosts. 
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Other viruses, such as the polyomavirus and herpes virus families, cause latent, persistent 
infections which are usually silent and asymptomatic but do occasionally reactivate and 
undergo lytic replication. Individuals with functioning immune systems are capable of 
mounting immune responses against both types of infection. However, viruses have 
developed mechanisms to evade the immune system and thus allow them to persist within the 
host. 
There are two major arms to the normal host immune response to viruses, the innate response 
and the adaptive response. 
1.7.1 Innate immune response 
After microorganisms breach the physical and chemical barriers protecting the skin and 
mucosal surfaces of the body, they contact tissue resident cells that are able to initiate an 
immediate immune response.  Microorganisms, including viruses, display simple invariant 
molecules, termed pathogen-associated molecular patterns (PAMPS) on their surface. These 
include peptidoglycans, lipopolysaccharides and unmethylated CpG DNA that are not present 
on the host cells. These “non-self” molecules can be recognised through interaction with 
pattern recognition receptors (PRRs) on the surface of innate immune cells such as 
macrophages, neutrophils and dendritic cells. There are a number of different PRR types with 
different functions. Engagement of microorganism with a phagocytic receptor stimulates the 
innate immune cell to bind, engulf and kill it. Engagement with signalling receptors, such as 
the Toll-like Receptors (TLRs), which result in production of pro-inflammatory cytokines and 
chemokines directed at damaging the microorganism and attracting other immune cells to the 
site of infection. Each TLR is specific for a particular ligand and are found on certain cell 
types, for example, TLR-7 engages with single stranded RNA and is found on plasmacytoid 
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dendritic cells, NK cells, eosinophils and B cells. TLR-9 interacts with DNA with 
unmethylated CpG sites, found on many DNA viruses, and is expressed by plasmacytoid 
dendritic cells, eosinophils, basophils and B cells. 
Type 1 interferons 
Interferon-α (IFNα) and interferon-β (IFNβ) are the two cytokines that make up the Type 1 
interferons (IFN). Upon TLR activation, several downstream signalling pathways are initiated 
including the NFκB and the interferon regulatory factor (IRF) transcription pathways. Almost 
all cells are able to produce Type 1 interferons when they are infected with a virus. Some cell 
types, particularly, plasmacytoid dendritic cells, which express TLRs 7 and 9 that recognise 
viral RNA or DNA, are particularly specialised at this. These cells then accumulate in 
peripheral lymphoid tissue at times of viral infection and produce large amounts of interferon-
α and interferon-β. Production of interferon-β induces surrounding cells to secrete interferon-
α and so is able amplify the size and length of response. Interferon- α and β both bind to 
interferon receptors on the infected and surrounding cells stimulating the JAK-STAT 
transcriptional pathway leading to synthesis of proteins, such as the enzyme oligoadenylate 
synthetase, that are capable of inhibiting viral replication [188]. Type 1 interferons are also 
responsible for the activation of cytotoxic Natural Killer (NK) cells both directly and through 
activating macrophages to produce stimulatory cytokines IL-12 and IL-18. Type 1 interferons 
stimulate production of chemokines capable of recruiting lymphocytes (CXCL9, CXCL10, 
CXCL11) and also increase expression of MHC Class 1 molecules on the surface of all cells, 
enabling enhanced recognition as well as protecting them from NK cell mediated killing 
[189]. Interferon-β promotes the differentiation of monocytes into mature dendritic cells 
allowing them to function as antigen presenting cells and initiate an adaptive immune 
response.  
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1.7.2 Adaptive immune response 
The innate response provides rapid protection against invading pathogens, however this can 
do so against only those that display molecular patterns that are capable of inducing a 
response. In order to provide protection against a more focused response to a range of 
pathogens, an adaptive immune system is required. This system is able to recognise a variety 
of molecules, termed “antigens”. The two major types of the adaptive immune response are 
humoral and cell mediated.  
 
1.7.3 Humoral immunity 
B cells contain highly specialised antigen-recognition molecules termed as immunoglobulins, 
which are bound to the cell membrane and also known as the B cell receptor (BCR). Naïve B 
cells travel into secondary lymphoid tissue and interact with follicular dendritic cells 
displaying antigen. Upon recognition of its cognate antigen by the BCR, the B cell is 
stimulated. It is then further stimulated by antigen specific CD4 T follicular-helper  (Tfh) cells 
that express CD40L and IL-4 which drive B cell clonal expansion and a proportion of these 
cells differentiate into IgM antibody secreting plasmablasts [190]. Remaining activated B 
cells form germinal centres within the lymphoid tissue and upon further interaction with CD4 
T cells, undergo somatic hypermutation of immunoglobulin gene and class switching, leading 
to the production of B cells with higher affinity BCR [191]. These B cells will then either 
differentiate into plasma cells secreting high affinity antibody or long-lived “memory” B 
cells, capable of providing a secondary response if the same antigen is re-encountered in the 
future. Secreted antibodies have a number of functions that help protect against infections. 
Firstly, they are able to prevent or “neutralize” binding of bacterial toxins or virus particles to 
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cells. Secondly, binding of antibody to pathogens causes “opsonisation” through either the 
activation of the classical complement cascade or by engagement of the Fc portion of 
antibody by Fc Receptors displayed by macrophages, neutrophils and dendritic cells, leading 
to phagocytosis of the antibody bound pathogen. 
 
1.7.4 Cell mediated immunity 
Unlike immunoglobulins which can recognise pathogenic material in the extracellular space, 
T cells interact with fragments of the antigen when displayed on the surface of a cell. There 
are two distinct T cells subsets, αβ T cells, which are the majority and ɣδ T cells, a minority 
population that differ in antigen recognition properties and function. As αβ T cells are most 
associated with an anti-viral role, we will concentrate on describing their development and 
function. Infected cells display protein fragments of intracellular pathogen as peptides which 
are delivered to the cell surface by specialised glycoprotein structures, named major 
histocompatibility complex (MHC) molecules and also called Human Leucocyte antigen 
(HLA) in humans. The peptide:MHC complex is recognised by the T cell through direct 
interaction with the surface T cell receptor (TCR). TCRs are made up of an α and β 
polypeptide chain, linked by a disulphide bond with each chain spanning the cell membrane 
and ending in a short cytoplasmic tail. The αβ TCR has homology with the BCR in that both 
have an amino-terminal variable (V) region, a constant (C) region and a short cysteine 
containing segment that forms a disulphide bond between the two chains. There are two major 
classes of αβ T cell, CD8 and CD4, which are able to recognise antigen presented in MHC 
Class I and Class II molecules respectively. 
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1.7.4.1 The development of αβ T cells 
T cell progenitors are released from the bone marrow and mature in the thymus by passing 
through a number of selective stages. During these stages, the T cells begin to express TCR 
that has undergone VDJ rearrangement of both α and β loci, CD3 and initially both CD4 and 
CD8. These double-positive T cells express only low levels of TCR and are stimulated to 
mature if able to recognise self-peptide:self-MHC complexes; a process known as positive 
selection [192]. These selected cells then begin to express high levels of TCR and only one of 
CD4 or CD8. These T cells then go through negative selection, whereby they are eliminated if 
they recognise self-antigens [193]. The remaining cells are then exported from the thymus 
into the periphery as mature CD4 or CD8 T cells. 
1.7.4.2 T cell priming 
In order for a naïve T cell to be stimulated to form effector T cells, it must recognise their 
cognate peptide in the context of the correct MHC molecule usually presented by a 
professional antigen presenting cell, such as a dendritic cell. Conventional dendritic cells are 
found under most surface epithelia and in most solid organs in an immature state. These cells 
can ingest extracellular pathogens either by endocytosis or macropinocytosis and present 
antigen in the context of MHC molecules (described in further detail below). Immature 
dendritic cells also express a variety of pathogen recognition receptors, such as TLRs and the 
lectin DC-SIGN. When these receptors are stimulated at a time of infection, it leads to a 
process of cell maturation, up-regulating expression of the lymphoid homing receptor CCR7, 
T cell co-stimulatory molecules CD80 and CD86 and also levels of both MHC Class I and II 
[194]. Mature dendritic cells then migrate to the peripheral lymphoid tissue with a phenotype 
capable of inducing strong T cell responses. 
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In order to meet antigen presenting cells displaying cognate antigen, naive T cells must also 
home towards lymphoid tissue. To do this, they express receptors such as the adhesion 
molecule CD62L and chemokine receptor CCR7, whose ligands, GlyCAM-1 and CCL19 and 
CCL21 respectively, are expressed by stromal and endothelial cells resident within the 
lymphoid tissue. Naïve T cells also express other molecules such as CD28, CD27 and the 
CD45 isoform, CD45RA on their cell surface. Alongside recognition of presented antigen via 
TCR and CD4 or CD8 co-receptor, further co-stimulatory signals are required to activate the 
T cell. These include ligation of CD28 on the naïve T cell with CD80 or CD86, found on 
antigen presenting cells or CD27 ligating with CD70 on the surface of activated T and B cells 
[195, 196]. Following adequate stimulus, the T cell undergoes clonal expansion forming 
effector and memory T cells which then migrate from the lymphoid tissue back into the 
circulation. The process of clonal expansion is mostly driven by secretion of the cytokine IL-2 
by the activated T cells alongside an alteration in the IL-2 receptor on the T cell such that the 
affinity for IL-2 is significantly increased. After 4-5 days of rapid proliferation, the activated 
T cells differentiate into effector T cells that down regulate CD62L and CCR7 expression and 
thus can leave the lymphoid tissue and independently respond to cells displaying their cognate 
epitope. These activated T cells can maintain expression of CD27 and CD28 but due to 
alternate splicing of the CD45 extracellular domain, express the CD45RO isotype rather than 
CD45RA [197].  
1.7.4.3 T cell memory 
Upon resolution of infection, the majority of effector T cells will die through apoptosis due to 
the lack of on-going stimulatory signalling. In the presence of IL-7 and IL-15, some effector 
cells are retained and go on to form memory T cell populations which can enable a rapid 
secondary response to a previously experienced pathogen even after many years [198].  There 
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are two populations of memory T cells termed the effector memory and central memory 
subsets which differ in surface expression of various molecules as well as in function [199]. 
The CCR7-negative effector memory T cells are able to circulate throughout the periphery 
and may lose expression of one or both of CD27 and CD28. These cells are able to rapidly 
produce cytotoxic molecules such as perforin, as well as inflammatory cytokines such as 
IFNɣ, IL-4 and IL-5 upon recognition of a previously encountered cognate antigen. The 
central memory T cells retain expression of CCR7 and so are able to recirculate back to 
secondary lymphoid tissues. They may also retain expression of CD27, CD28 and CD45RO 
and produce cytokines such as Interferon-ɣ (IFNɣ) and tumour necrosis factor-α (TNFα) but 
no cytotoxic molecules [200].   
1.7.4.4 CD4 T cell response 
Upon priming, CD4 T cells can differentiate into a number of subtypes, each with a distinct 
function. This is not pre-determined and depends on the co-stimulatory cytokine profile which 
drives specific transcription factor usage at the time of T cell activation. Th1 cell development 
is induced by the cytokines IL-12 and IFNɣ and driven by the up-regulation of transcription 
factors Signal Transducer and Activator of Transcription (STAT)-1, STAT-4 and T-bet [201]. 
Th1 cells are also termed inflammatory T cells and assist in the killing of intracellular 
pathogens such as viruses and mycobacteria through the activation of IL-12 producing 
macrophages. Th1 cells stimulate phagocytosis by macrophages through first engaging with 
antigen held within the MHC Class II surface molecule leading to the production of IFNɣ. 
Macrophages responding to this stimulation then bind to the Th1 cells through interaction of 
CD40, found on the macrophage, and CD40L, found on the Th1 cell. The combination of 
these signals causes the macrophage to up-regulate its antimicrobial properties and 
phagocytose the infected cell. Th1 cells additionally produce the stimulatory cytokine IL-2, 
  Chapter 1: Introduction 
36 
 
leading to further recruitment and proliferation of T cells to the site of infection, as well as 
GM-CSF which activates release and maturation of macrophages from the bone marrow 
[202]. There is increasing evidence that Th1 cells can also have a direct cytotoxic effector 
function on virally infected cells through a perforin-dependent mechanism [203, 204]. 
The Th2 cells are also termed T helper cells as they are integral to B cell activation and the 
production of high affinity antibody. They can also control parasitic infections by stimulating 
responses by mast cells and eosinophils. Development towards this phenotype is driven by the 
cytokine IL-4 that up-regulates the transcription factors STAT6 and GATA-3 [205, 206]. Th2 
cells produce the cytokines IL-4 and IL-13 following interaction with its cognate antigen on 
the surface of the B cell and this, in addition to CD40-CD40L interaction, results in B cell 
activation and clonal expansion within the germinal centre. Th2 cells also produce the 
cytokines IL-5 and IL-6 which are able to help direct the differentiation of B cells into IgE-
producing plasmablasts which are predominantly active in parasitic infection.   
Th17 cells are induced early on in the adaptive immune response and act to stimulate 
neutrophils to kill extracellular fungi and bacteria [207]. These cells do not produce IFNɣ, 
instead secreting cytokines of the IL-17 family which act on local stromal and epithelial cells 
stimulating production of the chemokine IL-8 which recruits innate immune cells. These cells 
may also have a role in provoking auto-immunity by inducing experimental autoimmune 
encephalomyelitis in mice [208]. They develop in the presence of cytokines IL-6 or IL-21 and 
TGF-β and in the absence of IL-4 and IL-12 through up-regulation of the transcription factors 
RORɣt or RORα in co-operation with STAT3 [209].  
There is thought to be a reciprocal relationship between Th17 cells and another CD4 T cell 
subset, termed regulatory T cells (Tregs) that develop from naïve cells in the presence of TGF-
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β but in the absence of IL-6/IL-21 and other pro-stimulatory cytokines [210]. The 
development of Tregs is dependent on the activation of the transcription factor FoxP3 and these 
cells are defined by expression co-expressing cell surface molecules CD4 and CD25 [211, 
212]. Tregs have important roles in both health and disease through their ability to suppress the 
immune response through the production of cytokines TGF-β and IL-10. They are able to 
terminate immune responses following clearance of pathogen as well as preventing 
inappropriate auto-immune responses [213].  
T follicular helper cells (Tfh) cells migrate into the lymphoid follicle through Bcl-6-mediated 
CXCR5 surface up-regulation and loss of CCR7. Through the expression of cell surface 
receptors such as ICOS and OX40 and production of the cytokine IL-21, Tfh cells are able to 
interact with cognate B cells leading to their activation and differentiation to form plasma 
cells capable of producing high affinity antibody responses [214].  
The stimulation by TGF-β alongside IL-4 causing up-regulation of transcription factor 
STAT6 and SMADs leads to the differentiation of another T cell subset, Th9 cells, so-called 
due to their secretion of the cytokine IL-9. Although the exact role these cells play in the 
immune response is not known they have been linked with causing inflammatory cell 
infiltrate and antibody production within the airways and may be important in conditions such 
as asthma [215]. 
1.7.4.5 CD8 T cell response 
CD8 T cells typically differentiate into cytotoxic T cells which amongst other functions are 
able to kill their target cells. These cells can be activated by mature dendritic cells, which can 
sometimes lead to clonal expansion of CD8 T cells without need of co-stimulation from other 
cell types. More usually, a co-stimulatory signal from the dendritic cells is provided by 
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interactions with CD4 T cells which, when they engage with the antigen presenting cell, 
produce IL-2 and CD40L. CD40L binds to CD40 on the dendritic cell, macrophage or B cell 
providing a further activation signal, increasing expression of CD80/86 and 4-1BBL on the 
dendritic cell. These provide further activation signals to the CD8 T cell leading to cell 
proliferation. 
The main effector molecules released by CD8 T cells are perforin, granzyme and granulysin 
which are contained within cytotoxic granules and released upon conjugation with the target 
cell at the immunological synapse. Perforin is a protein capable of disrupting the cell 
membrane and so enables delivery of the granule contents to the target cell. Granzymes are a 
family of cytotoxic proteases, of which granzyme A and B are most abundant in humans, with 
the ability to cleave cellular proteins. Within the highly acidic granules in which they are 
stored, perforin and granzymes are inactive, however when released into the neutral pH 
extracellular space in a calcium-dependent process, they become activated and cause 
apoptosis of the infected cell. Both granzymes and perforin are needed for cell killing [216, 
217]. Granulysin is a cytotoxic protein that can penetrate into the cell through pores caused by 
perforin and leads to the apoptosis of intracellular bacteria by causing lysis of their 
membranes [218]. CD8 T cells can also release the effector cytokines IFNɣ, TNFα and TNFβ. 
IFNɣ is particularly important through blocking viral replication and increasing antigen 
presentation by the infected cell through activation of the MHC Class I and II antigen 
processing pathways. Alongside IFNɣ, TNFα and TNFβ are able to activate and recruit 
macrophages to sites of infection. The activated CD8 T cells also express the membrane-
associated protein Fas ligand (FasL), which interacts with its receptor Fas, usually present on 
the cell surface of other activated lymphocytes as well as virally infected cells and leads to 
caspase-mediated apoptosis even when perforin is not functional [219]. This mechanism, 
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therefore, limits lymphocyte proliferation after infection has been cleared and prevents an 
auto-immune reaction. TNF-related apoptosis-inducing ligand (TRAIL) is expressed on CD8 
T cells following stimulation with IFNα and IFNβ and when this protein interacts with cells 
such as those that have been virally infected or transformed bearing TRAIL receptors such as 
TRAIL-R or TRAIL-R2, this leads to caspase-dependent apoptosis of the target cell [220, 
221]. 
 
1.7.5 Antigen presentation and processing 
T cells are only capable of responding to antigen when it is held in the form of a processed 
peptide within an MHC molecule. Although there are hundreds of different versions of MHC 
molecules, termed alleles, an individual will only express a small number of these and each 
product of the allele is capable of binding a range of peptides. MHC molecules have highly 
polymorphic peptide binding grooves that leads to alterations in the specificity of the peptide 
amino acid sequence that it will bind to. There are two classes of MHC, Class I and Class II, 
which present to CD8 and CD4 T cells respectively (see Figure 1.5). Although both molecules 
are similar in overall structure there are important differences in the route through which 
antigens are usually processed and loaded onto the MHC molecules and how they are 
presented on the cell surface. The expression of MHC Class I and II is regulated by cytokines, 
particularly interferons released by both innate and adaptive immune responses. Interferon-α 
and –β increase Class I expression on all cell types. Interferon-ɣ can also increase expression 
of MHC Class I and II as well as inducing Class II expression in certain cell types, such as 
fibroblasts, that do not constitutively express it. 
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Figure 1.5. Schematic diagram of MHC Class I and MHC Class II antigen processing pathways as 
described in sections 1.7.5.1 and 1.7.5.2. TAP (transporter associated with antigen-processing), Ii (invariant 
chain), CLIP (class II-associated invariant-chain peptide). Taken from [222] 
 
 
1.7.5.1 MHC Class I pathway  
MHC Class I is expressed by all nucleated cells and consists of an α polypeptide chain that 
spans the cell membrane alongside a non-polymorphic β2-microglobulin polypeptide chain. 
The complete molecule folds such that it forms a peptide binding groove on the most distal 
region of the complex at the cell surface. The peptides that go onto fit into this groove are 
derived in a number of ways from protein antigens. Pathogen-derived protein can directly 
enter the cytosol following, for example, a viral infection. It is also possible that antigens 
from endocytosed viral particles or phagocytosed viral infected cells can be translocated into 
the cytosol in a process called cross presentation. The peptide source can also come from the 
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rapid degradation of newly synthesised proteins known as defective ribosomal products 
(DRiPS) including peptides translated from mRNA that has undergone frameshift mutation or 
from proteins that have been folded incorrectly [223]. The pathogen-derived or self-proteins 
are then degraded by a large protease complex named the proteasome. Cytosolic peptides are 
then transported into the endoplasmic reticulum (ER) by the ATP-dependent proteins TAP 
(Transporter associated with Antigen Processing)-1 and TAP-2 [224]. The TAP-1 and TAP-2 
genes are up regulated by interferons which are produced by innate immune cells as a 
response to viral infection [225]. Peptides too long to bind to Class I MHC can be shortened 
within the endoplasmic reticulum by the aminopeptidase, endoplasmic reticulum 
aminopeptidase associated with antigen processing (ERAAP), which can be up regulated by 
IFNɣ [226]. 
MHC Class I molecules are assembled in the ER through interactions with the chaperone 
proteins, calnexin, calreticulin, ERp57 and then binds to TAP via the associated protein 
tapasin [227].  Peptide transported in the ER via TAP is then loaded onto the MHC Class I 
molecule forming a complex that can be transported via the Golgi apparatus, where it is 
glycosylated, to the cell surface for display to CD8 T cells. The stability of MHC molecules is 
markedly increased when they are bound to peptide leading to sustained expression on the cell 
surface. Peptides held within Class I molecules are usually 8-10 amino acids long and held by 
contacts usually between atoms in the free amino and carboxy termini of the peptide [228]. 
Class I MHC can bind longer peptide if binding at the carboxy terminus is possible, these are 
then subsequently cleaved by exopeptidases in the endoplasmic reticulum [229]. Each MHC 
allele binds to peptides that exhibit a certain amino acid signature, consisting of two or three 
residues in particular positions within the sequence that allow stable anchoring to the MHC 
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molecule.  This means that an individual MHC allele can bind to a range of peptides that 
share these features.  
1.7.5.2 MHC Class II pathway 
MHC Class II is expressed by a more limited number of cell types involved in the immune 
response such as B cells, macrophages and dendritic cells which are termed professional 
antigen presenting cells. MHC Class II molecules consists of a non-covalent complex of α and 
β chains, folded together much like the MHC Class I molecule. MHC Class II molecules 
present peptides that have mostly been derived from exogenous proteins and generally these 
are taken up by cells through endocytosis into vesicles which enter the endosomal pathway 
[230]. These vesicles fuse with others that have an increasingly acidic content and also 
contain proteases called cathepsins that degrade the protein into peptide fragments [231]. 
These peptides are then transferred into the late endosomal compartment known as the MHC 
Class II compartment (MIIC) where it can interact with MHC Class II molecules [232].  MHC 
Class II is synthesised in the ER and its stable assembly is aided by binding to peptides with a 
membrane protein called the MHC Class II-associated invariant chain (MHC II-Ii) which acts 
as a scaffold. This interaction between invariant chain (Ii) and MHC Class II also prevents 
premature binding to peptides that have been transported to the ER or that are encountered 
while travelling to the endosomal compartment [233]. The invariant chain plays a further 
important role by targeting MHC Class II molecules to the endocytosed vesicles containing 
the degraded antigen ready for peptide loading. Upon reaching the acidified endosome, the 
invariant chain is cleaved, leaving a short peptide fragment, termed class II-associated 
invariant chain peptide (CLIP) still bound to the Class II binding pocket [234].  CLIP is 
removed when a MHC Class II like molecule, HLA-DM binds to Class II, leaving the binding 
pocket groove for the exogenously-derived peptide fragments to be loaded [235]. The Class II 
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peptide binding cleft has a more open conformation than that of the Class I and as such, 
peptide binding to MHC Class II is not constrained by peptide length and tend to be between 
13 and 17 amino acids [236]. Here the peptide is held by peptide side chains that protrude into 
pockets within the peptide binding cleft and by interactions between peptide backbone and 
side chains of conserved amino acids within the binding cleft itself.  The Class II 
molecule:peptide complex can be released from the endosome and travel to the cell surface to 
enable recognition by CD4 T cells. 
 
1.8 Immunity and ageing 
The ageing process has been well documented to affect the adaptive immune system. 
Although absolute lymphocyte counts tend to stay stable with age, there are changes in the 
proportions of the cell types with a decline in T and B cell number alongside an increase in 
NK cells. The number of naïve T and B cells decrease with age as a result of a shift towards 
myeloid rather than lymphoid precursor production from the bone marrow [237]. Alongside 
this, the thymus involutes in most adults over the age of 40, limiting production to that of 
peripheral differentiation only. This reduced pool of naïve lymphocytes also becomes 
increasingly dysfunctional, with impairment of production of cytokines, such as IL-2, 
following stimulation [238, 239].  
Through exposure to higher numbers of lifetime pathogens, the memory cell compartment is 
increased with ageing. However, the function of T cell memory deteriorates with age as seen 
through the diminished response to vaccines such as influenza, as well as the common 
reactivation of infections such as varicella zoster virus (VZV) [240-242]. A reason for this, 
particularly affecting CD8 T cells, is through replicative senescence, driven by the chronic 
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stimulation of T cells by persistent infections, such as CMV, EBV and VZV [243, 244]. This 
leads to the loss of the co-stimulatory molecules CD27 and CD28, the shortening of telomeres 
and terminal differentiation to CD45RA expressing T Effector Memory RA+ (TEMRA) cells. 
TEMRA are resistant to normal apoptotic mechanisms that usually control the size of memory 
T cell clonal populations that respond to a particular antigen resulting in the oligoclonal 
expansion of CD8 T cells that fill immunological space and reduce the diversity of the T cell 
repertoire from 108 Vβ TCR in young people to 106 in the elderly [245]. 
Expansion of CD28-CD8+ T cells appears to correlate with frailty and poor responses to 
vaccines such as influenza and pneumococcus [242]. Indeed the combination of CMV 
seropositivity, an inversed CD4:CD8 ratio and expansion of the CD28-CD8+ T cell has been 
termed the “immune risk profile” and is associated with higher mortality rates in the elderly 
population [246]. 
Age-associated changes to the CD4 cell compartment are much less well defined with 
apparent preservation of both number and function in the majority of elderly people [237, 
247]. However, changes in the ability of CD4 T cells to provide adequate help may be 
reduced in older people through mechanisms such as dysfunction within the CD40-CD40L 
system which may limit B cell and CD8 T cell responses to infection or vaccination [248]. 
As the production of naïve B cells decreases in the elderly, there is a consequent expansion of 
antigen experienced B cells leading to a reduced repertoire of B cells in older humans [249]. 
Alterations in immunoglobulin generation, class switching and affinity maturation is seen in 
old humans, potentially as a result of reduced AID expression [250].  This may all have a 
contributory role in the decline of quality of humoral response in the elderly as seen, for 
example, following vaccinations for influenza and pneumococcus [240, 251].   
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Healthy elderly people can generate large numbers of dendritic cells with a phenotype and 
antigen presentation capacity similar to those from younger people.  However, there are 
reports of an impaired capacity to cross tissue barriers and a relatively poor cytokine response 
following TLR stimulation [252]. Also the ability to trigger IFNɣ or IL-10 production from 
virus-specific T cells is reduced, suggesting the interaction with T cells may be impaired with 
aging or chronic illness, perhaps secondary to reduced GM-CSF levels [253]. 
Age related changes also occur in the innate immune system. Older adults appear to have a 
dysregulated inflammatory response, often leading to lingering low level inflammation, 
termed “inflamm-aging” [254]. In comparison to younger people, the elderly have higher 
levels of basal pro-inflammatory cytokines such as IL-6, which has been associated with an 
increase in mortality [255]. This may be due to higher levels of non-cell associated DNA 
released from senescent or damaged cells that may contain DAMPs that activate innate 
immunity and inflammation.  
This increase in cytokine production does not seem to be simply due to increased production 
of innate cell populations, although some studies have reported increased numbers of 
CD14+CD16+ monocytes in the elderly. Despite higher levels of basal inflammatory cytokine 
production, production of cytokines such as IL-6 and TNFα, following stimulation from 
monocytes are impaired in older people. Although changes in neutrophil number are not 
commonly seen with aging, neutrophilia has been associated with increased mortality in the 
elderly. There is also some evidence that neutrophils from older adults have functional 
impairments, particularly related to chemotaxis and phagocytosis [253, 256].  
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1.9 Cutaneous Immunity 
The skin provides a physical barrier to invading pathogens but needs mechanisms to combat 
infection should this barrier be breached. To this end, the skin contains a large number of 
resident immune cells capable of dealing with invading pathogens and these are shown 
schematically in Figure 1.5.  The majority of these cells function as part of the innate immune 
system or as antigen presenting cells (APCs) and include keratinocytes and Langerhan’s cells 
(LCs) which are found in the dermis and with mast cells, neutrophils, innate lymphoid cells 
(ILCs), dendritic cells (DC) and macrophages found in the epidermis.  
                              
Figure 1.6. A schematic diagram of the different immune cell types populating human skin. The stratum 
corneum composed of dead keratinocytes acts as a physical barrier. The epidermis is a dense and poorly 
vascularized region that comprises mainly of keratinocytes, few melanocytes and Langerhans cells (LCs) and 
CD8 T-cells. The dermis contains fibroblasts, T-cells (CD4 αβ, and γδ), innate lymphoid cells (ILCs), dendritic 
cells (DCs), macrophages, mast cells, and neutrophils amongst others. Taken from [257] 
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Keratinocytes produce IL-1α and TNF in response to stimulation of TLRs they express e.g. 
TLR-9 after recognising PAMPs. This leads to the activation of the NF-κβ pathway which 
induces local inflammation and increases the expression of cell adhesion molecules such as E- 
and P-selectin, Intracellular Adhesion Molecule-1 (ICAM-1) and Vascular Cell Adhesion 
Molecule-1 (VCAM-1) [258]. Langerhan’s cells resident in the epidermis and dendritic cells 
from the dermis are both activated by the innate immune response and take up antigen and 
undergo maturation before travelling to the local lymph nodes to engage with and activate T 
cells.  Activated effector T cells express integrins such as Lymphocyte Function-associated 
Antigen 1 (LFA-1) and Very Late Antigen-4 (VLA-4) which can bind to ICAM-1 and 
VCAM-1, found on inflamed tissue, and allows migration into these sites. More specifically 
to T cells homing to the skin, CD3 stimulation in the presence of IL-12 induces expression of 
cutaneous lymphocyte antigen (CLA) which binds to E-selectin on the vasculature. The vast 
majority of T cells found in both inflamed and non-inflamed skin express CLA [259]. Further 
chemokine receptors are also associated with skin-homing T cells including CCR4, CCR6 and 
CCR10. CCR4 is able to bind to its ligand CCL17 which is expressed in high levels on the 
endothelium of cutaneous blood vessels as well as on keratinocytes and fibroblasts [260]. 
CCR10 is seen on a subset of CLA+ cells and its ligand is CCL27, also known as cutaneous T 
cell attracting chemokine (CTACK) is expressed on cell types such as keratinocytes [261]. 
CCR10 up-regulation has been shown to occur in the presence of 1,25(OH)2 Vitamin D3 
which can be produced in the skin as a result of sunlight exposure and this may be a 
mechanism which works synergistically with IL-12 by which some antigen specific T cells 
are retained in the skin [262, 263]. These antigen-specific CD4 and CD8 T cells are termed 
tissue resident memory (Trm) T cells are thought to up-regulate expression of the integrin 
CD103 upon exposure to TGF-β in the skin which can interact with its ligand E-Cadherin 
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found on keratinocytes [264].  The TCR of these T cells can be activated at a lower threshold 
than that seen with circulating T cells and so can lead to rapid clearance of pathogen upon re-
exposure [265, 266]. A normal cutaneous immune response can be abrogated by a number of 
factors. Exposure to ultraviolet radiation (UVR) has been implicated in recruitment of 
regulatory T cells and in inhibition of antigen presentation via direct damage to antigen 
presentation cells (APCs) or via functional inhibition of APCs by cytokines (IL-10, tumour 
necrosis factor-α) released by keratinocytes and mast cells [267]. Ageing is also associated 
with reduced cutaneous immunity through the accumulation of immunosuppressive Tregs 
[268], the up regulation of inhibitory molecules such as PD-1 on cutaneous T cells [269] and 
reduction in TNFα production by macrophages which in turn reduces T cell migration into 
tissue [270]. Both UV light exposure and ageing factors are particularly relevant when 
considering MCC as shown below. 
 
1.10 The importance of immunity in MCV+ MCC 
The three major risk factors associated with MCC are ageing, UV light exposure and 
immunosuppression, all of which are associated with either local or systemic immune 
dysfunction. There also appears to be a prognostic impact of immune dysfunction in MCC 
patients, with immunosuppressed patients [39] and those with low absolute lymphocyte 
counts [41] associated with poorer clinical outcomes. 
MCV cutaneous viral loads are increased in MCC patients compared to patients with other 
skin disorders [271].  In HIV+ patients, in whom risk of MCC is higher than expected, MCV 
viral DNA is more commonly seen in skin swabs compared with HIV- controls. Furthermore, 
HIV+ patients with poorly controlled disease (defined using CD4 count and HIV-1 viral load) 
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have significantly higher MCV viral loads in the skin compared with HIV+ patients with well 
controlled disease [272]. These findings suggest a loss of MCV viral immune control may be 
important early in the pathogenic process of MCV+ MCC development. Interestingly, the 
recovery of immune function, for example with withdrawal of immunosuppressive 
medications in solid organ transplant patients with MCC, has led to tumour regression [273]. 
This suggests that the anti-viral immune response may also have an anti-tumour effect and as 
such, investigations into potential mechanisms through which the loss of MCV of viral 
control occurs and the impact this may have both on the development and treatment of MCC 
are underway and are discussed below. 
 
1.10.1 Alterations and potential therapeutic avenues in innate immunity 
As previously described, the innate response to viruses includes recognition of viral PAMPS 
by PRRS such as TLR3, 7 and 9. The expression of TLR2, 4, 5, 7 and 9 has been investigated 
by immunohistochemistry in a panel of 128 MCC tumours and retained expression was noted 
in most specimens. A decrease in TLR7 expression was associated with older age and a 
decrease in TLR9 expression was predominantly seen in MCV+ tumours [274]. The down-
regulation of the TLR9 surface expression is thought to occur through inhibition of the 
transcription factor C/EBPβ by MCV LT, potentially in co-operation with sT, although the 
exact mechanism is unknown [275]. A small numbers of cases of MCC have been treated 
successfully with Imiquimod, a synthetic TLR7 agonist usually used to treat squamous cell 
skin cancer (SCC) [276, 277]. This topical treatment results in increased infiltration by 
effector T cells producing IFNɣ, perforin and granzyme as well as reducing production of 
immunosuppressive cytokines IL-10 and TGF-β although the mechanism for this remains 
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unproven [278]. Upon TLR stimulation several downstream transcriptional signalling 
pathways are activated including the NFκB pathway. NFκB is usually held in its inactive 
cytoplasmic form via binding to the inhibitor of κB (IκB) proteins. As part of the NFκB 
signalling pathway, IκB is phosphorylated by the inhibitor of κB kinase (IKK) complex 
leading to its rapid degradation and the consequent activation of NFκB which can translocate 
to the nucleus and up-regulate downstream transcriptional activity. This leads to the 
production of pro-inflammatory cytokines and chemokines as well as the up-regulation of co-
stimulatory molecules on DCs that activate T-cells. MCV sT-antigen is able to inhibit this 
pathway by recruiting the cellular phosphatase PP2C and directly interacting with the NFκB 
essential modulator (NEMO) protein which prevents the phosphorylation of the IKK sub-
units IκB kinase α (IKKα) and IκB kinase β (IKKβ), which in turn prevents phosphorylation 
of IκB and limiting the translocation of NFκB to the nucleus [279].  
Although not proven to be virally-induced, MCC can commonly evade NK-mediated cell 
killing through the hypoacetylation of promoters of the MHC class I chain-related protein 
(MIC) -A and –B genes, leading to non-production of these stress-induced NKG2D receptor 
ligands. This process can be reversed, both in vitro and in vivo, using a epigenetic modifying 
HDAC inhibitor resulting in the re-introduction of NK-mediated cytotoxicity [280]. In MCV+ 
MCC cell lines and an in vivo xenograft MCV+ model, exposure to type 1 interferon’s led to 
an increase in apoptosis and reduction in cell proliferation [281]. This has led to the use of 
type 1 interferons to treat cases of MCC, however, patient numbers are small and results are 
inconsistent [282, 283]. 
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1.10.2 Humoral Immunity 
Published data suggests all patients with MCV positive MCC have IgG antibodies to MCV 
VP-1 in their serum. In over 60% of these cases, antibody titres were high (>10,000). In 
comparison, healthy people have a mean titre around 60-fold lower than this [74, 75, 121].  
The fact that VP-1 capsid protein is not expressed by MCV+ MCC implies this may be driven 
by viral reactivation in the setting of immune suppression. Anti-VP-1 antibodies have a 
neutralising function and this is stronger in MCC patients compared with healthy control 
patients with comparable VP-1 antibody levels [74, 137]. Interestingly, patients with higher 
anti-VP-1 antibody titres have a significantly longer progression free survival and overall 
survival compared with those patients with low titres, perhaps reflecting a role in mediating 
some control over MCC progression [121, 284].  
Serological response against T-Antigen (specifically a portion of the common region shared 
between large and small T-antigen), which is expressed in tumours, is less prevalent, seen in 
less than 1% of the general population. However, in MCC patients, it is seen in around 40% 
[284, 285]. In this case antibody titres are potentially driven by tumour-associated antigen 
load as longitudinal studies have shown that titres follow disease burden with a fall following 
treatment and return with disease recurrence [285]. In patients who do relapse, the rise in 
antibody titre predates clinical evidence of disease and so may be a useful monitoring test in 
certain patients. 
 
1.10.3 Cellular Immunity 
Given its recent discovery, detailed information regarding the cellular immune response 
against MCV is limited. However, such responses have been studied for other members of the 
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polyomavirus family.  In wild-type mice infected with murine polyomavirus, viral DNA is 
detected in most organs for the first months before becoming rapidly undetectable a pattern 
repeated in CD4 -/- and CD8-/- single knockout mice. However, in CD4 and CD8 double-
knockout or mice that have undergone chemo/radiotherapy inducing immune suppression, 
polyomavirus was still detectable after 2 months suggesting that both CD4 and CD8 T 
lymphocytes are required for initial viral control [286]. The CD4 subset plays an important 
role in providing help to maintaining both a polyomavirus-specific CD8 T cell pool as well as 
humoral antibodies which are both reduced in MHC Class II deficient mice persistently 
infected with murine polyomavirus [287].  
In humans, the frequency of BKV and JCV virus-specific T cells in the peripheral blood have 
been measured through ex-vivo stimulation by peptides corresponding with the virus proteins. 
A repeated finding in healthy seropositive donors is that the total frequency of T cells in the 
peripheral blood is low and these responses tend to be CD4 predominant [288-290].  For 
example, one study using ELISpot recognition assays to assess frequency of BK-specific T 
cells responding following stimulation showed healthy donors had a median response of 
24(15-95) responding cells/million peripheral blood mononuclear cells (PBMC). The number 
of VP-1 specific cell was equally low with a median of 25 (7-113) responding cells/million 
[291].   
Through extended culturing of T cell responses, CD8 T cell responses to distinct JC and BK 
VP-1 and T-antigen epitopes have been defined and the ex-vivo frequency of T cells 
measured using MHC class I tetrameric complexes to identify epitope-specific cells. Although 
responses are frequently detected in healthy patients, these have always been of low 
frequency, ranging from 0.01% to a maximum of 0.53% of total CD8 cells directed at a single 
epitope [292-294]. In patients suffering with polyomavirus-mediated diseases, such as PML, 
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an increased T cell frequency appears to be associated with an improved prognosis, 
particularly if the response develops early [295-297].  Recently it has been shown that in 
humans combating PML, efficient CD4 T cell JCV recognition is important to allow CD8 T 
cell infiltration into brain lesions and that this CD8 infiltration is hindered if CD4 epitopes are 
altered by mutation which leads to delayed viral clearance [298]. Given the homology in VP-1 
and T-antigen seen throughout the polyomavirus family, a number of potentially cross-
reactive BK and JC CD8 T cell epitopes have been discovered and these may be important in 
providing control for both viruses [299-301]. Whether this same phenomenon occurs within 
the other more recently discovered members of the polyomavirus family and the potential 
importance it may have to general polyomavirus immune control has not been fully 
addressed.   
Assessments focusing on MCV-specific T cell responses have been undertaken and appear to 
show similarities with those seen with other polyomaviruses. In vitro, MCV VP-1 expressing 
virus-like-particles (VLPs) are able to induce T cell proliferation in MCV seropositive healthy 
donors to a greater extent than seronegative donors. These proliferating T cells produce IFNγ, 
IL-10 and IL-13 but the response disappeared if anti-MHC class II antibodies or CD4 cells 
depletion was used, indicating it to be CD4-mediated response [302]. This group did attempt 
to assess potential cross-reactivity between MCV and TSV specific T cell responses in 
healthy donors by comparing IFNɣ and IL-10 secretion from CD4 T cells following 
stimulation with either MCV or TSV VP-1 expressing VLP. They found that donors who 
were MCV seropositive and TSV seronegative made stronger responses to MCV VLP and 
vice versa with TSV VLP, indicating that at least some of the T cell response appears to be 
virus-specific [303]. 
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Efforts to identify MCV-specific T cells by using peripheral blood from MCC patients and 
healthy controls in recognition assays against peptides spanning MCV VP-1 as well as the 
truncated LT and sT have been carried out in one study. Overall T cell responses were small 
and were more readily identified in patients than in healthy donors (37% v 8%) although the 
difference was not considered statistically significant [304].  This identified 26 peptides (five 
from the common T (CT) region shared by LT and sT, nine from the remainder of LT, ten 
from sT and two from VP-1) able to induce T cell responses from both healthy donors and 
patients. Although the Class II HLA allele presenting the epitope was not identified, eight of 
these responses were shown to be CD4-mediated and only one was CD8-mediated. In the 
majority of cases (sixteen) the subtype of the responding T cell was not identified [304]. In 
one case, CD4 T cells specific for a LT (aa57-69) peptide were isolated from the tumour of an 
MCC patient and these were found to secrete both Th1 and Th2 cytokines, IFNγ, IL-5 and IL-
10 after ex vivo expansion and challenge with this peptide [304].  
The single CD8 T cell response identified in the aforementioned study came as a result of 
performing T cell cloning on T lymphocytes extracted from an MCC tumour and was then 
found to be directed against a HLA:A24 restricted LT epitope (aa92-101). These cells were 
found at very low frequency in the peripheral blood of the patient, but enriched within the 
tumour (0.14% of total CD8 T cells in blood versus 4% in tumour). Using an HLA:A24 
tetramer specific for this epitope, it has been possible to quantify frequency of MCV-specific 
T cells in a wider spectrum of patients and healthy donors. This has confirmed that these 
epitope-specific responses are seen in the peripheral blood of the majority of HLA:A24 
MCV+ MCC patients but at low frequency (0.01-0.24% of total CD8 T cells). These MCV-
specific T cells are not seen in HLA:A24 healthy controls or in a MCV-MCC patient [305]. 
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Due to the difficulty in discovering MCV-specific CD8 epitopes using screening recognition 
assays, a second study by Lyngaa et al searched for MCV-specific T cells using a high 
throughput epitope discovery platform [306]. In particular, they looked in MCC patients and 
healthy donors for T cell responses specific for HLA-A1, -A2, -A3, -A11 and -B7 epitopes 
from MCV proteins VP-1, truncated LT and sT.  VP-1 responses were found in both MCC 
patients and healthy donors and 23 novel VP-1 epitopes were discovered. In addition, LT (9 
epitopes found) and sT (3 epitopes found) responses were exclusively seen in MCC patients 
and again were of low frequency (0.05-0.1% CD8 T cells) in peripheral blood ex vivo [306]. 
The role of T cell-mediated immunity in polyomavirus-associated cancer has been 
investigated since it was known that the SV40 virus was capable of promoting tumour growth 
in rodents. It is thought that both CD4 and CD8 T cells are important to a successful anti-
tumour response [307]. In a series of experiments, mice were immunised with recombinant 
SV40 T-antigen protein, subjected to CD4 and/or CD8 T cell depletion immediately before 
and after challenge with the mKSA, SV40-transformed, tumour cell line. Tumours were seen 
to develop in immunised mice in which CD8 but not in the CD4 T cells were depleted, 
causing the authors to suggest that CD8 immunity is key to preventing tumour development in 
this model [308].  In a follow-on study, when CD4 and CD8 depletion occurred around the 
time of immunisation, tumours only developed in the CD4 depleted mice. In the CD8 
depleted mice, a significantly larger anti-T-antigen antibody response was seen leading the 
authors to suggest that an important role of CD4 cells may be to activate B cells to produce 
anti-T-antigen antibodies which bind to tumour cells and lead to killing of tumour by antibody 
directed cell killing [309]. Interestingly in this same study, when CD8 T cells were depleted 
around time of injection with mKSA tumour cell line, there was no tumour growth but 
tumours did develop in CD4 depleted mice. This challenges the original hypothesis that CD8 
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T cells are essential for clearing SV40 mediated tumourigenesis and a potential explanation 
offered for this is that the CD4 T cells may act directly as effectors through secretion of 
cytokines such as IFNɣ [309].  
Since the discovery of a polyomavirus-associated malignancy in humans, MCC, investigators 
have begun to focus attention on whether T cell immunity can have an anti-tumour role. Some 
strong evidence in support of this idea emerged when retrospective unbiased gene expression 
analyses of MCC patients were data stratified into groups with both favourable and poor 
prognosis. This revealed an over representation of immune response genes in tumours with 
favourable prognoses, including genes that encode components of cytotoxic granules 
(granzymes), chemokines (CCL19), lymphocyte-activation molecules, and CD8 receptor 
molecules [310]. This suggested that the T cell response to tumour may be important in 
determining outcome and now a number of studies have examined the degree of T cell 
infiltration into MCC tumours in comparison with clinical outcome (summarised in Table 2). 
The earliest studies conducted, limited by small sample size, found that heavy infiltration was 
associated with a poor prognosis. However, recently, two large studies looking at over 100 
cases each have suggested that the opposite is true. The first, by Paulson et al, found that in 
significant number of cases, T cells appeared to be “stalled” at the tumour periphery, a finding 
that has been replicated by others [311, 312]. However, in tumours with CD8 T cell 
infiltration there was a significant and independent association with an improvement in 
overall survival [310]. The second study, by Sihto et al, found that increased numbers of CD3, 
CD8 or FoxP3 T cells were all associated with improved survival rates as was high CD8/CD4 
and FoxP3/CD4 ratios [313]. 
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Table 1.2. Studies investigating prognostic impact of tumour infiltrating lymphocytes (TIL) in MCC. 
N=number of patients in study. Adapted from [51]. 
 
Study N TIL characterisation Survival Comment 
Mott et al. 
2004  
[314] 
 
25 Minimal/moderate=17(68%)                  
Heavy=8(32%)  
Heavy infiltration was 
associated with poor 
prognosis in multivariate 
analysis. 
Depth of invasion was 
associated with poor 
prognosis in multivariate 
analysis 
Llombart 
et al. 2005 
[315]  
20 Absent=8(40%) 
Discontinuous=12(60%) 
Continuous=0  
Absent is an independent 
prognostic factor of DFI 
in multivariate analysis.  
Tumour size>30 mm, stage 
II, and >50% Ki67+ tumor 
cells prognostic indicators 
of disease free interval in 
univariate analysis.  
Andea et 
al. 2008 
[316]  
156 Absent=81(53%)           
Present non-dense=55(36%) 
Dense=17(11%)  
Present non-dense and 
Dense associated with 
longer survival in 
univariate analysis.  
Nodular growth pattern, 
low tumour depth, and 
absence of lymphovascular 
invasion associated with 
longer survival on 
multivariate analysis. 
Paulson et 
al. 2011 
[311] 
130 Not identified=44(34%)   
Non-brisk/Brisk=86(66%)  
Intratumoural CD8+ was 
independently associated 
with improved survival 
in multivariate analysis. 
  
Overall TIL infiltration was 
associated with better 
prognosis on univariate but 
not multivariate analyses.  
Sihto et 
al. 2012 
[313] 
116 Numbers of intratumoural 
CD3+, CD8+, CD16+, 
FoxP3+, and CD68+ cells 
(IHC) per 1 high power field  
High CD3+, CD8+, 
FoxP3+ cells, high 
CD8+/CD4+ or 
FoxP3+/CD4+ ratios, 
significantly associated 
with favourable overall 
survival.  
Numbers of T cells are 
generally higher in MCV+ 
than in MCV-ve MCC, 
high intratumoural T cell 
counts also associated with 
favourable survival in 
MCV-ve MCC.   
Paulson et 
al. 2014 
[317] 
137 Intratumoural CD8+ 
lymphocytes analysed. 
Absent (n=46), low (n=85), 
moderate/strong (n=6) 
3 year MCC-specific 
survival: 
Moderate/strong 100%                    
Low 72%                                            
Absent 56% 
Increased intratumoural 
CD8+ infiltration 
associated with improved 
MCC specific survival 
independent of stage, age 
and sex. 
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The finding that T cells can often be “stalled” at the periphery of MCC tumours suggests that 
there may be active inhibitory mechanisms at play, of which there are a number of possible 
mechanisms. MCC tumour cells may establish a local immunosuppressive microenvironment 
in order to thrive by produce immunosuppressive cytokines, such as TGF-β, molecules such 
as Fas-L, or inhibiting T-cell responses through production of galectin-1 and indoleamine 2,3-
dioxygenase (IDO) [318, 319]. 
MHC Class I expression is down-regulated alongside other components of cellular antigen–
presenting machinery such as the TAP, in a large number of MCV+ MCC tumours through an 
as yet unidentified mechanism. This leads to the inability of CD8 T cell to identify tumour 
cells through lack of presented antigen and as such they can evade immune control [320].  
T cells can also be inhibited from infiltrating the tumour through down-regulation of 
appropriate tissue-specific T-cell homing signals. In MCC cases where intra-tumoural T cell 
infiltration is poor, this may be due to the down-regulation of vascular E-selectin through 
production of nitric oxide by the tumour [321]. This means that T cells expressing CLA, a 
skin-homing adhesion molecule which binds E-Selectin, will not adhere to the endothelium 
and so not be able to enter the skin to infiltrate the tumour. Lastly, other suppressive T cell 
populations, such as Tregs may inhibit CD8 anti-tumour responses.  The role of these in MCC 
is not known, but both positive and negative outcomes have been associated with their 
presence and so the situation remains unclear [313, 322]. 
Since it has been hypothesized that CD8 T cells may be important as anti-tumour effectors, 
some work on the potential epitopes against which these responses may be directed has been 
conducted, focusing on the MCV T-antigen, commonly expressed in a truncated form by 
MCC tumours.  In the previously described paper by Iyer et al in which the original CD8 
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HLA A:24 LT epitope (EWWRSGGFSF) was found, transfection of LT and HLA:A24 into 
the Cos7 cell line proved that this epitope was capable of being processed and presented by a 
model cell line. Additionally it was shown that Cos7 cells expressing LT could be killed by 
the LT-epitope specific T cells derived from TIL [304]. Furthermore, T cells specific for the 
HLA-A2 LT epitope KLLEIAPNC (aa 15-23), after in vitro expansion, were able to lyse cells 
from the HLA-A2 MCV+ MCC cell lines MKL-2 and WaGa, importantly indicating that at 
least some MCC tumour cells are likely to be able to process and present antigen to CD8 T 
cells thus increasing the evidence that T-antigen specific T cells may exert an anti-tumour 
effect [306].  
The functionality of CD8 T cells in vitro does not always mirror what the in vivo situation. 
Indeed, in the HLA:A24 patient from whose TIL the EWWRSGGFSF-specific T cells were 
discovered, 20% of HLA:A24 tetramer binding tumour infiltrating cells produced IFNɣ in 
comparison with only 2% of cells from the peripheral blood. In four other HLA:A24 patients, 
two did not have a tetramer positive cell population, while from the other two in whom a 
tetramer binding CD8 response was detected, these cells failed to produce IFNɣ following 
peptide stimulation [304].  
Recently, it has been confirmed that MCV epitope specific CD8+ T cells in MCC patients 
express inhibitory markers PD-1 and TIM-3 [305]. The interaction of programmed death 
(PD)-1 expressed on T cells with its ligand or PD-L1 is an potentially important mechanism 
of T-cell inhibition that could be mediating this problem [322]. In one study, PD-L1 
expression by MCV+ MCC tumour cells or by tumour infiltrating lymphocytes was seen in 
49% and 55% of patients respectively with MCV negative tumours appearing to be uniformly 
negative for PD-L1 expression. All tumours with moderate or strong T cell infiltration were 
associated with PD-L1 expression particularly concentrated around areas of lymphocyte 
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infiltration [323]. It is known that chronic viral antigen exposure often leads to the 
development of an inhibitory T cell phenotype with poor effector function and sustained 
expression of inhibitory receptors [324, 325]. Whether MCV infection is capable of driving 
this process in MCC is not yet known although the observed higher MCV viral load on the 
skin of MCC patients as compared to the general population may suggest MCC patients are 
exposed to increased levels of viral antigens [271]. The targeting of the PD-1/PDL-1 axis 
therapeutically to overcome T cell inhibition has been widely tested recently, most 
successfully in melanoma [326]. Very recently a phase 2 clinical trial utilising a PD-1 
antibody, pembrolizumab, to treat 26 MCC patients with advanced disease was associated 
with a response rate of 62% in patients with MCV+ MCC [327]. This strongly suggests that 
immune-modulating therapy that enables improved T cell anti-tumour responses are of benefit 
to MCC patients and underlines the importance of T cell immunity in this cancer. 
 
1.11 Project Aims 
As we have described, MCV is a common skin-associated virus that leads to asymptomatic 
infection in the majority of healthy adults. The MCV-associated cancer, MCC, is rare and 
appears to be strongly linked with immunosuppression and the loss of MCV-directed immune 
control.  
The first aim of this project is to further investigate the clinical finding that although 
immunosuppression is a risk factor for development of MCC, the majority of MCC patients 
have no known immune dysfunction.  MCC patients are known to have higher levels of MCV 
antibodies than healthy controls. However, an assessment of levels of antibodies against other 
polyomaviruses, particularly those that have been more recently discovered, has not been 
  Chapter 1: Introduction 
61 
 
conducted. There has also been little work looking at these same antibody responses in 
healthy donors or in patients at a higher risk of developing MCC. To address this issue and 
with help from our collaborators in Germany, we will firstly assess the serum of a cohort of 
MCC patients for the presence and size of antibody responses against a number of members 
of the polyomavirus family. We will then directly compare these with antibody responses 
from a healthy control group, an elderly but otherwise healthy group, patients with a history 
of NMSC and patients with CLL. These results will potentially help clarify two important 
issues. Firstly, whether the increase in MCV antibody levels seen in MCC patients is a 
phenomenon generalizable to other polyomaviruses suggesting that the loss of MCV viral 
control seen may also be occurring with other similar viruses and reflects an underlying 
problem with polyomavirus-directed immunity in these patients. By assessing the same 
antibody responses in the other donor cohorts mentioned, we can see if those donors who 
have risk factors for developing MCC, such as ageing, sunlight exposure and immune 
dysfunction, share any similarity in terms of antibody responses with MCC patients that may 
help further explain how these risk factors are linked with the development of MCC. 
Next, using blood samples from MCC patients and NMSC patients with no history of 
immunosuppression, we will perform a broader analysis of their peripheral immune function 
to see if there are differences in the MCC cohort that will explain why these patients have 
developed MCC. To do this we will measure a number of immune parameters including the 
frequency of T and B cell subsets, assess the proliferation response to a mitogenic stimulus 
and look at antibody levels both in general and also at levels specific for various vaccine 
antigens. 
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The second aim of this project focuses on T cell immunity against MCV, driven by increasing 
evidence that T cells specific for the MCV T-antigen may have an important role not only in 
controlling viral infection but also as a potential therapeutic agent in the treatment of MCC. 
Currently, our knowledge of the T cell response against MCV in healthy patients is very 
limited and in particular, to our knowledge, no attempt has been made to characterise the T 
cell response against epitopes on the entire breadth of the T-antigen expressed by the wild 
type replicating virus. 
We intend to characterise the T cell response, in healthy donors of known MCV serostatus, 
against the MCV T-antigen to assess the frequency of specific cells as well as the regions on 
the T-antigen they are specific for. This can then be compared with a similar characterisation 
of MCV T-antigen responses in both MCC patients alongside an age-appropriate control 
cohort of NMSC patients. Differences in either size or targets of responses between the 
cohorts can then be examined to see if there are any clear changes in the MCC group that help 
explain why viral control was lost.     
After identifying MCV-specific T cells in our donors from these initial screening experiments, 
we will define a repertoire of T-antigen epitopes and characterise the epitope-specific T cells 
by establishing T cell clones from these same donors. Following the discovery of any CD8 
epitopes, we will use tetramer analysis to allow us to characterise the phenotype of ex-vivo 
MCV-specific cells, particularly focusing on the differentiation status and tissue-homing 
profile of these cells. We will also assess whether these MCV-specific T cells are capable of 
recognising antigen presenting cells expressing the T-antigen, the first step in determining 
whether such cells will have any therapeutic utility. 
  Chapter 1: Introduction 
63 
 
Lastly, both viruses and cancer utilise mechanisms to evade T cell immunity and the presence 
of these may be important in determining whether T cell directed treatments would have 
clinical beneficial. Of particular interest is the potential role that the T-antigen viral proteins 
that are expressed by MCC may play in this.  To investigate this we will focus on assessing 
the effects that these proteins may have on T cell recognition through the individual 
transfection of wild type LT, tumour-associated forms of LT and sT into model cell lines as 
well as looking at any changes these proteins may have on MHC Class I and II expression. 
This introductory work may help uncover mechanisms that the virus uses to evade T-cell 
recognition which, through the expression of these same proteins by MCC, may also have an 
importance within the tumour environment.  
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Chapter 2  
Materials and Methods 
2.1 Patients and blood/tissue preparation 
Patients: Peripheral blood was donated by patients with Merkel cell cancer (MCC) or non-
melanoma skin cancers (NMSC) recruited from skin oncology clinics at Queen Elizabeth 
Hospital, Birmingham, UK. Clinical information was obtained through a combination of 
patient interview and retrospective case note review. Healthy donors were recruited from 
University employees. Written informed consent was obtained before venepuncture All 
experiments were undertaken with ethical approval from the Trent Local Research Ethics 
Committee (Reference number: 08/H0405/59).The serum from MCC patients collected prior 
to 2012 was carried out by Prof David Blackbourn and Dr Neil Steven within the currently 
held ethical approvals. The serum samples from Chronic Lymphocytic Leukaemia (CLL) and 
elderly healthy donors were collected by Dr Helen Parry and Prof Paul Moss as part of her 
PhD thesis and were approved by the South East Wales Research Ethics Committee.  
 
Peripheral blood mononuclear cell (PBMC) preparation: PBMCs were obtained from 
peripheral blood collected either by venepuncture into heparinised vacutainer tubes, or from 
buffy coat preparations (National Blood Service). Blood donations were diluted 1:1 in RPMI-
1640 media and then layered onto Lymphocyte Separation Media (PAA) before centrifugation 
at 1600 rpm for 30 minutes, with no brake applied. PBMCs were aspirated from the density 
gradient interface with a Pasteur pipette and then washed thrice with RPMI-1640. The 
PBMCs were then counted with a haemocytometer and were either used fresh or if being 
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stored were divided into 5x106 cell aliquots, pelleted and then re-suspended in freezing 
medium and cryopreserved.  
 
HLA typing: The HLA status of the majority of healthy donors was already known. In cases 
where further typing was necessary, this was confirmed through PCR-based DNA typing 
conducted at the Anthony Nolan Trust, Hampstead, London. 
 
Serum collection: Serum was collected by allowing heparinised or EDTA blood tubes to 
stand for 20 minutes at room temperature and then aspirating the resulting layer of straw 
coloured fluid, centrifuging this at 2000rpm for ten minutes and then transferring the resultant 
supernatant to a fresh 1.5ml eppendorf tube for storage at -20oC.  
 
Cryopreservation of cells and recovery of cryopreserved cells: Cells to be stored were 
pelleted by centrifugation at 1800rpm for 7 minutes before the supernatant was tipped off and 
the cells were re-suspended in 1ml of freezing medium (RPMI-1640/20% FCS/10% DMSO). 
The cells were then immediately transferred into sterile 1.5ml cryovials (Nunc) and stored in a 
Mr Frosty (Nalgene), containing isopropanol. Initially this was placed in -80oC freezer but for 
longer-term storage, cells were transferred into liquid nitrogen tanks. Cells were thawed from 
storage by placing cryovial in a 37oC water bath and then transferring the cells into a 15ml 
tube (Corning) followed by the slow addition of 10mls of media. The cells were then pelleted 
by centrifugation at 1800rpm for 7 minutes and re-suspended in the media for onward use. 
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Tumour lymphocyte extraction: Freshly resected MCC tumour was taken directly from 
operating theatre and excess tissue not required for diagnostic purposes was placed into cold 
standard cell culture media and put on ice. The sample and media was then placed in a sterile 
petri dish within a tissue culture hood and diced into small pieces using disposable scalpels. 
The petri dish contents was then aspirated using a Pasteur pipette ensuring all cells removed 
and contents put into a MACS C-Tube (Miltenyi). This was then placed on a gentleMACS 
cell dissociator (Miltenyi) and spun on programme “mouse-spleen 4”. The homogenised 
tissue and media were then placed through a fine sterile mesh and washed through with cold 
RPMI-1640. For Class I/Class II assessment, cells were stained for flow cytometry at this 
point as described in relevant section. For lymphocyte isolation, the collected filtrate 
(approximately 50mls) was added to a 50ml tube and centrifuged for 7 minutes at 1600rpm, 
room temperature. During this stage, a layered Percoll (GE Healthcare) gradient was set up in 
a 15ml tube with 4mls of 30% Percoll (diluted with sterile 10x PBS) carefully layered on top 
of 4mls of 70% Percoll. The pelleted cells were re-suspended in 4mls of cold RPMI-1640 and 
layered on top of the Percoll and centrifuged at 1600 rpm for 30 minutes with no brake 
applied. The cell layer at the 70%:30% interface was carefully aspirated as the lymphocytes 
and a portion were frozen down for storage while the rest was plated in 24 well plates and 
stimulated with MCV-specific peptides using the same method described below to generate 
polyclonal T cell cultures.  The remaining cells at the other interfaces in the tube were also 
either stored or cultured as “tumour cells”. 
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2.2 Serological assays 
 
Polyomavirus VP-1 and T-antigen seroresponses:  This was possible only through 
collaboration with Dr Tim Waterboer, German Cancer Research Center (DKFZ), Heidelberg, 
Germany. Serum samples from MCC patients, NMSC patients, CLL patients, Healthy elderly 
and healthy young donors were all sent for analysis. Samples were anonymised and no 
clinical data including diagnosis was sent. VP-1 and T-antigen seroresponses were quantified 
for ten polyomaviruses using a previously described fluorescent bead-based multiplex assay 
[181]. Raw assay data was returned, matched to correct patient/donor and then analysed 
statistically using Prism 6.0 software (Graphpad). 
 
CMV serology: An in-house CMV IgG ELISA assay was used in order to assess CMV 
serostatus, by the presence or absence of CMV-specific antibodies, as previously described 
[328]. All reagents were generously donated by Prof. Paul Moss.  Mock and UV-inactivated 
CMV-infected cell lysates were coated onto 96-well MaxiSorp plates (Nunc) at 1/4000 
dilution and incubated overnight at 4oC. The following day the plates were thoroughly washed 
before serum samples were diluted to 1:600 and added in duplicate wells to both the CMV-
lysate and mock-lysate coated plates for 1 hour. Standards made from a mixture plasma 
samples from 3 CMV-positive donors were also plated in parallel. After three washes with 
PBS/0.05% Tween 20, the anti-human IgG-horseradish peroxidase secondary antibody (HRP) 
was then added to the wells for one hour. After further washing, TMB (3, 3′, 5, 5′-
tetramethylbenzidine) substrate was added and the plate incubated in the dark for 10 minutes 
before adding 1 M HCl. The plate was read using an ELISA plate reader at 450 nm (Bio-rad). 
To determine CMV antibody levels, mock values were first subtracted from lysate values. The 
data were then analysed using statistical software Prism Version 6 (GraphPad), and CMV 
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titres were calculated with reference to the standard curve. Donor serum with a calculated titre 
greater than ten were considered to be seropositive.  
 
Serum Immunoglobulin G,A,M and functional antibody measurements: Serum Ig G,IgA 
and IgM were measured by the staff at the Clinical Immunology Service, University of 
Birmingham using a Roche HITACHI Cobas®6000, with Roche IgG, IgA and IgM reagent 
kits as per manufacturer’s instructions. Antibody measurement against a variety of common 
bacterial antigens (pneumococcal (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F 
and 23F), tetanus, diphtheria, haemophilus influenza B) was undertaken by a previously 
described multiplexed bead based assay [329]. The definitions of protective antibody 
concentrations used have been previously published and are the standards used in the 
laboratory [330-332]. 
 
2.3 Tissue culture reagents 
 
Cell lines: Lymphoblastoid cell lines (LCLs), MelJuSo (MJS) cells and MCC tumour cell 
lines (MKL-1 and MCC13) were used in this work. MCC tumour cell lines were a kind gift 
from Prof Adrian Whitehouse, University of Leeds. In addition MJS cells stably transfected to 
express HLA-DR51 were also used in some experiments (kind gift from Dr Jianmin Zuo, 
University of Birmingham) 
 
RPMI-1640 supplemented with 2mM L-glutamine (Sigma) was stored at 4°C and used for 
washing cells and as part of the media used in the culture of all cells used in this thesis.  
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Foetal calf serum (FCS, PAA Laboratories) was stored at -20°C in 50ml aliquots until use. 
Once an aliqout was thawed, it was kept at 4oC. 
 
Penicillin-streptomycin solution (P/S, Invitrogen) contained 5000IU/ml penicillin and 
5000 µg/ml streptomycin and was used at a final dilution of 1/100 in culture medium.  
 
Opti-MEM1 (Invitrogen) was stored at 4°C and used for cell transfections. 
 
Phosphate buffered saline (PBS) was made by dissolving one Dulbecco A tablet 
(Oxoid) per 100ml of distilled water; and was autoclaved if required. 
 
Recombinant interleukin-2 (IL-2, Peprotech) stored at -20oC and used at 50 IU per ml. 
Lymphocyte Separation Media (PAA) was stored at 4oC. 
 
Human serum (HuS, PAA) was virus and mycoplasma free and stored in 50ml aliquots at    -
20C until use, after which it was stored at 4oC. 
 
MLA-144 supernatant (MLA) The gibbon cell line MLA-144 is an established IL-2 
secreting cell line used to stimulate T cell growth. These non-adherent cells were maintained 
in standard culture media for 2 weeks without feeding, after which supernatant was harvested 
after centrifugation at 1600rpm for 10mins and then sterile-filtered through steritop 0.22µm 
filter (Millipore) by vacuum suction. The filtered MLA was stored at -20oC in 60ml aliquots. 
 
  Chapter 2: Methods 
70 
 
Synthetic peptides: Peptides that spanned the full length of MCV LT and sT-antigens 
(sequence from Merkel cell polyomavirus isolate 206, Accession number: FJ173812) were 
synthesised (Alta Bioscience). Each peptide was 15 amino acids in length and overlapped 
each other by 10 amino acids. These were each dissolved in dimethyl sulfoxide (DMSO, 
Sigma) for 30mins at RT and then stored at -20oC.  
The resulting 185 peptides were split into five pools of 35-40 peptides (for NMSC/MCC 
patient ELISpots) or 16 pools of 10-12 peptides (healthy donor ELISpots) and used at a final 
concentration of 5µg/ml.  Further individual peptides were ordered as necessary from Alta 
Bioscience and treated using these same methods. 
 
Biuret assay: This was used to determine the concentration of dissolved peptides. Twenty µl 
of each peptide solution was added to 100µl biuret reagent (Sigma) in 96-well V-bottom 
plates (Nunc). In order to allow calculation of peptide concentrations, duplicate wells of 
bovine serum albumin (BSA, Sigma) standards ranging from 0 to 40mg/ml were also 
included. The plates were incubated for 30 minutes at room temperature to allow colour 
development before being centrifuged at 1300rpm for 5 minutes. One hundred µl of 
supernatant from each well was then transferred into 96-well flat bottom plate (Nunc), and the 
absorbance was measured at wavelength of 540nm using an automatic microplate reader (Bio-
Rad).  
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2.4 Culture media recipes 
 
Standard culture medium: was used as standard media for culturing LCLs and MJS cells. It 
was made up of RPMI-1640 + 10% FCS + 50IU/ml penicillin + 50ug/ml streptomycin. Non-
adherent cells were split once or twice a week by removing half of the culture and replacing 
with fresh media. Adherent MJS and MCC13 cells were split by careful removing of media so 
as not to disturb cells, twice washing with 5ml sterile PBS which was removed before careful 
addition of approximately 1ml of 1x Trypsin-Express (Gibco). Flask was then gently tapped 
until become non-adherent and then re-suspended in standard culture media of which 1/10 
was transferred to a new flask which was then topped up with fresh media as appropriate.    
 
T cell cloning medium: was used during routine T cell feeding and T cell cloning 
experiments. As standard it was made up of RPMI, 30%MLA-144 filtered supernatant, 
10%FCS, 1%HuS, 1%Pen/Strep and 10IU/ml IL-2.  When used for T-cell cloning, the media 
was supplanted with anti-CD3 antibody (30ng/ml, eBioscience). 
 
Mycoplasma Testing: Testing for presence of mycoplasma infection in cell cultures was 
kindly performed by Mr Gordon Ryan, University of Birmingham on a regular basis using the 
MycoAlert Mycoplasma detection assay kit (Cambrex) according to the manufacturer’s 
instructions. 
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2.5 Immunological techniques 
 
Thymidine Incorporation Proliferation assay: Lithium-heparinised whole blood was 
diluted 1:5 with RPMI-1640 and added in triplicate to wells of a 96-well plate containing 
media with phytohaemagglutinin (PHA) to give a final concentration 25µg/ml, or media 
alone. Plates were placed in a humidified incubator at 37oC, 5% CO2 for 72 hours before 
addition of 0.5µCi 3H–Thymidine/well. After 6 hours, plates were stored frozen at -20oC.  
Following this, cells were thawed to room temperature and harvested onto glass fibre filter 
paper using a Skatron cell harvester and read using Beta scintillation counter with results 
given as counts per minute. The mean count was calculated from the triplicate values of PHA-
stimulated and un-stimulated counts and fold change assessed by dividing mean PHA-
stimulated value by mean media alone values.  
 
IFNɣ Enzyme-linked Immunospot (ELISpots): These assays were conducted using PBMCs 
freshly isolated from healthy donors, MCC patients and NMSC patients. The day prior to 
venepuncture, 20µl of 70% ethanol was added to each well of the ninety-six well plates (EMD 
Millipore) with Immobilon-P polyvinylidene difluoride membranes. The ethanol was left for 
one minute, flicked off and then the plate washed twice with 150µl filtered PBS. The PBS 
was flicked off and the plate coated with 50µl of monoclonal antibody 1-D1K (Mabtech) 
diluted to 7.5ug/ml in filtered PBS, ensuring the bottom of each well was fully covered. The 
plate was left overnight at 4oC. The following day, after PBMCs had been prepared, the 1-
D1K antibody was flicked off and the plate washed six times with 150µl RPMI.  After the 
final wash, the plate was then blocked with 150µl of filtered RPMI-1640/10% FCS added to 
each well and left at room temperature for two to four hours. PBMCs were then made to a 
density of 5 x 106 cells/ml with filtered RPMI-1640/10% FCS.  The RPMI-1640/10% FCS 
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block was flicked off the plate and PBMCs plated out at 100µl/well (so achieving 0.5x106 
cells/well). Then 10ul of peptide pools (made up as described above) were added to the 
appropriate wells alongside the negative control dimethyl sulfoxide (DMSO) and the positive 
controls, 5µg/ml Phytohaemagglutinin (PHA) and also in the MCC/NMSC patient assays, 
2µg/ml of the pre-made CMV, EBV, Flu (CEF) peptide mix (Mabtech).  The plates were 
incubated overnight at 37oC 5% CO2. The following day, the cells from the plate were flicked 
into virkon and the plate washed with 150µl filtered PBS/0.05% Tween 20. To each well, 
50µl of 1µg/ml biotinylated monoclonal antibody 7-B6-1 (Mabtech) were added before 
leaving the plate at room temperature for 2-4 hours. The plate was then washed six times with 
PBS/0.05% Tween 20 again before addition of 1:1000 dilution of Streptavidin-Alkaline 
Phosphatase (Mabtech) and further incubation at room temperature for 1-2 hours. After a 
further six washes, the chromogenic substrate 5-bromo-4chloro-3-indolyl phosphate and nitro 
blue tetrazolium (BioRad) was added to the wells and the plate incubated in the dark for 15 
minutes to 1 hour. After the appearance of spots representing individual IFNɣ secreting T 
cells the reaction was stopped by washing the plate with tap water. When dry, the number of 
spots was quantified automatically with the AID automated ELISpot reader and data 
transformed to give the number of spot forming cells 106 PBMC. 
 
Generation of polyclonal T cell cultures:  In order to expand MCV T-antigen-specific T 
cells from the blood of healthy donors, a previously developed protocol [333] was used in 
which polyclonal PBMC cultures were established by pelleting 1-106 PBMCs and then 
stimulating them through the addition of the MCV T-antigen peptide pools (5µg/ml) for 
ninety minutes at 37oC/5%CO2, re-suspending cells every twenty minutes. The cells were 
then washed in RPMI-140 before culturing for 7 days in cell culture media containing 
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25ng/ml of IL-7 (Peprotech) in a 24-well plate (Iwaki). On days 3 and 6 of culture, 
recombinant IL-2 was added to a final concentration of 10 IU/ml.  
 
IFNɣ capture enrichment of MCV-specific T cells   On day 7 of culture, the polyclonal T 
cells were re-stimulated with the MCV T-antigen peptides (5µg/ml) for one hour (re-
suspending every 15 minutes), washed and then incubated at 37oC/5%CO2 for three hours in 
RPMI-1640/5% human serum. The IFNγ Secretion Assay–Cell Enrichment and Detection Kit 
(Miltenyi) was then used to increase yield of MCV T-antigen specific T cells. In brief, the 
cells were initially washed in MACS buffer (PBS, 1% BSA and 2mM EDTA) before re-
suspension in 80µl of RPMI/10% FCS with 20µl of IFNɣ-catch reagent. The cells were 
incubated on ice for 5mins, and then 10mls of warm RPMI-1640/10% FCS was added and 
incubated at 37oC for 45mins on a cell roller. After a further wash in MACS buffer, the cells 
were re-suspended in 80µl of MACS buffer with 20µl of IFNɣ-detection antibody added. 
After ten minute incubation on ice, the cells were washed and re-suspended in 80µl of MACS 
buffer with 20µl of magnetic microbeads. The cells were then kept at 4oC for 15mins, shaken 
every five minutes). Finally, the cells were washed once more and re-suspended in 500µl of 
MACS buffer before being applied to a MACS MS column (Miltenyi) within a magnetic 
field. After washing as per manufacturer’s instructions, the column was removed from the 
magnetic field and the retained labelled cells collected by flushing the column with 1ml of 
MACS buffer. The cells were then counted using a haemocytometer ready for use in limiting 
dilution cloning. 
Limiting dilution cloning  The T cells collected following IFNɣ enrichment were seeded at 
0.3, 3 and 30 cells per well in 96-well round-bottom tissue culture plates (Iwaki). This was 
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done in a total volume of 100µl per well of T cell cloning media containing 105 cells/well 
irradiated (4000 rads) mixed allogeneic buffy coat feeder cells that had been activated 
overnight with 10µg/ml phytohaemaglutanin (PHA). Alongside this the anti-CD3 monoclonal 
antibody OKT3 (eBioscience) was also added at 30 ng/mL. After one week, a further 100µl of 
standard T cell medium was added to each well. 
 
Identification of peptide specific clones:  After two to three weeks, visual assessment of 
proliferating microcultures was conducted and a small aliquot of cells (approx. 20µl) was 
taken from wells in which the cell pellet had enlarged. These cells were then screened for 
peptide specificity using T cell recognition assay and IFNɣ ELISA as described below. Wells 
containing T cell clones with confirmed MCV peptide specificity were then transferred into 
24 well plates (Nunc) using 1ml/well T cell media and irradiated (4000 rads) buffy coat feeder 
cells (106 cells/well) for expansion. These T cell clones were then maintained in culture by 
feeding twice weekly with T cell media by removing 1ml and replacing this with 1ml of fresh 
media.  
 
 
T cell recognition assays:  To test the ability of T cell clones to recognise targets, autologous 
LCLs were either sensitised with appropriate peptide or with DMSO (negative control) by 
pelleting cells, re-suspending with 5µg/ml peptide or equivalent amount DMSO and 
incubating at 37oC/5%CO2 for 1 hour, shaking every 15 minutes.  LCLs were then washed 
three times with RPMI-1640 and suspended in standard culture medium at a cell density of 
1x106 cells/ml. Then 50µl of these cells were added in duplicate to appropriate wells of V-
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bottom 96-well plates. T cells were then counted and washed in standard culture media to 
give 1x105 cells/ml and 50µl of T cells were added to the LCLs. As a further control, T cells 
were also plated in the absence of LCLs to ensure response was specific. The plates were then 
incubated overnight at 37ºC/5% CO2 ready for IFNɣ ELISA the following day. 
When transfected MJS cells were used as target cells to assess T cell recognition, these 
experiments followed the same above protocol with transfected MJS cells being treated 
exactly as peptide sensitised LCLs.  In such experiments, peptide-sensitised MJS cells 
(5µg/ml) were used as the positive control. 
 
IFNɣ Enzyme-Linked Immunosorbent Assay (ELISA):  IFNɣ ELISA was commonly used 
to quantify T cell recognition. The day before the assay, 96-well MaxiSorp plates (Nunc) 
were coated with 50µl/well of anti-human IFNɣ antibody (0.75ng/ml) (Thermo Scientific) in 
coating buffer (0.1M Na2HPO4, pH 9). The plates were then incubated overnight at 4ºC. On 
the day of the assay, the plates were washed with wash buffer (PBS/0.05% Tween 20) and 
then blocked with 200µl of blocking buffer (PBS/0.05% Tween 20/10% BSA) for two hours 
at room temperature. The plates were then washed five times with wash buffer and then 100ul 
of cell supernatant from the T cell assay was harvested and added to appropriate wells on the 
MaxiSorp plates. To enable quantification of results, doubling dilutions of recombinant IFNɣ 
standard was also plated in triplicate at 100µl/well (Peprotech, 2000pg/ml – 31.25pg/ml). 
Plates were then incubated at room temperature for three to four hours and then washed five 
times with wash buffer. Then 50µl of biotinylated anti-human IFNɣ (3.75µg/ml, Thermo 
Scientific), diluted in blocking buffer, was added to each well and the plates incubated for a 
further hour at room temperature. After a further five washes, 50µl of streptavidin-peroxidase 
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(ExtraAvidin-Peroxidase, Sigma), diluted 1/1000 in blocking buffer, was added to each well 
and plates incubated at room temperature for 30 minutes. The plates were washed eight times 
in wash buffer and then 100µl of the peroxidase substrate (3, 3’, 5, 5’-tetramethylbenzidine 
(TMB) solution, Life Technologies) was added and the plates incubated for up to ten minutes 
to allow for colour development. The reaction was stopped by the addition of 100ul of 1M 
hydrochloric acid, resulting in a soluble yellow product. The plates were then read on ELISA 
plate reader (Bio-rad) using dual wavelengths of 450nm and 695nm. The amount of IFNɣ 
release could be calculated after constructing a standard curve using the values derived from 
the recombinant IFNɣ standards.  
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Table 2.1. List of antibodies used in thesis 
 
 
 
Target Fluorochrome Clone Origin Dilution Manufacturer 
TCRα/β  Vio-blue BW242/412 mouse 1/40 Miltenyi 
CCR4 PE-Cy7 IG1 mouse 1/20 BD 
CCR6 PerCP-Cy5.5 11A9 mouse 1/20 BD 
CLA APC HECA-452 rat 1/10 Miltenyi 
CD4 APC-Cy7 RPA-24 mouse 1/40 BioLegend 
CD8 AmCyan SK1 mouse 1/33 BD 
CD45RA AF700 A100 mouse 1/100 Cambridge Biosciences 
CCR7 FITC 150503 mouse 1/10 R&D Systems 
Propidium Iodide Texas Red N/A N/A 1/20 Miltenyi 
CD4 PE RPA-T4 mouse 1/50 BD Pharmingen 
CD8 PE RPA-t8 mouse 1/50 BD Pharmingen 
HLA-B7 PE BB7.1 mouse 1/20 Merck Millipore 
HLA DR (Class II) APC/PE L243 mouse 1/50 Biolegend 
HLA A,B,C (Class 
I) 
APC/PE w6/32 mouse 1/50 Biolegend 
CD45 V500 30-F11 mouse 1/33 BD Horizon 
IgD V450 IA6-2 mouse 1/33 BD Horizon 
CD45RA V450 HI100 mouse 1/33 BD Horizon 
CD3 APC-Cy7 SK7 mouse 1/33 BD 
CD8 PerCP SK1 mouse 1/33 BD 
CD25 APC 2A3 mouse 1/33 BD 
CD19 APC-Cy7 SJ25C1 mouse 1/33 BD 
CD4 PE L120 mouse 1/33 BD 
CD127 PE-Cy7 HIL-7R-
M21 
mouse 1/33 BD Pharmingen 
CD27 PerCP-Cy5.5 L128 mouse 1/33 BD Pharmingen 
Mouse IgG1  PE MOPC-21 mouse 1/50 BD Pharmingen 
Mouse IgG2a PE G155-178 mouse 1/50 BD Pharmingen 
Rat IgM APC ES26-
13D3.4 
rat 1/20 Miltenyi 
anti-HLA-DR n/a HB-55 mouse 10μg/ml ATCC 
anti-HLA-DQ n/a SPV-L3 mouse 10μg/ml Serotec 
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Determining T cell clone functional avidity: This was calculated by sensitising the T cells 
clone’s LCL with cognate peptide at 10-fold dilutions ranging from 10-5M to 10-11M for 1hr at 
37oC, mixing every 15 minutes. The LCLs were then washed thoroughly before incubating 
with the T cell clone overnight as per standard T cell assay. The amount of IFNɣ secreted by 
the T cells was quantified by ELISA as previously described and the functional avidity was 
defined as the concentration of peptide capable of eliciting 50% maximal IFNɣ secretion. 
 
Determining epitope HLA restriction: This was assessed by collating a panel of LCLs 
which shared one or two HLA-alleles with the donor from whom T cell in question was 
derived. For CD8 epitopes, each LCL was pulsed with the clone’s specific peptide at 5µM for 
1 hour, agitating every 15 minutes. Sensitised LCLs were then washed 4 times with RPMI-
1640, re-suspended in RPMI-1640 medium/10% FCS and incubated overnight with the T cell 
clone in a standard T cell assay. IFNɣ release from the T cells was measured by ELISA. LCLs 
expressing the correct HLA restriction molecule would induce IFNɣ secretion and thus this 
could be identified through a process of elimination. 
For CD4 epitopes, the autologous LCL was sensitised with peptide as above, washed three 
times and then pre-incubated with either anti-HLA-DR, anti-HLA-DQ or no antibody at 
10μg/ml for 1hr (see Table 2.1).  T cells were then added to the LCLs without washing 
antibody off and left overnight in incubator at 37oC/5%CO2. The following day, IFNɣ ELISA 
was performed and if IFNɣ secretion had been inhibited by a blocking antibody, only 
partially-matched LCLs for that particular family of Class II molecule were used to determine 
the exact restricting allele.  
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Protein feeding assay: MKL-1 and MCC13 whole cell lysates were prepared from 2x106 
cells which were pelleted and then applied to a sonicator on ice. Protein concentration was 
measured using a spectrophotometer (Nanodrop). 2x106 LCLs from donors from whom 
MCV-specific CD4 clones had been previously isolated were spun in a centrifuge to form a 
cell pellet before washing and re-suspending in 500 µl of AIM-V media (serum free, Gibco) 
in a 48 well plate (Iwaki). Whole cell lysate was then added to the cells so that final 
concentrations of 400µg/ml and 200µg/ml. These cells were then placed in incubation 
overnight at 37oC and 5% CO2. The next day the cells were washed in RPMI-1640 and then 
used in T cell recognition assay followed by IFNɣ ELISA (as described above) standard T cell 
assays with the appropriate CD4 T cells. 
In cell fixation experiments, LCLs were pelleted and then re-suspended in 1ml 1% 
paraformaldehyde for 10 min followed by quenching with 1ml 0.2 M glycine for 10 min. 
Cells were then washed with PBS twice before being re-suspended in media. For cells fixed 
immediately following feeding with lysate, re-suspension was in AIM-V media. For cells 
fixed 18 hours following feeding with lysate, re-suspension was with standard cell culture 
media. 
 
Modified vaccinia Ankara (MVA) infection assays: MCC tumour cell line cells (both 
HLA-A11+) were infected with a recombinant MVA virus expressing the EBNA3B reporter 
gene or PSC-11 control MVA at a multiplicity of infection (MOI) of 10 for 90 minutes. These 
were then washed three times prior to incubation with EBV antigen specific T cells in T cell 
recognition assay described above. In experiments when cells were exposed to irradiation, this 
was done immediately following MVA infection. 
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Standard flow Cytometry: For determining CD4/CD8 status of T cell clones and Class I/II 
expression levels, flow cytometry was based on the same protocol. 2-3x105 cells were placed 
in 5ml FACS tubes (Falcon) and washed with 2ml of PBS/2%FCS. Tubes were then pelleted 
at 2000rpm for 5 minutes and supernatant tipped off.  The cells were then re-suspended in 50-
100µl of PBS/2%FCS containing appropriate concentrations of flurochrome-conjugated 
antibodies (See Table 2.1).  The tubes were then incubated in the dark on ice for 30mins 
before washing again in 2.5ml of PBS/2%FCS and re-suspended in 200µl of PBS/2%FCS 
and, if to be analysed at a later time, also  200µl of 4% paraformaldehyde (Sigma) in PBS. 
Analysis was conducted using the LSRII flow cytometer (BD Biosciences). 
 
Multi-colour flow cytometric characterisation of peripheral immune cells: EDTA-treated 
whole blood from MCC and NMSC patients underwent immediate erythrocyte lysis with 
ammonium chloride. Cells were then washed in RPMI and stained with a pre-defined panel of 
multi-colour antibodies used routinely within the Clinical Immunology Service for 
investigation of immunodeficiency (See Table 2.1). The cells were incubated, fixed with 
FACS lyse buffer and then washed with CellWash buffer (BD) before being analysed on the 
FACSCanto II flow cytometer (BD) using DIVA software.   
 
Absolute lymphocyte subset cell quantification: This work was carried out by the 
biomedical scientists in the Clinical Immunology Service, University of Birmingham. In brief, 
whole blood in EDTA was added to tubes containing Multi-test 6-color TBNK antibody 
reagent and counting beads (BD) as per manufacturer’s instructions. After incubation with the 
antibodies and beads, erythrocytes were lysed with 1x FACS Lysing solution (BD) and 
  Chapter 2: Methods 
82 
 
samples analysed on FACSCanto II flow cytometer (BD) using DIVA software. The absolute 
lymphocyte count was defined automatically by size appropriate CD45+ cells. Subset counts 
were defined by presence of appropriate markers: T cell (CD3), CD4+ T cell (CD4), CD8+ T 
cell (CD8), B cell (CD19), NK cell (CD16/CD56).  
 
Absolute neutrophil count:  Results from MCC patients were obtained from clinical records 
from blood tests undertaken by hospital clinical haematology laboratory as part of routine full 
blood count that includes a white cell differential measurement. 
 
Tetramer synthesis: Biotinylated monomers were synthesised from appropriate synthetic 
peptides by the Protein Expression Facility, University of Birmingham. For use in flow 
cytometry, monomers needed to be conjugated to the flurochrome, phycoerythrin (PE).  To 
this end, calculated volumes of Streptavidin, R-Phycoerythrin Conjugate (SAPE, 
ThermoFisher) were added in a slow, step-wise manner over approximately 8 hours such that 
the final molar ratio of monomer to streptavidin was 4:1.  
 
Tetramer flow-cytometry staining: In order to characterise tetramer-specific cells, a two-
step staining procedure was conducted. Initially, 5x105 PBMCs from appropriate donors were 
washed with PBS/2%FCS and pelleted with centrifugation at 1600rpm for 5 minutes. 
Supernatant was then tipped off completely and the cells were re-suspended in 50µl PBS/2% 
FCS containing 1/50 dilution of fluorochrome-conjugated tetramer. These tubes were then 
placed in an incubator at 37oC/5% CO2 for 15 minutes.  Cells were then immediately washed 
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with 2mls of ice-cold PBS/2%FCS, centrifuged as before and supernatant tipped off. While 
the tubes remained on ice, further multi-colour antibodies were added as previously 
mentioned and left for 30 minutes on ice in the dark. The cells were then washed once more 
and re-suspended in cold PBS/2%FCS and kept on ice until analysed on the LSRII flow 
cytometer (BD Biosciences).    
 
Cell surface MHC Class I and Class II levels following IFNɣ or irradiation: To assess the 
impact that IFNɣ had on up-regulating MHC Class I and Class II expression on the cell 
surface of MKL-1 and MCC13 tumour cell lines, 0.3x106 cells were plated in standard culture 
media in duplicate wells of a 24 well plate (Iwaki). Additionally, healthy donor-derived 
fibroblasts (kind gift from Andrew Hislop) were also used to act as positive control. For each 
tested cell line, to one well was added 200ng/ml recombinant IFNɣ (Peprotech) and to the 
other media alone. The plates were incubated at 37oC/5%CO2 for 96 hours before harvesting. 
MKL-1 cells were non-adherent and so just aspirated after mixing while MCC13 cells 
required trypsinisation. Harvested cells were then washed twice with PBS/2%FCS  before 
being split into three aliquots, one for staining with fluorochrome-conjugated Class I 
antibody, another with fluorochrome-conjugated Class II antibody and the third for staining 
with isotype control (See Table 2.1). Cells were stained and analysed on LSRII flow 
cytometer as previously described. 
To assess the impact of irradiation on the same surface markers, MKL-1, MCC13 and MJS 
cells were split into three 25cm2 flasks in standard culture media each and incubated 
37oC/5%CO2. After cell populations had grown to near confluence, flasks from each cell line 
were exposed to 0Gy (not irradiated), 4Gy or 10Gy irradiation using the ɣ-irradiator (BMSU, 
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University of Birmingham). Following appropriate irradiation, cells were harvested and 
stained for Class I, Class II and isotype control as before. 
 
2.6 Molecular biology reagents and techniques 
 
LB Media LB (Luria Broth) was prepared by dissolving 20g/L of LB powder (Invitrogen) in 
sterile distilled water and then then sterilised by autoclaving at 121ºC for 20 minutes. 
 
LB Agar was prepared by dissolving 20g/L of LB agar powder (Invitrogen) in sterile distilled 
water and sterilised by autoclaving. 
 
Ampicillin (Roche) was used at a final concentration of 100µg/ml in LB agar and LB media 
for use in molecular gene cloning techniques 
 
MCV gene expression plasmid construction: A codon-optimised MCV wild-type LT 
(WTLT) DNA sequence (from MCV344 strain, Accession number: FJ173806) was 
synthesised and cloned into entry vector plasmid pDONR221 (Geneart, Invitrogen). DNA 
was extracted from 2x106 MKL-1 cultured cell line cells using a Nucleospin Tissue DNA 
extraction kit as per manufacturer’s guidelines (Machery-Nagel). MCV350 DNA was derived 
from the pcDNA3.MCV350 plasmid originally synthesised by Moore and Chang [42] and 
made available via the AIDS reagents programme. sT DNA was originally extracted from the 
pcDNA3.MCV350 plasmid but was found to have an C>T substitution mutation at aa 898 
leading to amino acid change from leucine to proline compared to the original deposited 
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sequence. Subsequently, sT-GFP plasmid DNA was used (kind gift from Professor Adrian 
Whitehouse, University of Leeds) which was found not to contain this mutation. 
Between 50-100ng DNA was used from each source in polymerase chain reactions (PCR) in 
order to amplify WTLT, MCV350 LT, MKL-1 LT and Small T (sT). The primers used in 
reactions (Sigma-Aldrich) are documented in Table 2.2. To facilitate later ligation into vector 
plasmid, appropriate restriction sites were engineered to the 5’ and 3’ DNA fragements as 
shown in the table. As both MCV350 LT and MKL-1 LT DNA were derived from genomic 
DNA and are encoded by 2 separate exons, each exon was amplified individually and then 
being joined together by a further PCR step. 
 
Table 2.2 Primer sequences used in molecular gene cloning 
DNA fragment 
amplified 
5’ primer (additional 
restriction site) 
3’ primer (additional 
restriction site)  
Fragment 
size 
Template DNA source 
WT LT ttgcggccgcttgccgccatgga
tttagtcctaaata (Not1) 
gctgcggccgcctttattgagaaa
aagtaccagaat (Not1) 
2482 pDONR221.LT 
MCV350LT/MKL-
1 LT exon 1 
gaagaattcgccgccatggattt
agtcctaaatag (EcoR1) 
tatataggggcctcgtcaacctca
tcaaacatagagaagt (N/A) 
261 pcDNA3.MCV350 
MCV350LT exon 2 gttgacgaggcccctatatatgg
gaccactaaattcaaag 
(EcoR1) 
cgtgcggccgcgtactaatctgta
aactgagatg (Not1) 
569 pcDNA3.MCV350 
MKL-1 LT exon 2 gttgacgaggcccctatatatgg
gaccactaaattcaaag 
(EcoR1) 
cgtgcggccgcgtactatagctta
tatacagcat (Not1) 
785 MKL-1 cell line DNA 
MCV350 LT gaagaattcgccgccatggattt
agtcctaaatag (EcoR1) 
cgtgcggccgcgtactaatctgta
aactgagatg (Not1) 
774 MCV350LT exon1+2 
MKL-1 LT gaagaattcgccgccatggattt
agtcctaaatag (EcoR1) 
cgtgcggccgcgtactatagctta
tatacagcat (Not1) 
990 MKL-1 LT exon 1+2 
sT gaagaattcgccgccatggattt
agtcctaaatag (EcoR1) 
gaggcggccgcagtctagaaaag
gtgcagatg (Not1) 
590 sT-GFP 
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PCR recipe was made as follows using Pfx DNA polymerase kit (Invitrogen) into PCR 
reaction tubes. 
Component Volume Final concentration 
10x PFX amplification buffer 5µl 1x 
10mM dNTP 1.5µl 0.3mM each 
50mM MgSO4 1 1mM 
5’ and 3’ primers (10mM each) 1.5µl 0.3µM each 
Template DNA (50-100ng) >1µl As required 
Pfx DNA polymerase 0.4µl 1 unit 
Distilled water To 50µl total volume  
 
The sample was denatured at 94oC for 5 minutes before undergoing 30 cycles of PCR 
amplification (Denaturing: 94oC, 15s→ Annealing: 65oC reducing to 60oC by 1oC per cycle 
for 5 cycles, 30s each→ Extension 68oC, 1min per kilobase of DNA).  
 
DNA ligation: MCV genes were to be inserted into the plasmid vector pcDNA3-IRES-NLS-
GFP (kind gift from Eric Reits, Netherlands Cancer Institute) through the use of EcoR1 and 
Not1 restriction sites. The MKL-LT, MCV350 LT and sT contained neither of these sites and 
so EcoR1 (5’) and Not1 (3’) were added as described above. The WTLT contained an EcoR1 
site within the gene sequence and so Not1 sites were used at both 5’ and 3’ ends. The MCV 
DNA fragments and the pcDNA3-IRES-NLS-GFP were cut in a large scale restriction digest 
using both EcoR1 (Roche) and Not1 (Roche) or just Not1 in the case of WT LT (Mix: 10µl 
DNA, 20U each restriction enzyme, 5µl Buffer H (Roche), 10µl Tris-HCl, made to 50µl with 
nuclease-free water). After 2 hours digestion in water bath at 37oC, 5µl loading buffer was 
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added to each sample and these were run on a 1% agarose gel for 1 hour. Appropriate size 
fragments were cut from the gel using a scalpel and then DNA extracted using a gel extraction 
kit as per manufacturer’s guidelines (Machery-Nagel). The insert and vector DNA were then 
mixed in a 3:1 molecular ratio with Quick T4 DNA Ligase and 2x Ligase buffer as per 
manufacturer’s instructions (New England BioLabs). After five minutes incubation at room 
temperature, ligated DNA was used to transform competent bacteria as detailed below. 
 
Transformation of competent bacteria: In order to amplify ligated plasmids, competent 
bacteria (XL-1 blue) were transformed by mixing 50-100ng of plasmid DNA gently with 
200µl of competent bacteria in an eppendorf tube that was then incubated on ice for half an 
hour. The bacteria where then shocked for 90 seconds in a 42ºC water bath before being 
rested briefly on ice. 800µl of LB broth was then added to the bacteria and the samples were 
left in a shaking incubator at 37ºC for one hour. Bacteria transformed with each vector/insert 
combination were individually spread onto two ampicillin-containing agar plates, one at high 
concentration (200µl) and one at a low concentration (20 µl). These plates were incubated 
overnight at 37ºC. 
 
Bulk preparation of plasmid DNA: From the incubated agar plated, individual bacterial 
colonies were picked with a pipette tip touched to a numbered area on a new ampicillin agar 
plate (placed back into 37oC incubator) before mixing into a 15ml falcon tube that contained 
3ml LB broth (and ampicillin). Usually four to six colonies were picked per transformation 
and these were placed in a 37ºC shaking incubator overnight. The next day plasmid DNA was 
extracted from the bacteria using a Nucleospin Plasmid DNA extraction mini-prep kit 
(Machery-Nagel) as per instructions and successful ligation assessed by repeat restriction 
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digest by the presence of both insert and vector fragments post digest. This was then 
confirmed through DNA sequencing which was conducted by the facility within the School of 
Biosciences, University of Birmingham). These colonies were then picked the following day 
from the numbered agar plate and inoculated into 200mls of ampicillin-containing LB media 
in a 1L conical flask which was incubated overnight in a 37ºC shaking incubator. The next 
day the entire bacterial culture was used for large-scale DNA extraction using a Maxi Prep 
plasmid DNA extraction kit (QIAgen), as per manufacturer’s guidelines. Recovered DNA was 
eluted in 50µl of nuclease free water and concentration quantified using a Nanodrop 
spectrophotometer (Thermo Scientific). DNA was subsequently stored long-term at -20ºC.  
 
Transfection of plasmid DNA into MJS cells: Plasmids containing MCV DNA were 
transfected into the melanoma cell line MelJuSo (MJS) to assess impact on MHC Class I and 
II levels as well as for use in T cell recognition assays. MJS cells were plated at a density of 
2x105 cells per well into a 24-well plate (Iwaki) and then incubated overnight in 500µl of 
RPMI-1640/10% FCS with no antibiotics at 37oC and 5% CO2. The following morning, 
1.2µg of each plasmid DNA were mixed separately with 50µl of Opti-MEM1 (Invitrogen). 
For co-transfection experiments, total DNA for both plasmids added up to 1.2 µg.  For each 
planned transfection, a further tube containing 2µl of transfection reagent Lipofectamine 2000 
(Invitrogen) was mixed with 50µl of Opti-MEM1. The tubes were incubated for 5 minutes at 
room temperature and then plasmid DNA and Lipofectamine 2000 were mixed together and 
left for 20mins at room temperature before a further 50µl of Opti-MEM1 was added to each 
plasmid transfection mixture.  The media was then carefully pipetted from the MJS cells 
without disturbing them and replaced with 150µl of the DNA and Lipofectamine 2000 
mixture. Once all transfections were completed, the plates were returned to the incubator at 
  Chapter 2: Methods 
89 
 
37oC and 5% CO2. After six hours, 500µl of RPMI-1640/10% FCS without antibiotics was 
added carefully to each well and then incubated for 24-48 hours prior to use. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Chapter 3: Results 
90 
 
Chapter 3  
Prevalence of multiple polyomavirus antibody seroresponses in Merkel cell 
cancer patients compared with other donor groups 
3.1 Introduction 
The majority of polyomaviruses cause asymptomatic infections and prevalence rates are based 
on serological assays measuring antibodies against viral antigens. Epidemiological studies 
measuring VP-1 antibody levels have shown that antibodies for the majority of the 
polyomavirus family are highly seroprevalent within the healthy adult population.  Studies 
comparing Merkel cell polyomavirus (MCV) VP-1 antibody levels with the amount of viral 
DNA in the normal skin of Merkel cell cancer (MCC) patients and healthy controls have 
shown a positive correlation between the two [125, 137]. Similar correlative findings are seen 
with BKV and JCV viruses in healthy donors and other patient groups with an increase in VP-
1 antibody levels associated with detectable viruria or viraemia [151, 334, 335]. Importantly, 
higher VP-1 antibody responses are seen in individuals who develop polyomavirus-associated 
diseases. MCV VP-1 antibody levels are higher in MCC patients than healthy controls [74, 
75, 152, 336] and this increase can predate tumour onset by a number of years [337].  JCV 
VP-1 antibody levels are higher in patients with multiple sclerosis treated with natalizumab 
and who go on to develop progressive multifocal leukoencephalopathy (PML) [338-340]. 
These data lead to the suggestion that higher polyomavirus VP-1 serum antibody levels reflect 
increased viral replication and that this may be important to the development of 
polyomavirus-mediated disease.  
The cause of increased polyomavirus viral replication may be due to the loss of viral immune 
control. This is evidenced by the fact that most examples of polyomavirus-mediated disease 
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are strongly linked with immune dysfunction. BKV-associated nephropathy occurs commonly 
in patients who are iatrogenically immunosuppressed following renal transplant and BKV 
viral loads are higher in these patients with nephropathy compared to those without [341].  
The TSV-associated skin disease, Trichodysplasia Spinulosa, occurs exclusively in 
immunosuppression and high TSV viral loads are seen in all TS lesions while TSV DNA is 
only infrequently  found in  skin from healthy donors only ever at very low viral loads [342]. 
In JCV-associated PML, JCV VP-1 serum antibodies are higher than in patients without PML 
[343] and JCV DNA is found more commonly in the serum and bone marrow of HIV+ 
patients compared with HIV negative donors [344, 345]. Systemic immunosuppression is also 
a recognised risk factor for MCV-associated MCC with a higher incidence in patients who are 
at risk of other polyomavirus-mediated disease such as those who have received organ 
transplants or who suffer with HIV. Indeed, patients with poorly controlled HIV (defined by 
higher viral loads and reduced CD4 counts) have significantly higher MCV viral DNA loads 
detectable from skin swabs compared to those with good disease control [272].   
It may be expected that when viral control for one polyomavirus is lost, this may also be seen 
with the other members of the virus family. There is some evidence for this in HIV+ patients 
where lymphoid tissue taken from autopsy patients is more commonly found to contain 
detectable levels of BKV, JCV, KI and WU viral DNA compared with controls [346]. 
Additionally, skin swabs assessing for the presence of HPyV6, HPyV7, TSV, HPyV9 and 
HPyV10 viral DNA showed significantly higher frequencies of DNA detection for each virus 
in HIV+ patients compared with healthy controls [169]. Whether all MCC patients exhibit a 
similar generalised loss of polyomavirus control is not fully understood. VP-1 antibody levels 
for BK, JC KI and WU polyomaviruses have been compared between MCC patients and 
healthy controls with no evidence of any difference seen between the groups for all four 
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viruses [74, 152]. This suggests that the loss of MCV viral control in most MCC patients may 
not extend to all polyomaviruses and may reflect the finding that although there is a clear link 
between immune suppression and MCC, the majority of MCC patients do not exhibit any 
obvious immune dysfunction [7]. However, a comparative assessment between MCC patients 
and other donors involving the control of more recently discovered polyomaviruses, 
particularly those that are associated with the skin (such as HPyV6, HPyV7, TSV, HPyV9 
and HPyV10) has not been conducted to our knowledge.  
Another patient group that is at increased risk of developing MCC are patients with Chronic 
Lymphocytic Leukaemia (CLL) [347, 348] but the exact link between the two diseases is 
unclear.  Although not a group that commonly suffers with other polyomavirus-mediated 
diseases, CLL is associated with immune dysfunction including hypogammaglobulinaemia 
that may impact on humoral polyomavirus control [349]. Indeed, a Spanish study assessing 
polyomavirus antibodies showed reduced prevalence of most polyomavirus VP-1 responses in 
CLL patients compared with controls [350].  It is possible that this finding of a general pattern 
of reduced polyomavirus-specific antibodies may contribute to the loss of viral polyomavirus 
control and lead to the increased risk of MCC.  It is important that as these are the results of a 
single study, such findings be firstly confirmed on an independent CLL cohort. They can also 
be directly compared with results from MCC patients and healthy donors to assess whether 
there are patterns of antibody responses that may help us to understand whether the link 
between CLL and MCC is through the loss of polyomavirus immune control.  
Although the majority of MCC patients have no known immune dysfunction, MCCs are more 
common in elderly patients and in geographical areas with  higher sun exposure as measured 
by UVB solar index [8].  Ageing is known to reduce cutaneous anti-viral immunity through 
the accumulation of regulatory and PD-1 expressing T cells [269]. UV light exposure leads to 
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a loss of antigen presenting Langerhan’s cells [267], an accumulation of regulatory T cells 
[351] and the stimulation to produce the immunosuppressive cytokine IL-10 [352].  As MCV 
is a skin-associated virus, the cause for reduced MCV immune control may be due to 
localised cutaneous rather than systemic immunosuppression. It may then be expected that in 
MCC patients a loss of viral control may be seen not only for MCV but also the other skin-
associated polyomaviruses (such as HPyV6, HPyV7 and TSV) while sparing viruses not 
thought to be skin associated (such as BK, JC, KI and WU). An investigation of the control of 
these other skin-associated viruses in MCC patients in direct comparison to non-skin 
associated viruses has never been conducted and will be useful to help answer these questions. 
If ageing and UV light exposure are able to contribute to a specific loss of skin-associated 
polyomavirus control in MCC patients, it may be expected that this same phenomenon occur 
with other conditions that share these risk factors.  Non-melanoma skin cancers (NMSCs) are 
much more prevalent in the elderly and occur most commonly on areas of sun-exposed skin.  
However, unlike MCC, they are not known to be associated with any viral infection [140, 
141, 353]. The question of whether the risk factors associated with a loss of cutaneous viral 
immunity can lead to similar patterns of skin-associated and non-skin associated 
polyomavirus antibodies detected in the serum is an interesting one that should be further 
explored.  
The majority of polyomavirus serological studies have focused on VP-1-specific antibodies 
and T-antigen seroresponses analysis has been much more limited. It may be expected that as 
T-antigen is a nuclear antigen rather than a capsid protein, antibodies may only be detectable 
at times of active viral replication. As MCC patients are thought to be undergoing increased 
MCV viral replication through having higher viral DNA loads in the skin than healthy 
controls, it may be expected that they would also have higher frequencies of MCV T-antigen 
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responses. Indeed, MCV T-antigen antibodies have been shown to have a prevalence of 40% 
in MCC patients compared with <1% in age and sex matched control subjects [354]. 
However, MCV T-antigen antibody levels, unlike VP-1 antibodies, do not appear to correlate 
well with MCV DNA in the skin, with levels instead tracking disease burden and often 
becoming undetectable at times of disease remission. This suggests increased T-antigen 
antibody prevalence may be mostly provoked by tumour cells expressing T-antigen rather 
than as a result of MCV viral replication.  Some recent studies have suggested that a 
proportion of prostate cancer may be linked with BKV infection and in such patients there is a 
higher prevalence of BK T-antigen antibody seroresponses compared to patients with BKV 
negative tumours [355, 356]. It has been therefore been postulated that polyomavirus T-
antigen antibody levels may be a useful biomarker to predict recurrence or assess treatment 
efficacy in patients with polyomavirus-associated tumours. To date, there has been no data 
from UK MCC patients that confirm this finding and give an indication of whether T-antigen 
antibody levels could be a useful clinical biomarker.  The investigation into other 
polyomavirus T-antigen antibody responses is more limited than with MCV. In healthy 
controls and MCC patients, seroresponses to BKV T-antigen were of low frequency with no 
significant difference between the two groups [354]. A number of gaps remain in our 
knowledge regarding polyomavirus T –antigen seroresponses, such as the overall prevalence 
of MCV T-antigen responses in groups other than MCC patients and young, healthy donors as 
well as the prevalence of T-antigen seroresponses against the other non-tumour associated 
polyomaviruses in any donor group. These data will help clarify whether these responses do 
have link with active viral replication or are only specific to detect the presence of tumour. 
The work in this chapter uses serological assessment of VP-1 and T-antigen antibody 
responses against a variety of polyomaviruses in a number of donor groups to increase 
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available knowledge on a number of topics.  Firstly, it will allow us to confirm previous 
serological findings seen in MCC patients in other geographical locations in the USA and 
Europe, but not to our knowledge in a UK population. In particular the finding that MCC 
patients have higher serum MCV VP-1 antibody levels in comparison to other donor groups 
and that MCV T-antigen antibody prevalence is positively correlated with MCC disease 
activity. 
Additionally, it will help to show whether MCC patients have an increased susceptibility to 
infection by other polyomaviruses other than MCV. This will be assessed through comparison 
of frequency and size of VP-1 seroresponses in healthy donors and also in NMSC and CLL 
patients, both of whom may share similar patterns of polyomavirus infection and antibody 
responses to MCC patients as discussed above. Lastly, we can assess the prevalence of a 
variety of polyomavirus T-antigen responses in the MCC, CLL, NMSC and healthy donor 
cohorts to see if these are detectable and if so does this provide evidence for a possible link 
between T-antigen responses and viral reactivation.  
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3.2 Results 
3.2.1 Donor populations 
In order to assess polyomavirus antibody responses from the serum of appropriate donor 
populations, MCC patients, CLL patients, NMSC patients and healthy donors (elderly and 
young) were recruited from the local area.  
 
3.2.2 MCC patients 
Between 2009 and 2015, forty-eight MCC patients were recruited from Queen Elizabeth 
Hospital Birmingham (QEHB). Samples prior to 2012 were collected by David Blackbourn 
and Neil Steven during an earlier phase of this project. The mean age of this patient 
population was 74 (range 41-91) with 56% being female. There were eight patients (17%) 
also suffering with non-melanoma skin cancers, one (2%) had chronic lymphocytic leukaemia 
and three were immunosuppressed (1 renal transplant, 1 systemic sclerosis, 1 sarcoidosis). 
When considering other relevant co-morbidities, three (6%) had other cancers (2 locally 
advanced breast cancer on hormone treatment and 1 renal cancer on no treatment). There were 
five (10%) with other illnesses that may impact on immunity including two with multiple 
sclerosis not on any immunomodulatory therapy, two with rheumatoid arthritis; one was on 
sulfasalazine and the other on methotrexate, and one with chronic obstructive pulmonary 
disease that has required numerous courses of steroids over a number of years.  Serum was 
collected from patients with both active disease and those in remission, with eleven patients 
having multiple samples taken. At first blood draw, 26 patients had active MCC, thirteen had 
been in remission for less than six months and nine had been in remission for over six months. 
The detailed demographics of these sub-groups are found in Table 3.1.  
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3.2.3 Other donor groups 
Serum from a number of control groups was collected to be used as comparators to the MCC 
group. We recruited twenty-three patients with either active or history of non melanoma skin 
cancer (NMSC) from the dermatology clinic at QEHB. The mean age of these patients was 75 
(range 49-87) and 39% were female. Of these, seventeen patients had basal cell cancer (BCC) 
and six had squamous cell cancer (SCC). None of these patients had any history of 
immunosuppression. Serum from twenty patients with CLL was kindly provided by Dr Helen 
Parry (University of Birmingham). Of these, ten had Stage A disease, one Stage B, eight 
Stage C and one Richter’s transformation. The mean age of this group was 71 (range 57-101) 
and 35% were female. Serum from twenty local healthy elderly participants of the “1000 
elders” programme, run by the University of Birmingham, was also provided by Dr Helen 
Parry. The mean age of this group was 81 (range 74-90) with 80% females. None of these 
patients were immunosuppressed. Serum from 23 healthy members of staff from the 
University of Birmingham was also taken. The mean age of this group was 43 (range 22-55) 
and 35% were female. 
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Table 3.1. MCC patient demographics.  
 
MCC patients were stratified by diseases state at time of serum sampling. If multiple samples had been taken, 
disease state at time of first sample was used. NMSC=Non melanoma skin cancer, CLL=Chronic Lymphocytic 
Leukaemia 
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3.2.4 Comparison of frequency of polyomavirus VP-1 seroresponses amongst the MCC and 
other donor cohorts 
Initially, we were interested to know whether MCC patients were likely to be infected with 
more polyomaviruses in comparison to other donor groups. To assess this, serum from MCC 
patients, NMSC patients, CLL patients and healthy donors was taken and polyomavirus VP-1 
seropositivity was determined using an established multiplexed bead based luminex assay 
testing for responses to ten of the twelve known human polyomaviruses [181]. Firstly we 
looked at the presence or absence of individual polyomavirus seroresponses in all the donors 
using an established cut-off value (MFI >250) to define seropositivity for each VP-1 antigen. 
In a recent large American epidemiological study using this same assay, there was no 
evidence of significant cross-reactivity between the various polyomavirus-specific responses 
[181]. When our donor seroresponses were analysed, there was no difference in the total 
frequency of polyomavirus-specific VP-1 antibody responses seen in individuals from the 
different cohorts, with median values of between six and seven responses found in all groups 
(Figure 3.1).  
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Figure 3.1. Number of polyomavirus VP-1 seroresponses present in MCC, NMSC, CLL, HED and HD 
groups. The number of positive seroresponses (defined as MFI>250) were identified for individual donors 
within each group. The box and whisker plots show the interquartile ranges (boxes) and minimum and maximum 
values (whiskers) for each cohort.  Horizontal lines and crosses represent median and mean numbers of 
responses respectively.  MCC=Merkel cell cancer, NMSC=Non-melanoma skin cancer, CLL=Chronic 
lymphocytic leukaemia, HED=Healthy elderly donors, HD=healthy donors. 
 
Next, we considered whether there were any differences in the patterns of individual virus 
seropositivity between the different cohorts (Table 3.2). MCV seropositivity was more 
common in MCC patients (85%), compared with the other populations, although there was 
only a significant difference when compared with CLL patients (45%, p=0.0017, Fisher’s 
Exact Test). VP-1 antibody responses against BK, KI, WU, TSV and HPyV10 were almost 
ubiquitous (70-100% positive) in all cohorts. JC VP-1 seroprevalence was similar in the 
MCC, NMSC, CLL and healthy elderly groups (43-45% positive) but appeared lower in the 
younger healthy donors (22%). This pattern was repeated for HPyV6 infections but no 
significant differences were seen between any of the groups. When assessing HPyV7, there 
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was no difference between any of the elderly cohorts and although a large difference was seen 
between the cohort with the highest and lowest response rates, NMSC (87%) and young 
healthy donors (35%) this was not statistically significant. 
 
Table 3.2. VP-1 antibody seroprevalence in each patient cohort. Age and sex characteristics are shown for 
each individual cohort. The percentage of donors considered VP-1 seropositive (defined as MFI>250) has been 
calculated for each polyomavirus. Difference between groups analysed using Fisher’s Exact test and statistically 
significant result highlighted, * p=0.0017. 
 
Overall, the frequency of polyomavirus VP-1-specific antibody responses suggests that MCC 
patients are no more susceptible to polyomavirus infections than the other donor cohorts 
assessed. MCV alone appears more prevalent in the MCC patient population as compared 
with the other control populations, particularly when compared with CLL patients. Rates of 
infections of the other polyomaviruses as judged by antibody response are broadly similar 
throughout the elderly donor cohorts, but occasionally lower in the younger healthy donors. 
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3.2.5 Comparison of size of polyomavirus VP-1 seroresponses amongst MCC and other donor 
groups 
MCC patients have comparable frequency of polyomavirus VP-1 seroresponses when 
compared to the other tested donor groups. As the size of the VP-1 response is thought to be a 
correlate for the degree of viral replication, higher VP-1 antibody values may be seen in 
donors in whom there are higher levels of replication. We were therefore interested to 
compare the sizes of VP-1 antibody responses between MCC patients, NMSC patients, CLL 
patients and healthy donors to see if any groups had higher values and against which viruses 
this occurred.  Here MFI values of antibody bound to antigen coated beads were assessed. 
A significant difference was seen in MCV VP-1 antibody levels with the 48 MCC patients 
having higher MFI values compared with the 86 other donors (mean MFI 4247 v 1526, 
p<0.0001, Mann-Whitney U Test) (Figure 3.2). There was no significant difference in the 
other polyomavirus VP-1 antibody MFI values tested when comparing MCC patients with all 
other donors (Figure 3.2). The reduction of MCV MFI seen in the non-MCC donor groups 
was shared by all comparator cohorts, with NMSC, CLL, healthy elderly and young healthy 
donors having significantly lower MFI values when compared individually against the MCC 
patients (Figure 3.3A). This pattern was maintained when only MCV seropositive donors 
were included in analysis (Figure 3.3B). When sizes of all VP-1 polyomavirus responses were 
compared for each individual donor cohorts, a significant difference was seen when HpyV7 
VP-1 levels from NMSC patients and healthy donors were compared (Table 3.3, p=0.006, 
Kruskall-Wallis test with Dunn’s multiple comparison correction). However, given the very 
small sample sizes of the cohorts involved, this difference must be interpreted with caution.  
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Figure 3.2. Polyomavirus VP-1 seroreactive responses from MCC (blue, n=48) patients were compared 
with all other donor groups pooled together (red, n=86). Each point represents an individual donor, horizontal 
line represents mean value for each group. A significant difference between MCC patients and other donors was 
only seen for MCV VP-1 seroresponse (mean MFI 4622 v 539, p<0.0001, Mann-Whitney U Test.) 
 
As MCC patients appeared to have higher levels of MCV VP-1 antibodies compared to other 
donors, we wanted to clarify if this effect was limited to patients at a certain disease stage. We 
therefore split the MCC cohort into three categories dependent on disease stage at time of 
blood draw (active disease, remission of less than six months and remission over six months). 
Comparing MCV VP-1 antibodies between these groups, there was no significant difference 
between the disease stages (Figure 3.4). In addition, when comparing VP-1 antibody levels of 
the other tested polyomaviruses there was no significant differences between any of the 
disease stages (Figure 3.4). Overall this data suggests that MCV VP-1 antibody responses are 
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higher in MCC patients and this is independent of stage of disease. The levels of VP-1 
response for the other polyomaviruses, including those that are skin-associated, are not 
significantly different between any of the donor cohorts assessed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Comparison of MCV VP1 seroresponses for all individual cohorts. (A) shows mean and standard 
error MFI values from the serum of all donors. (B) shows mean and standard error when only MCV seropositive 
donors are considered. Statistical comparison made with Kruskal-Wallis Test corrected for multiple comparisons 
using Dunn’s Test. 
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Figure 3.4. VP-1 antibody seroresponses for all studied polyomaviruses in MCC patients at different 
disease stages. MCC patients who had serum analysed for VP-1 seroresponses were categorised into groups 
depending on disease state at time of blood draw, active disease (red circles), in remission for period of less than 
6 months (blue squares) and in remission for over 6 months (green triangles). In patients who had multiple 
samples, only the first available sample was included. Horizontal lines represent mean values. No significant 
differences were seen between any of the MCC disease stages (Kruskal-Wallis test). 
 
3.2.6 Polyomavirus VP-1 antibody levels in MCC patients throughout disease course 
Our previous data showed that MCC disease status did not appear to affect size of 
polyomavirus VP-1 antibody responses when the entire cohort was considered. However, we 
were also interested to assess and confirm this in individual patients. Multiple serum samples 
from different time points were available in eleven MCC patients to enable longitudinal 
comparison of VP-1 antibody titres. All cases were MCV seropositive. In four cases, samples  
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were taken at only at times of active disease and in one patient, samples were taken both 
during active disease and when in remission (Figure 3.5). In six patients samples were taken 
while in remission only (Figure 3.6).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Serial VP-1 seroresponses in MCC patients with active disease. Four patients with active MCC 
had multiple serum samples taken and each were analysed for VP-1 seroresponses against multiple 
polyomaviruses. The number of days after initial diagnosis that sample was taken is shown. P45, P46 and P47 
had both samples taken at time of active disease. P45 received recent chemotherapy prior to second sample (*). 
P52 had an initial sample taken while in active disease and second sample taken while in remission.  
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In the majority of cases, MCV VP-1 antibody levels remained grossly stable over time. This 
was the case even in the two patients (P46 and P77) who suffered disease progression and in 
the single patient (P52) who gained disease control (Figure 3.5). One patient, P45, who had 
initial sample taken during metastatic disease and second sample taken following a period of 
chemotherapy, did show a reduction of VP1 antibody titre (9777 to 6516 MFI), but this was 
unfortunately not reflected by a clinical response to treatment and the patient died soon 
afterwards.  
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Other than MCV VP-1 antibody responses, we also assessed VP-1 antibodies against the other 
polyomaviruses.  In all but one patient (P45), at least one other VP-1 antibody response was 
higher than MCV, but the viruses responsible differed between patients, the most common 
being WU and BK (3 patients each) (Figure 3.5&3.6). In most cases, as with MCV, VP-1 
antibody levels remained stable over time with some notable exceptions, for example, P46, 
had an increase in JCV VP1 antibody titre (Figure 3.5), while from the patients in remission, 
P85 had an increase in HPyV10 VP1 antibody titre and P106 and P107 had increases in WU 
titre (Figure 3.6). The most striking change seen, however, is the dramatic fall in BKV VP1 
antibody titre seen in P84 from over 11000 MFI to 866MFI. This data shows that in the vast 
majority of individual MCC cases, VP-1 antibody levels against both MCV and the other 
polyomaviruses remain stable over time, independently of the burden of disease. In almost all 
cases another polyomavirus VP-1 antibody level was greater than that of MCV although the 
candidate virus was not consistent and only skin-associated in a minority of cases. 
 
3.2.7 The potential for cross-reactivity between individual polyomavirus T-antigen antibodies 
Having assessed VP-1 antibody responses, we next turned attention to T-antigen antibody 
seroresponses which have been much less investigated. As the polyomavirus family share 36-
80% identical amino acid sequence of the T-antigen (Table 3.4) there is a concern of possible 
cross-reactivity between tested antigens. In order to see if this could have an effect on our 
results, we looked for a correlative association between MCV T-antigen levels and levels of 
the other individual viral LT-antigens in all of our donors. The strength of these correlations 
were then tested statistically using the non-parametric Spearman’s test (Figure 3.7).   
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BKV JCV KI WU MCV HPyV6 HPyV7 TSV HPyV9 HPyV10 STL HPyV12 
BK   83 53 55 49 43 44 44 44 48 47 38 
JC     51 53 48 44 43 46 42 47 47 38 
KI       70 46 41 44 47 44 46 47 39 
WU         47 41 43 46 42 48 49 46 
MCV           46 47 47 46 47 48 49 
HPyV6             69 42 42 47 46 41 
HPyV7               45 45 48 48 36 
TSV                 50 49 47 45 
HPyV9                   47 46 42 
HPyV10                     61 43 
STL                       40 
HPyV12                         
 
Table 3.4. Percentage of shared LT homology between members of the polyomavirus family. BLAST 
analysis comparing amino acid similarity between pairs of polyomaviruses. The following sequence ascension 
codes were used: BKV NC_001538, JCV NC_001699, KI NC_009238, WU NC_009539, MCV NC_010277, 
HPyV6 NC_014406, HPyV7 NC_014407, TSV NC_014361, HPyV9 NC_015150, HPyV10 JX262162 STL 
JX463183, HPyV12 JX308829. 
 
There were correlations seen between MCV T-antigen antibody responses and those against 
other viral T-antigens, most significantly between MCV LT exon 1 antigen and the LT exon 1 
antigen  of HPyV6 (r=0.42, p=<0.0001), HpyV7 (r=0.38, p=<0.0001) and TSV (r=0.46, 
p<0.0001). This data suggests that there may be relationship between MCV T-antigen 
antibody responses and T-antigen antibody responses against other polyomaviruses, 
particularly those that are skin-associated. Unfortunately, determining whether this correlation 
is due to multiple co-infections occurring with MCV or simply a product of cross-reactivity is 
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impossible with the data available. This means that although the assay used is the best that is 
currently available for this work, our results must be interpreted with caution and any findings 
will need further validation before firm conclusions can be drawn.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Non parametric Spearman correlation analysis between MCV T-antigen (Large T exon 1) MFI 
values compared with other polyomavirus T-antigen responses. Analysis was conducted using non-
parametric Spearman correlation calculation comparing MCV VP-1 responses (x-axis) with other 
polyomaviruses individually (y-axis) using data from all donors (n=134).Each point represents a single donor. 
Significant correlations are highlighted in bold type.  
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3.2.8 Comparison of polyomavirus T-antigen seroresponses amongst MCC and other donor 
groups 
Previous studies have shown that MCV T-antigen antibody responses are seen at much higher 
frequency in MCC patients compared with healthy donors, but little is known of the 
prevalence in CLL patients, who have an increased risk of MCC and NMSC patients, who 
share MCC-associated risk factors. Data on the frequency and size of T-antigen antibody 
responses for other polyomaviruses is limited, even in healthy donors. In order to increase our 
understanding of the prevalence and level of T-antigen antibodies, we assayed serum 
collected from MCC patients, NMSC patients, CLL patients and healthy donors for 
polyomavirus-specific T-antigen seroresponses.  Polyomavirus T-antigen antibodies were 
measured using a multiplex bead based assay and seropositive responses were determined 
using defined MFI cut-off values. For MCV, seroreactivity to four different T-antigen 
epitopes were measured (LT exon 1, LT exon 2, Large T and sT). To simplify comparison 
between the groups, donors with MCV T-antigen responses were classified as either having 
T-antigen response (if one or more MCV T-antigen positive) or not having response (if no 
MCV T-antigen positive).For BKV, JCV, HPyV6, HPyV7, TSV and HPyV10, a single LT 
exon 1 antigen response was measured. When focusing only on MCV T-antigen antibody 
seroresponses (Figure 3.8A), these are limited only to MCC patients and seen in 50% of 
patients with active disease, 31% of those in remission for less than 6 months and 22%, of 
those in remission for over 6 months.  
We next looked at the individual donors in each cohort and quantified the detectable T-
antigen seroresponses against any of the measured polyomaviruses seen. When conducting 
this analysis, it was clear that a number of donors had multiple detectable T-antigen 
responses. Overall, there was a clear trend showing that MCC patients with active disease had 
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an increased number of T-antigen responses compared with the other cohorts, in whom 
detection of any T-antigen responses was uncommon (Figure 3.8B). This was statistically 
significant when compared with the CLL (p=0.002) and the young healthy donor (p=0.02) 
populations but not with the MCC patients in remission (p>0.99), the NMSC patients 
(p=0.21) and healthy elderly patients (p=0.11). In these groups, although infrequent, there 
were individuals whose serum contained detectable levels of T-antigen antibodies specific for 
polyomaviruses other than MCV. In some NMSC patients and healthy donors, multiple T-
antigen responses could be seen. This data suggests that MCV T-antigen antibodies are 
specific to MCC patients and more prevalent in those with active disease at time of blood 
draw. MCC patients with MCV T-antigen responses were also frequently seen to have 
detectable responses against other polyomavirus T-antigens. Although, detection of any T-
antigen seroresponses was rare in the non-MCC donor cohorts, there were instances of this, 
including a small number with multiple T-antigen responses. 
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Figure 3.8.  T-antigen seroresponses in MCC, NMSC, CLL, HED and HD groups. (A) The percentage of 
donors from each cohort with a positive (MFI>400) MCV T-antigen seroresponse. (B) The total numbers of T-
antigen seroresponses for donors in each studied cohort. Circles represent individual donors, horizontal and 
vertical lines represent mean and standard error of mean. Active=Active disease, Rem<6m=MCC Remission for 
less than 6 months, Rem>6m=MCC Remission for over 6 months, NMSC= Non melanoma skin cancer, 
CLL=Chronic Lymphocytic Leukaemia, HED=Healthy Elderly Donors, HD=Healthy younger donors 
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3.2.9 Polyomavirus T-antigen antibody levels in MCC patients throughout disease course 
Data from other studies has shown that serum levels of MCV T-antigen antibody correlate 
with disease burden in MCC patients. To examine this and other co-resident polyomavirus T-
antigen antibody seroresponses, we used serum from the MCC patients for whom multiple 
samples were available (as described previously) and first tested for MCV T-antigen antibody 
levels. As a number of MCC patients had been shown to have multiple viral T-antigen 
antibodies detected in the serum, we were also interested to see how levels of other non-MCV 
T-antigen antibodies changed with time (Figure 3.9).  Three patients with active and 
progressing disease (P45, P46 and P77) had high MCV LT exon 1 and sT-antigen antibody 
values that appeared relatively stable over time. P52, who was successfully treated after 
donating the first serum sample, which contained high MCV LT and sT antibodies, saw a 
large drop in levels by the time of the second sample, taken over 3 years later. The same 
decrease was also seen for the other elevated T-antigen responses seen at first sample. The 
patients who had multiple samples taken whilst in remission (e.g. P102, P106) mostly showed 
T-antigen responses below the levels of detection. P84 whose first sample was taken two 
years after initial diagnosis, had levels of MCV T-antigen antibodies just above the limit of 
detection and these both decreased by time of second sample collection, 18 months later. 
Interestingly, P85 also had detectable T-antigen antibodies against MCV and JC at a low level 
2 months after receiving curative treatment for MCC. By the time of the next sample, 3 years 
later, the MCV T-antigen antibody levels had decreased below the limits of detection, 
however, JC T-antigen antibody levels remained stable and at the time of a third sample, 6 
months later, JC T-antigen antibody levels had increased further. Overall, the longitudinal 
assessment of MCV T-antigen antibodies in MCC patients does show antibodies are more 
detectable at times of active disease. Also, although changes in T-antigen antibody levels 
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against other polyomaviruses in patients with multiple responses can follow the same pattern 
as seen with the MCV T-antigen antibody, this may not always be the case. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. Serial T-antigen seroreactivity in MCC patients. Serum samples from patients who had donated 
at least twice were analysed for T-antigen seroresponses against multiple polyomaviruses. The number of days 
after initial diagnosis and disease state at time of sampling is shown. P45, P46 and P47 had both samples taken at 
time of active disease. P52 had an initial sample taken while in active disease and second sample taken while in 
remission. P84, P85 and P102 all had samples taken when in remission only. 
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3.3 Discussion 
This study assessed the size and frequency of polyomavirus VP-1 and T-antigen antibody 
responses in the serum of a number of patients and volunteer groups. It demonstrated that all 
donor groups tested showed similar median numbers of total viral VP-1 responses indicating 
that multiple infections are common. As no difference in the number of serum antibody 
responses was seen when the healthy controls and the patient groups at higher risk of immune 
dysfunction (MCC or CLL patients) were compared, this suggests that these groups are not at 
increased risk of accumulating polyomavirus infections. The size and frequencies of anti VP-1 
antibody responses are similar for the majority of polyomaviruses in the donor groups of 
similar age profile (MCC, NMSC, CLL and HED). In the younger healthy control group, 
prevalence of some VP-1 antibody responses were lower (JC, HPyV6 and 7) which may be 
expected as rates of polyomavirus infection increase with age [165, 178]. As expected given 
the strong link between MCV and MCC, the prevalence of MCV VP-1 antibodies was highest 
in the MCC group [75, 152]. The CLL patient group had the lowest frequency of MCV 
seroresponses while responses to other polyomaviruses appeared broadly maintained.  A 
previous study assessing serum from a large group of CLL patients using methodology 
identical to that in our present work has shown that the frequency of multiple polyomavirus 
responses are lower in CLL patients compared to healthy control donors [350].  It is therefore 
possible that the reduced frequency of MCV VP-1 responses in the CLL group may reflect a 
decreased ability of these patients to mount MCV-specific humoral immune responses that 
may be related to the hypogammaglobulinaemia commonly associated with CLL [349]. This 
may allow for uncontrolled viral replication and increase the chance of CLL patients 
subsequently going on to develop MCC.  However given the small size of the cohorts 
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involved, it is not possible to say that these findings are not due to chance alone and further 
confirmatory work is required.  
As the sizes of VP-1 seroresponses are thought to correlate with the degree of on-going viral 
replication, this study also compared the sizes of response to individual virus VP-1 antigens 
between the donor groups. Only MCV VP-1 antibody levels showed any statistical difference, 
with significantly higher levels in serum of MCC patients when compared to all other cohorts, 
as seen in previous studies [74, 121]. There was no significant difference in MCV VP-1 
antibody MFI values between healthy donors and both NMSC and CLL patient groups 
although CLL patients had the lowest mean MCV VP-1 antibody MFI values even when 
analysis is limited to seropositive individuals only. This suggests that although CLL patients 
are able to mount polyomavirus-specific antibody responses, the size of these may be limited 
when compared to other patient groups. MCV VP-1 specific antibodies are believed to have 
neutralising function [74, 337] and so a loss of these could also have a negative impact on 
MCV immune control and increase risk of MCC. Although a lack of MCV-specific antibodies 
may provide a possible reason for the increased incidence of MCC in CLL patients, the 
finding that the majority of MCC patients with documented immune compromise  still mount 
high MCV-specific VP-1 antibody responses [121]. This suggests that a lack of specific 
antibodies is not the only underlying link between immunosuppression and MCC and that this 
is likely to be multi-factorial. 
The significantly higher MCV VP-1 seroreactivity seen in MCC patients compared with 
NMSC patients suggests that it is not simply the exposure to shared risk factors such as age or 
increased UV light exposure that is responsible for a loss of MCV viral control. A large study 
assessing MCV VP-1 seroreactivity in patients with squamous cell skin cancers (SCC) 
compared with matched healthy controls found that mean VP-1 MFI levels were higher in the 
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SCC group possibly due to reduced MCV immune control [138]. In our study, we did not see 
any difference in MCV VP-1 MFI results in the NMSC cohort when compared to either the 
healthy elderly or the younger healthy control groups. This may be due to important 
differences between the studied cohorts with for example, immunosuppressed SCC patients 
being included in the published study while being excluded in our work.  Additionally, the 
small cohorts used in the present study may make it difficult to identify small differences 
between groups. In our study, when non-MCV VP-1 antibody seroreactivities are compared, 
there are no significant differences seen in MFI values for either skin-associated or non-skin-
associated viruses between any individual donor cohorts. This would appear to indicate that 
using the current assay, there is no specific loss of viral immune control of skin-associated 
polyomaviruses in MCC and NMSC patients suggesting that whatever the mechanism for loss 
of viral control of MCV in MCC patients, it may be specific for MCV and not impact upon 
responses against the other tested polyomaviruses. 
In serial serum samples from MCC patients, MCV VP-1 seroreactivity remained stable 
independently of disease burden,  confirming the findings of a previously published study 
[354]. VP-1 antibody responses against other polyomaviruses also mostly appear stable over 
time. This pattern is similar to what is seen with JCV VP-1 antibodies in serial samples taken 
from seropositive multiple sclerosis patients on treatment with natalizumab [357]. Similarly,  
in renal transplant patients suffering with BKV-associated nephropathy, VP-1 antibody levels 
appear to rise after disease onset and this increase is maintained at least 6 months following 
successful treatment [358]. In another study assessing both humoral and cellular BKV 
immune response kinetics in HLA-A2+ kidney-transplant patients suffering with BKV-
associated nephropathy, increases in BKV VP-1 antibody levels occurred soon after disease 
onset. Interestingly, patients with higher frequency of BK-specific CD8 T-cells exhibited 
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lower peak antibody levels which declined rapidly. Conversely, patients with low frequency 
CD8 responses had high level VP-1 antibody responses that were long-lasting [359].  The 
authors of this study suggest that the cause of chronically high antibody levels may be due to 
persistently active virus that is not being controlled due to defective cellular immunity. 
Whether this could possibly be the reason that high MCV VP-1 antibody levels are seen in 
MCC patients is and interesting question yet to be answered. However despite this,  it is 
unlikely that cellular immunity alone controls MCV and that the VP-1 antibody response is 
still likely to have an important role  exemplified by the finding that high MCV VP-1 
antibody levels in MCC patients correlate with a better prognosis [121].  
Unlike VP-1, polyomavirus T-antigen antibody seroresponses were an overall infrequent 
occurrence although MCV T-antigen antibody responses were seen commonly in MCC 
patients with active or recently treated disease, in agreement with published data [354]. This 
suggests that this assay may have potential utility as a disease biomarker in MCC patients 
from the UK. A significant proportion of patients with MCV T-antigen antibody responses 
had responses against other T-antigens. The role of T-antigen antibody responses in 
polyomavirus infections is not clear and data is extremely limited. In young kidney transplant 
patients, BKV LT antibodies were less frequent, smaller and arose later than the VP-1 
antibody  response [360]. In this group, LT antibody levels were highest in patients with 
sustained viraemia indicating the antibody response may occur as a consequence of increased 
antigen exposure. Interestingly, the rise of BKV-specific LT antibodies coincided with the 
decline of viral load, suggesting this may be a marker of emerging immune control [360].  
A number of MCC patients showed multiple viral LT antibody responses aside from MCV 
with moderate positive correlations (r =0.38-0.46) seen between MFI values for MCV those 
of HPyV6, 7 and TSV LT antibodies. To definitively determine whether these correlations are 
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due to multiple co-infections or assay cross-reactivity is not easy. Cross-reactivity of 
polyomavirus LT antibodies have not been intensively investigated particularly with regard to 
the more recently discovered family members but it has been seen previously, particularly 
between SV40 and BKV [361, 362].  With regard to the particular assay used in our study, it 
is possible that there is some unavoidable cross reactivity (T. Waterboer, personal 
communication) which means that our results must be interpreted with caution. However, in 
some non-MCC patients multiple T -antigen antibody responses occurred in the absence of an 
MCV response and not all MCC patients with MCV LT seroresponses displayed multiple LT 
responses. These findings may argue against simple cross-reaction as a cause for multiple T-
antigen-specific responses and may suggest that in some circumstances (e.g. a period of 
reduced immune surveillance) multiple viruses are allowed to reactivate at the same time, 
hence increasing the prevalence and accessibility to the immune system to T-antigens 
resulting in the antibody responses seen. If a generalised reduction in cutaneous immunity 
was present in MCC patients, it may be expected to result in the predominant reactivation of 
skin-associated viruses, particularly MCV, HPyV6, HPyV7 and TSV. Perhaps it is 
unsurprising then that these are the four viruses for which T-antigen antibody responses 
appear to correlate most strongly, as described above. As our earlier work using VP-1 
antibody levels did not demonstrate any obvious signs of a reduction in control of these skin-
associated viruses, investigations into whether the use of T-antigen antibodies is a more 
sensitive method to assess this are warranted. 
Overall, this work broadens our current knowledge of the seroprevalence and seroreactivity of 
VP-1 and T-antigen antibody responses in a large group of MCC patients and provides 
comparison with responses from both relevant patient and healthy donor cohorts. It provides 
confirmatory evidence that the majority of MCC patients exhibit features suggesting a loss of 
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MCV viral control that is not explained solely by increasing age or exposure to UV light 
exposure. It appears that the increased risk of MCC in CLL patients may have in part due to a 
lower prevalence and level of MCV-specific antibodies, a mechanism not shared with MCC 
patients. Lastly, results from T-antigen antibody responses may suggest that in MCC patients 
multiple and predominantly skin-associated polyomaviruses may be reactivated at the same 
time indicating that a generalised loss of cutaneous anti-viral immune control may be 
prevalent in this group.    
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Chapter 4  
A comparative analysis of immunological markers in peripheral blood of 
Merkel cell cancer (MCC) and non-melanoma skin cancer (NMSC) patients 
4.1 Introduction 
Merkel cell cancer (MCC), an aggressive cutaneous cancer of neuroendocrine origin, is 
extremely rare with an age-standardised incidence of 3.5 cases/million in a European 
population [26]. Conversely non-melanoma skin cancers (NMSCs), primarily basal cell 
(BCC) and squamous cell cancers (SCC), are extremely common, making up approximately 
20% of all new cancer diagnoses.  NMSCs and MCC share a number of risk factors, both 
being strongly associated with UV light exposure [30, 363] and a marked increased incidence 
in patients over the age of 50 [8, 364] . There also appears to be an important role of the 
immune system in the development of MCC and NMSC given the increased incidence of both 
cancer types in immunosuppressed patients with, for example, haematological malignancies 
[37, 365]or solid organ transplants [33, 366]. However, the mechanisms underlying this 
remain unclear. 
An important difference between MCC and NMSC stems from the recent discovery of Merkel 
cell polyomavirus (MCV) DNA clonally integrated within the genome of the vast majority of 
MCC tumours [42]. MCV has subsequently been identified as a common pathogen, thought to 
infect the skin asymptomatically and persist latently in the majority of the healthy adult 
population [75]. It is hypothesised that in immunosuppressive states, normal 
immunosurveillance is disturbed, allowing viral reactivation and an increased likelihood of 
viral DNA integration into the host cell genome and the consequent development of cancer. 
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Despite intensive investigation, a strong link between NMSCs and any viral aetiology, 
including MCV, has not been found [142, 367]. 
While the above model of MCC development is attractive, the vast majority of MCC patients 
have no history of immunosuppression [7]. The widely held belief is that these patients are 
instead affected by changes mediated by the well-recognised phenomenon of 
immunosenescence [237].   This age related decline in the functioning of the adaptive immune 
system involves a progressive impairment in response to new antigens through reduced naïve 
T and B lymphocyte output from the thymus and bone marrow respectively [238, 239]. Also 
in elderly populations chronic infection with viruses such as cytomegalovirus and Epstein-
Barr virus is associated with the inflation of terminally differentiated CD8+ T cells, specific 
for a small range of viral targets [243, 246, 368]. These cells, termed T effector memory 
CD45RA+ (TEMRA) cells, are themselves dysfunctional and potentially decrease the ability 
to make other functional memory responses [369, 370]. These changes in adaptive immunity 
may negatively affect the ability to recognise tumour-associated antigens and thus eliminate 
or control tumour development [371]. The potential importance of functional T cell immunity 
has been demonstrated in MCC through the finding that patients with MCC tumours with 
significant CD8 T cell infiltration have a significantly improved prognosis compared to those 
with no or little infiltration [317]. Alongside this, MCC patients with higher absolute 
lymphocyte counts have an improved overall survival compared with those with low counts, 
independent of factors such as  immunosuppression and stage of disease [41].  
Older patients are also at an increased risk of developing autoimmune diseases and also 
underlying low grade inflammation, the latter thought to be mediated through the relative 
preservation of the innate immune system.  Collectively these can impact on cell-mediated 
responses and additionally create an environment capable of cell damage and potential 
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oncogenic transformation through the release of inflammatory mediators [254, 256]. 
Increased numbers of both circulating and tumour associated neutrophils, inflammatory 
effectors that may play a role in this context, correlate with a poor prognosis in a number of 
cancers [372, 373].  In MCC, a single study showed increased tumour associated neutrophils 
associated with a trend towards poorer prognosis [374], but little is known regarding the 
importance of circulating neutrophil levels.  
This investigation aimed to formally characterise the immune markers present in peripheral 
blood samples from patients with MCC and NMSC but no history of immunosuppressive 
conditions in order to identify any deficits. In particular, given the similar risk factors and 
demographic profiles of patients affected by both cancers, we were interested to look at 
features associated with immunosenescence and whether there were differences that would 
favour the development of a virally-associated cancer in individuals with MCC compared to 
those with non-virally associated NMSC.  
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4.2 Results 
4.2.1 Patient Characteristics 
To investigate the immunophenotype peripheral blood samples from patients with a history of 
MCC or NMSC were recruited from a single UK tertiary referral centre. The detailed patient 
demographics of 21 patients with active or past history of MCC are shown in Table 4.1. No 
patients with a history of overt immunosuppression, as defined by HIV infection, 
haematological malignancy or history of organ transplantation were included. A patient with 
locally advanced breast cancer treated with endocrine therapy only and a patient with 
rheumatoid arthritis treated with sulphasalazine and never requiring long term steroids were 
included. Within this group, 4 patients had a past history of multiple NMSCs. The mean age 
of the cohort was 75 years (range 53-88), 67% were female and 86% were MCV seropositive. 
At the time of blood draw 6 patients had active disease while in patients who were disease 
free, remission lengths ranged from 2-40 months. 
As a comparator group, 25 NMSC patients with active or past history of basal cell cancer 
(BCC) or squamous cell cancer (SCC) but not MCC or overt immunosuppression were 
recruited (see Table 4.2). The mean age of the group was 73 (range 48-87) with 40% female 
and 13 patients had active disease at the time of blood draw. From 23 evaluable patients 52% 
were found to be MCV seropositive. 
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4.2.2 Absolute Lymphocyte counts 
Initially to assess general adaptive immune status of MCC patients, absolute lymphocyte 
subset cell counts were determined from whole blood taken from 21 patients and compared to 
blood collected from 22 NMSC patients (Figure 4.1A). The analysis showed that MCC 
patients had a non-significant reduction in median absolute CD45+ lymphocyte count 
(NMSC:1.53 x109/L, MCC:1.18 x109/L , p=0.07). There was a reduction in all lymphocyte 
subsets with reduced median counts of CD3+ T cells (NMSC:1.09 x109/L, MCC:0.83 x109/L, 
p=0.16) and reduced median counts of NK (CD56+, CD16+) cells (NMSC:0.27 x109/L, 
MCC:0.19 x109/L, p=0.13). However, a significant reduction was seen within the CD19+ B 
cell fraction (NMSC:0.21 x109/L, MCC:0.08 x109/L, p=0.0008) . A similar trend occurred 
when considering frequencies of the different cell types as a proportion of total lymphocytes, 
with the only significant difference between NMSC and MCC patients being in B cell subset 
frequencies (NMSC:11.1% v MCC:7.1% , p=0.006) (Figure 4.1B).Within the CD3+ T cell 
population, there was no significant difference between CD4 and CD8 populations between 
the two cohorts both in absolute (Figure 4.1C) or percentage (Figure 4.1D) terms.  An 
increasing CD4/8 ratio has been described as a marker of an aging immune system [237], but 
there was no significant difference between the values  from NMSC and MCC patients 
(Figure 4.1E). Overall, MCC patients NK and T cell subsets showed similar frequencies and 
numbers while B cell numbers and frequencies were significantly reduced. 
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Figure 4.1. Absolute and percentage lymphocyte subset 
counts for all Merkel cell carcinoma (MCC) (n=21) and 
non melanoma skin cancer (NMSC) (n=22) patients. (A) 
Absolute CD45+ lymphocyte and subsets (CD3+ T cells, 
CD16+CD56+ NK cells and CD19+ B cells) counts from 
NMSC and MCC patients. (B) Lymphocyte subset frequency 
expressed as proportion of total CD45+ lymphocyte counts 
for NMSC and MCC patients. Absolute number (C) and 
frequency (D) of CD4 and CD8 T cell for both NMSC and 
MCC patients. (E) Ratio of CD4:CD8 T cell number for both 
cohorts.  Horizontal lines represent median values. Statistical 
analysis used Mann-Whitney U Test. Where no p value is 
given, result was not significant.   
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4.2.3 B cell differentiation and antibody production 
Given the unexpected finding of reduced total CD19+ B cell numbers in the MCC cohort, we 
further investigated this by examining the differentiation phenotypes of these B cells to assess 
whether this was a subset specific or generalised phenomenon. B cell subsets were defined 
using the markers IgD and CD27 which identify naïve B cells (N, IgD+ CD27-), non-
switched memory cells (NSM, IgD+ CD27+) and switched memory B cells (SM, IgD- 
CD27+). Representative plots from a NMSC and MCC patient are presented in Figure 4.2A. 
Comparing the frequency of B cell subsets in the NMSC to MCC cohorts showed the MCC 
patients had reduced proportions of naïve B cells, equivalent frequencies of non-switched 
memory and increased switched memory populations (p=ns, Figure 4.2B). When considering 
absolute B cell numbers, reductions were seen in all MCC patients B cell populations but 
particularly notable in the naïve subset (p=0.005, Figure 4.2C).  
A reduction in B cell number may be associated with changes in humoral immunity, in 
particular, antibody production. We assessed patient serum immunoglobulin A, G and M 
concentrations in serum samples from 17 of the NMSC patients and 16 of the MCC patients. 
There was no significant difference in mean serum immunoglobulin concentrations between 
the cohorts (Figure 4.3A, Median IgM 0.68g/L NMSC v 0.62g/L MCC , Median IgG 8.90g/L 
NMSC v 9.85g/L MCC , Median IgA 2.81g/L NMSC v 1.91 g/L MCC).    
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Figure 4.2. B cell peripheral blood phenotype of NMSC (n=25) and MCC (n=21) patients. (A) Flow 
cytometry was used to determine frequencies of B cell phenotype subsets. The strategy and plots from a 
representative NMSC patient (P148) and MCC patient (P84) are shown. CD45+CD19+ B cells were 
divided into naïve (N;IgD+CD27-), non-switched memory (NSM; IgD+CD27+) and switched memory 
(SM; IgD-CD27+). (B) Frequencies of B cell subsets as a percentage of total CD19+ B cells for NMSC and 
MCC patients. (C) Absolute numbers of B cell subset cells were determined using patient-specific absolute 
B cell counts from Figure 4.1. 
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Figure 4.3. Assessment of humoral immune response in NMSC (n=25) and MCC (n=21) patients. (A) 
Serum immunoglobulin (IgG, IgA, IgM) concentrations from NMSC (n=17) and MCC (n=16) patients. (B) 
Numbers of responses considered protective (serum concentration >0.35µg/ml, for all 12 antigens tested) 
against T-independent pneumococcal antigens in NMSC (n=17) and MCC (n=16) patients. Pneumococcal 
vaccination rates were 76% in NMSC group and 75% in MCC group. (C) Number of same NMSC and MCC 
patients with protective T-dependent antibody response against tetanus toxoid antigen (defined as serum 
concentration >0.1µg/ml). Horizontal lines represent median values. Statistical analysis by Mann-Whitney U 
test. 
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As total serum antibody levels were unchanged between groups, we next assessed whether 
there were differences in specific antibody responses to vaccine antigens which were either 
independent or dependent on T cell help.  To quantify responses against T-independent (TI) 
antigens, anti-polysaccharide antibodies against 12 pneumococcal strains were measured. 
NMSC patients had a mean number of 7/12 protective responses, defined as serum antibody 
level >0.35µg/ml for each antigen, compared with 5/12 in MCC patients (p=0.03) (Figure 
4.3B). Both groups had nearly identical pneumococcal vaccination rates, 76% NMSC v 75% 
MCC, with a median time since vaccination of 10 years in both groups. Specific antibody 
responses were also measured for a number of T-dependent antigens including tetanus and 
diphtheria toxoids as well as conjugated haemophilius influenzae B polysaccharide.  There 
was no significant difference in numbers of patients with protective responses with 8/15 MCC 
patients compared with 12/17 NMSC patients having serum level >0.1 µg/ml, p=0.84 (Figure 
4.3C). Other TD responses (haemophilius influenzae B and diptheria, data not shown) also 
showed no difference between cohorts. 
 
4.2.4 CD8 T cell differentiation phenotype 
Memory and effector CD8 T cells have an important anti-viral role through killing infected 
cells and suppressing virus replication [200]. However, chronic virus infections particularly in 
the elderly, can lead to the global expression of a highly differentiated TEMRA phenotype on 
these cells which may be associated with dysfunction [368, 370, 375].   As MCV is thought to 
be maintained as a chronic infection, we next sought to compare the CD8 T cell memory 
differentiation phenotype of the two patient groups to determine whether MCC or MCV 
infection is associated with changes in these populations. Using an established phenotyping 
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strategy (Figure 4.4A) [269], we analysed for cell surface marker expression of CD27 and 
CD45RA on CD8 T cells from all donors  and found variable frequencies of different memory 
cell populations (Figure 4.4B).   
 
 
 
 
 
 
 
 
 
Examining whether MCV could affect the frequency of the TEMRA population showed no 
evidence for this comparing MCV seropositive and seronegative patients from both disease 
groups (Figure 4.5A). CMV infection is known to drive the excessive accumulation of 
TEMRA cells and influence the overall CD8 T cell repertoire [368]. To remove this 
potentially confounding factor from our analysis we analysed NMSC and MCC patients for 
CMV serostatus and found similar rates of seropositivity between the groups (56% NMSC 
and 62% MCC patients). As expected CD8 T cells from CMV positive patients more 
frequently showed a highly differentiated CD8 phenotype in terms of frequency and absolute 
cell numbers [375] (Figure 4.5B). When considering CMV seronegative donors, both groups 
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Figure 4.4. Definition and examples of  CD8+ T cell phenotype subsets by flow-cytometric analysis.  (A) 
Flow cytometry strategy to define CD8+ T cell phenotype subsets, Naïve-like (N; CD27+CD45RA+), Central 
memory (CM; CD27+CD45RA-), Effector memory (EM; CD27-CD45RA-), T Effector memory CD45RA 
(TEMRA;CD27-CD45RA+). Representative flow plots from patients with differing subset frequency patterns; 
with either small (P138) or large (P143) TEMRA populations. 
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shared a pattern of increased naïve and central memory T cell frequency and reduced effector 
memory and TEMRA populations. However here there were differences between the two 
groups of CMV negative patients, with CD8 populations from MCC patients having a 
significantly increased median frequency of naïve T cells (21.9% NMSC v 42.3% MCC, 
p=0.01) and reductions in both effector memory (7.7% NMSC v 4.4% MCC, p=0.003) and 
TEMRA (11.6% NMSC v 3.0% MCC, p=0.02) population compared with NMSC patients. 
When considering absolute cell numbers (Figure 4.5C), the increased naïve cell frequency 
seen in MCC patients becomes insignificant.  However, the significant reductions in effector 
memory (median 0.02 v 0.007 x109cells/L, p=0.01) and TEMRA populations are maintained 
(median 0.025 v 0.0065x109cells/L, p=0.046) suggesting that in the absence of CMV co-
infection, MCC is associated with reduced numbers of these subsets.   
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Figure 4.5. Frequencies of each CD8 phenotype subset expressed as proportion of total CD8+ T cells for 
NMSC (n=23) and MCC (n=21) patients. Of the NMSC patients 2 were excluded as serological investigation 
not possible. MCV seropositive and CMV seropositive patients are show in red in (B) and (C) respectively. (D) 
Absolute CD8+ T cell subset numbers in CMV seronegative NMSC (n=9) and MCC (n=8) patients. Horizontal 
lines represent median values. Statistical analysis by Mann-Whitney U test. 
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4.2.5 Lymphocyte proliferation following mitogenic stimulation 
We next turned to study the functional capacity of the lymphocytes from these patients by 
assessing their ability to proliferate in response to the mitogen phytohaemagglutanin. 
Comparison of lymphocytes from NMSC patients and MCC patients revealed a reduction in 
lymphocyte proliferation from MCC patients (573 (NMSC) v 299 (MCC) fold increase over 
non-stimulated cells, data not shown). To determine if reduced proliferation was associated 
with disease state, patients were stratified depending on presence or absence of active disease 
at time of blood draw. Comparing fold proliferation over background, NMSC and MCC 
patients in remission both had similar responses to stimulation (326 (NMSC) v 303 (MCC) 
fold increase). However, when considering patients with active disease, there was a marked 
difference between the two groups: NMSC patients showed high proliferation over 
background while MCC patients had very low proliferative response to stimulation (734 fold 
(NMSC) v 18 fold (MCC) increase, p=0.0002) (Figure 4.6A).  
A potential cause for reduced proliferation of lymphocytes  in MCC patients with active 
disease may be an increase in circulating regulatory T cells (Tregs) and neutrophils which have 
been reported to suppress T cell function [376, 377]. We assessed then numbers of Tregs, 
defined as CD4+CD127lo/CD25high) and neutrophils in all MCC patients comparing those 
with active disease to those in remission. Although there was no difference in Tregs number 
between the MCC patients with active or past disease, there was a trend of increasing absolute 
neutrophil count seen in MCC patients with active disease (4.25x109cells/L NMSC v 5.95 
x109cells/L MCC , p=0.08) (Figure 4.6B and 4.6C).  These results suggested that Tregs or 
neutrophil numbers were unlikely to account for the decrease in proliferation seen in 
lymphocytes taken from MCC patients with active disease. 
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Figure 4.6. Lymphocyte proliferation after 72 hours PHA stimulation of whole blood as determined by 3H 
Thymidine uptake. (A) Whole blood from NMSC (n=23) and MCC (n=19) patients with either active disease 
or disease remission were analysed. Results are expressed as fold change in scintillation count between PHA-
stimulation and background (media only). Absolute number of regulatory T cells (B) and absolute neutrophil 
count (C) for MCC patients in remission or with active disease.  Regulatory T cell counts were determined by 
flow cytometric assessment of frequency of CD4+CD127lo/CD25high cells and converted to absolute numbers 
using patient specific counts as shown in Figure 1. Horizontal lines represent median values. Statistical analysis 
by Mann-Whitney U test. 
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4.3 Discussion 
This study was prompted by the observation that although immunosuppression is a strong risk 
factor for the development of MCC, the majority of patients, who are elderly, exhibit no 
obvious underlying immunodeficiency. The rarity of this tumour and the potential 
confounding from often multiple co-morbidities makes identifying distinct aberrations with 
the immunity of MCC patients extremely challenging. Analysis of peripheral lymphocyte 
subsets showed most were similar between the cohorts although MCC patients showed 
decreases in the B cell compartment mostly from a decrease in the naïve subset and also a 
decreased frequency of T-independent antibody responses.  Lymphocytes from both patients 
groups in remission showed similar proliferative potential, however compared to this group 
and NMSC patients with active disease, lymphocytes from MCC patients proliferated poorly.   
There were a disproportionate number of females in the MCC group, which was difficult to 
avoid given the known increased incidence of MCC in females, which was not present in the 
NMSC cohort [27, 364]. However, as female gender is associated with a reduced incidence of 
an immunosenescent phenotype [378], this makes the changes that we have observed in the 
MCC cohort more striking.  
Although, absolute lymphocyte count was not significantly different between the cohorts, B 
cell number was reduced in both percentage and absolute terms in the MCC group, with 
median values below the 5th percentile of the reference adult population [379]. A reduction in 
B cells is a recognised feature of immunosenescence likely due to preferential differentiation 
of haematopoietic cells to a myeloid rather than lymphoid fate. The most reduced B cell 
phenotype in the MCC cohort was the naïve IgD+CD27- phenotype, with relative sparing on 
the CD27+ memory cells, which mirrors results from other studies investigating immunity in 
the elderly [380, 381].  The prognostic impact of absolute lymphocyte count has been 
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investigated in a retrospective study finding that patients with lower absolute lymphocyte 
count had a worse overall survival independently of factors such as the presence of 
immunosuppression [41]. In this previous study, it was not possible to elucidate whether 
reduction in lymphocyte count was global or limited to a single subset. The present study 
suggests that in non-immunosuppressed patients, the reduction may preferentially involve the 
B cell subset.  
The reduction of circulating B cells seen within the MCC group did not translate into a 
reduction in serum IgG, IgA or IgM concentration when compared with the NMSC patients. 
This echoes the findings of a previous study [251], examining serum immunoglobulin levels 
of elderly donors. We were also able to test frequency and titre of specific antibody responses 
against a variety of T-independent and T-dependent bacterial antigens. The ability to mount 
protective T-dependent antibody responses post-vaccination are not thought to decline with 
age [382], however a significant proportion of elderly people do not make protective 
responses to the T-independent pneumococcal vaccine [383]. All measured T-dependent 
antibody responses (tetanus, diphtheria, haemophilus influenza) were similar between the two 
cohorts while T-independent responses against pneumococcal antigens showed that NMSC 
patients had more protective responses than MCC patients despite almost identical 
vaccination rates.  The reason for this difference is unclear but may be related to the decreased 
numbers and frequency of peripheral naive B cells seen in MCC patients.   
Immunosenescent changes in the T lymphocyte population have been mainly attributed to the 
CD8 T subset [384]. This is thought to be through the expansion of highly differentiated 
memory T cell populations specific for chronic viral infections. We wanted to investigate the 
role that MCV may play in this process, however in the MCC cohort, it was difficult to 
compare seropositive to seronegative groups as there were few seronegative patients. By 
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contrast, in the NMSC group, MCV seropositivity (52%) did not appear to correlate with 
differentiated memory T cell expansion. This is perhaps unsurprising as the size of ex-vivo T 
cell responses for polyomaviruses, such as JCV, BKV and MCV has consistently been found 
to be difficult to detect [289, 293, 385]. However, CMV seropositivity, which was similar 
between both cohorts, was associated with expansions of CD8 TEMRA  cell population 
expansion as has been described previously [246].  Although, CMV co-infection and memory 
inflation is not a pre-requisite for the development of MCC, it potentially may influence MCV 
control or MCC development as CMV infection is accompanied by a reduction of TCR 
diversity which negatively impacts on other anti-viral immune responses [386, 387]. It is also 
interesting to note, when removing the dominant confounding effect of CMV seropositivity 
on lymphocyte subsets, by looking exclusively at CMV negative patients, the MCC cohort 
had lower numbers of effector memory cells than their NMSC peers.  Potentially then there 
may be less T cell mediated immune surveillance in this population leading to poorer control 
of viral driven disease. There is some evidence for the loss of viral control being important for 
MCC pathogenesis with one study showing  increasing serum MCV antibody titres, a known 
surrogate for rising viral load in the skin, can be seen prospectively in patients later diagnosed 
with MCC, in some cases years in advance [137, 337]. After development of MCC, there is 
evidence that patients whose tumours have increased CD8+ T cell infiltration within them 
have improved outcomes [317]. However, the differentiation phenotype of these infiltrative 
cells has not been well characterised and whether they belong to an effector memory subset 
would be interesting question to answer. 
Studying the functional capacity of lymphocytes from the different groups in terms of 
proliferation it was clear that in remission, both MCC and NMSC patients have similar 
proliferative capacity.  This suggests that it is unlikely that MCC patients have an underlying 
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abnormality preventing proliferative lymphocyte responses upon challenge. However, active 
MCC is associated with a marked reduction in proliferative capacity.  Cancer-related 
immunosuppression is widely reported and may be due to the effect of one or a combination 
of influences including increased concentrations of suppressive cytokines such as  IL-10, T 
cell exhaustion or accumulation of cell types with suppressive function such as Tregs or 
myeloid derived suppressor cells (MDSCs) [371]. Investigating Tregs counts, we found that 
there was no difference seen between the patient groups.  Neutrophils, especially from the 
elderly, have been shown to produce more anti-inflammatory cytokines than those from 
young patients [388] and tumour associated neutrophils are capable of inhibiting anti-tumour 
immune response [389]. Investigating neutrophil counts showed a borderline significant 
increase between MCC patients with active disease compared to those without. Although this 
increased neutrophil count may represent increased inflammatory activity related to the 
tumour these may be inhibiting lymphocyte proliferative function in active disease cases. It 
has recently been shown that a raised neutrophil:lymphocyte ratio is a poor prognostic marker 
in MCC associated with worse survival [390]. The impact of circulating MDSCs or 
expression of T cell exhaustion markers was not examined in this study, however it has been 
shown that circulating MCV-specific T cells express high levels of exhaustion markers such 
as PD-1 in patients with active disease [305].  Conceivably targeting this expression may have 
clinical usefulness in future therapies.  
Recent advances in measuring human cutaneous immune responses have shown that the 
function of skin-infiltrating T cells can be quantified and that this immunity wanes with 
ageing [269]. Furthermore in the elderly population at risk of MCC and NMSC tumours, 
localised cutaneous mechanisms of immune suppression such as increases in Tregs or 
expression of exhaustion markers have been identified that are also likely to contribute to 
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cancer development and progression [323, 391, 392]. The question of whether the normal skin 
of patients who have MCC or NMSC display any of these changes or whether they only occur 
following tumour onset is as yet unanswered but should be the focus of on-going research.  
The observations made in this study provide new information that suggests there are 
differences in immune phenotype between MCC and NMSC patients, although this cannot be 
attributable to a single mechanism of immune dysfunction. The subtle differences involving T 
cell, B cell and humoral immunity in MCC patients suggest an on-going multi-factorial 
process that consistent with immunosenescence.  The reasons that MCC patients appear more 
greatly affected when compared with NMSC patients with exposure to broadly similar risk 
factors is not known and warrants further investigation. It does, however, fit with the currently 
held hypothesis that patients who develop MCCs may be less able to control viral infections, 
such as MCV, that initiates tumourigenesis. MCC patients may also be less able to control 
other types of infections (e.g. pneumococcal), particularly at times of active disease, which 
may have clinical importance when treating these patients with agents such as chemotherapy.  
Lastly, given the breadth of changes seen in MCC patients, the use of immunomodulatory 
therapies for MCC may need to be multi-targeted in order to exert maximal benefit.
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Chapter 5  
T cell Immunity Against MCV Large T and Small T-antigens 
5.1 Introduction 
The cellular immune response is integral to establishing control and limiting the pathogenic 
consequences of viral infections. Polyomaviruses usually cause asymptomatic chronic 
infections in their hosts however disruptions to the virus host balance, such as 
immunosuppression for bone marrow or organ transplant, can result in BK virus-associated 
nephropathy and JC virus-associated progressive multifocal leukoencephalopathy [149, 150]. 
This suggests T cell immunity has an important role in the control of polyomavirus infections 
and prevention of disease in humans. Recently, another polyomavirus, Merkel cell 
polyomavirus, has been strongly associated with Merkel cell carcinoma, which can be seen in 
apparently immunocompetent individuals but exaggerated disease may be seen in patients 
whose T cell responses are suppressed, also implying a role for these effectors in control of 
disease caused by this virus [42, 337].  
The nature of T cell immunity directed to MCV in controlling MCV viral reactivation and the 
role it plays in controlling development of MCC is poorly understood. Data presented in the 
previous chapter has shown that the reduced T cell frequency by itself is unlikely to explain 
tumour occurrence in MCC patients compared to a relevant control group of NMSC patients.  
However, it is not clear whether any differences exist in the frequency or function of MCV-
specific T cells between these groups. Similarly existing knowledge on the quantity of 
circulating functional MCV-specific T cells and how this varies between healthy people and 
MCC patients is limited. Of the studies undertaken, T cell responses to the truncated T-
antigen fragments retained in MCC tumours showed a trend toward increased Common T 
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(CT, the first 78 amino acids shared by both LT and sT proteins), LT- and sT-specific T cell 
frequencies in MCC patients compared to controls. However there was no assessment of 
responses to the terminal portion of LT which is present in intact MCV infections and no 
stratification of healthy donors based on MCV seropositivity. [385]. 
In order to better understand how T cell control of MCV is mediated, it is necessary to 
identify specific T cell epitopes presented by MCV infected cells that are capable of 
stimulating immune responses. So far the number of currently identified MCV LT and sT T 
cell epitopes is limited, however an intensive search using MHC multimers loaded with 
potential epitope-peptides identified nine LT and three sT MHC Class I epitopes, again 
focusing on the truncated LT-antigen [306]. On examining peripheral blood of MCC patients 
and healthy donors, only MCC patients displayed evidence of T cell responses against these 
T-antigen epitopes. Additionally, a number of MCV peptides capable of inducing functional 
responses from either CD8 and CD4 T cells have been mapped, however their counterpart 
MHC molecules have mostly not been identified [385]. The only formally identified epitope 
using this screening method is an HLA:A24 LT sequence (aa92-101), recognised by T cells 
isolated from tumour and blood of an MCC patient. Using MHC class I tetramer analysis, T 
cells recognising this epitope were enriched in tumours as compared to the peripheral blood. 
Also in two other HLA:A24 MCC patients, tetramer staining cells were present at a low 
frequency in the peripheral blood, however these did not appear functional, as defined by lack 
of production of IFNɣ after ex vivo stimulation with the peptide. 
Alongside CD8 T cells, there is increasing evidence of the importance of CD4 T cells with 
regard to controlling both polyomavirus infection [298, 324] as well as polyomavirus 
mediated tumours [309]. There have been no formally MHC restricted CD4 epitopes 
identified to date, although a number of peptides from truncated LT and sT have been shown 
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to induce CD4 T cell responses in PBMCs from both MCC patients and healthy controls 
[385]. Similarly CD4 T cells specific for a CT (aa57-69) peptide isolated from the tumour of 
an MCC patient have been found to secrete the Th1 and Th2 cytokines, IFNɣ, IL-5 and IL-10 
after ex vivo expansion and challenge with this peptide potentially raising a role for these 
effectors in MCC [385].  
In terms of understanding the role of MCV-specific T cells in vivo, studies have been 
performed examining the ex vivo frequency and cell surface phenotype of CD8 T cells 
specific for the HLA:A24 presented peptide from LT [305]. Here the frequency of these 
MCV-specific T cells positively correlated with disease burden, and these T cells expressed 
high levels of checkpoint inhibitor receptors such as PD-1 and Tim-3. This MCV-specificity 
in MCC patients also expressed the skin homing receptor Cutaneous Lymphocyte Antigen 
(CLA) on 39% of tetramer positive cells (mean value, n=4), which was significantly more 
frequent than that seen on T cells specific for non-skin-tropic viruses EBV and CMV [321]. 
This finding may be expected given that MCV DNA is found commonly on the skin, which is 
thought to represent shed viral particles [125]. So far ex-vivo analyses of MCV-specific T cell 
responses have only been conducted on material from MCC patients and so the phenotype of 
such cells in MCV-seropositive healthy donors, who are apparently controlling their MCV 
infection, is largely unexplored.   
The aims of this work were to firstly quantify MCV LT- and sT-specific T cells in the 
peripheral blood of MCC patients and compare these to two other groups namely patients 
with non-melanoma skin cancers and healthy volunteers. Secondly using blood from suitable 
donors and primary MCC tumours, establish MCV-specific T cell clones specific for LT and 
sT epitopes.  These T cell clones were then used to map responsive LT and sT peptides, their 
restricting elements identified and the clones used to examine antigen processing and 
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presentation of these epitopes by antigen expressing cells.  Lastly, I aimed to characterise the 
MCV-specific T cells ex vivo phenotype using tetramer based flow cytometric analyses. 
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5.2 Results: 
5.2.1 Detection of MCV-specific T cell responses in different patient groups 
In this first section of the study, experiments were conducted to identify MCV-specific T cell 
responses which would allow estimation of the size and epitope identity of LT- and sT-
reactivities.  Initially, it was planned that tumours which had been resected from patients 
would have the lymphocyte component stimulated with a panel of overlapping peptides which 
spanned the LT and sT sequences (Figure 5.1), to amplify MCV-specific T cells and these 
used to identify epitopes.  However, of the tumours collected (n=3) diagnostic pathology 
analysis indicated that none of these expressed LT and were considered MCV negative (P. 
Taniere personal communication).  Consistent with this, when lymphocytes were stimulated 
with the LT and sT peptides and assessed for IFNɣ production, no MCV-specific responses 
were detected in lines grown from these tumours (data not shown). 
As a second source of MCV-specific T cells, PBMC samples were accessed from MCC 
patients and initially the size of the MCV LT- and sT-specific response estimated by IFNɣ 
ELISpot in response to stimulation with the overlapping T-antigen peptides.  As the MCC 
patients were typically frail and PBMC recoveries were generally low, the overlapping 
peptides were grouped into pools of 30-40 peptides and these pools used to stimulate 
responses. Additionally a second comparator patient group was included; patients with non-
melanoma-skin cancer (NMSC).  These patients have a similar demographic profile, with 
similar risk factors and also included a more equal proportion of MCV seropositive and 
seronegative donors. 
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Figure 5.1. Schematic representation of overlapping peptide pools used in T cell recognition assays. Each 
pool was made up of 15mer peptides spanning Common T (CT), Large T (LT) and Small T (sT) regions of the 
MCV T-antigen protein. 
 
PBMC were isolated from MCC and NMSC patients, who had been previously assessed for 
MCV serostatus (see Chapter 3), and these challenged with the overlapping panels of LT and 
sT peptides in IFNɣ ELISpot assays.  As controls, in these assays the PBMC samples were 
assessed for their response to two positive controls: first a mitogenic stimulus 
phytohaemagglutinin (PHA) and second, a mixture 23 peptides corresponding to common 
MHC Class I CMV, EBV and influenza epitopes (CEF) which induces IFNɣ responses in 
90% of Caucasian people. The negative control was the peptide solvent dimethyl sulfoxide 
(DMSO). 
Using this protocol, ELISpots were performed on blood from 18 MCC patients and 17 NMSC 
patients. Of the MCC patients, 15 of 18 were MCV seropositive (83%) while 10 of 17 NMSC 
patients were MCV seropositive (59%). The overall results of the ELISpots expressed as spot 
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forming cells (SFC) per million PBMC are shown in Figure 5.2A-D, with MCC and NMSC 
patients split depending by MCV serostatus. Responses to PHA appeared to be similar in all 
four groups and there was no significant difference when analysed using the Kruskall-Wallis 
test. Lymphocytes from the majority of donors made responses to CEF peptides although a 
number of MCV seropositive donors in both MCC and NMSC groups showed stronger 
responses to these peptides compared to the MCV seronegative groups.  No significant 
difference in SFC numbers was seen between the groups using Kruskall-Wallis test.  The 
responses to these control antigens indicated that the lymphocytes within the PBMC 
preparations were functional. 
When considering responses to MCV T-antigen peptide pools, these were of low frequency in 
all four groups with no donors having greater than 100 IFNɣ SFC per million PBMC. Of the 
weak responses observed these were seen after stimulation with the pool containing peptides 
corresponding to the LT aa721-816 and sT aa70-186 in MCV seropositive groups (both MCC 
and NMSC) compared with seronegative groups. However, statistical analysis using the 
Kruskall-Wallace test indicated that there was no difference in frequencies of responses 
between any of the 4 donor groups. Overall, these assays showed that there are low 
frequencies of IFNɣ secreting MCV T-antigen-specific T cells in the peripheral blood of 
MCC and NMSC patients.  
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Figure 5.2. IFNγ ELISpot results using peripheral blood mononuclear cells from MCC and NMSC 
patients stimulated with MCV T-antigen peptides. PBMCs from MCV seropositive and seronegative MCC 
(A+B) and NMSC (C+D) patients were used in IFNγ ELISpot assays following stimulation with MCV T-antigen 
peptides, Phytohaemagglutinin (PHA) and CMV, EBV and Flu (CEF) peptides (both positive controls) and 
DMSO (negative control). The magnitude of response was calculated from the mean value of duplicate wells – 
background (DMSO) and adjusted to no.IFNγ producing cells/million PBMCs. Each point represents an indidual 
donor response to each pool of peptides. 
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5.2.2 Quantification of MCV-specific T cell frequency in the peripheral blood of healthy 
donors 
Both MCC and NMSC patients in the studied cohorts were elderly with median age over 70 in 
both groups. Although patients with known immunosuppression were not included in this 
study, it was conceivable that the anti-viral immune response in the elderly may not be as 
robust as in younger healthy donors. Therefore, a further cohort of 19 healthy volunteers was 
recruited of whom 14 (74%) were MCV seropositive and had a mean age of 44 years old 
(range 22-60). This allows for further comparison with a group of donors that have been 
exposed to MCV, but do not fall into the characteristic demographic of patients that develop 
MCC. However, when IFNɣ ELISpots were conducted on PBMCs from these donors using 
the MCV T-antigen peptides, the majority again showed low frequencies of MCV specific 
IFNɣ secreting T cells in both the MCV-seropositive (Fig 5.3A) and -seronegative (Fig 5.3B) 
populations. There did appear to be an increased number of MCV seropositive donors making 
detectable responses against sT aa125-186 compared with MCV seronegative donors, but no 
statistically significant association was seen. From this cohort, two donors made larger 
responses to a particular pool of peptides. One of these, MCV seropositive donor 14464, 
made a response to the pool of peptides corresponding to LT aa 541-610. The second donor, 
MCV seronegative 14461, made a response against peptides corresponding with LT aa 601-
670. Overall, MCV-specific cells which secrete IFN-g after challenge with peptides are found 
in a low frequency in peripheral blood of healthy MCV seropositive donors as well as 
seronegative donors.  
 
 
  Chapter 5: Results 
154 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. IFNγ ELISpot results using peripheral blood mononuclear cells from MCV+ and MCV 
negative healthy volunteers stimulated by MCV T-antigen peptides.  PBMCs from 14 MCV seropositive (A) 
and 5 seronegative (B) healthy donors were used in IFNγ ELISpot assays following stimulation with MCV T-
antigen peptides, Phytohaemagglutinin (PHA, positive control) and DMSO (negative control). The magnitude of 
response was calculated from the mean value of duplicate wells – background (DMSO) and adjusted to no. IFNγ 
producing cells/million PBMCs. Each point represents an individual donor response to each pool of peptides. 
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5.2.3 Generation of MCV-specific T cell clones using blood from healthy donors 
The results of the previous section quantifying IFN-g secreting PBMC in response to 
challenge with the T-antigen peptides indicated that weak responses were mostly found in all 
donor groups and this would make epitope mapping difficult.  To identify T-antigen epitopes, 
an alternative strategy was used through the generation of MCV-specific T cell clones which 
could be used to map epitopes and restricting elements as well as be used as tools to study 
antigen processing of T-antigens. This work focussed on generating T cell clones from 
PBMCs of healthy donors due to the increased ability to perform larger volume blood 
donations as well as being able to access the two donors who made strong ELISpot responses 
to specific peptide pools.  
A panel of MCV seropositive healthy donors as well as seronegative donor 14461, who made 
a significant response to LT 601-670 peptide pool, were selected to generate T cell clones. 
PBMCs from these donors were expanded into polyclonal cultures enriched for MCV 
specificities by stimulating these with the T-antigen peptides and allowing them to grow for 
one week. T-antigen-specific cells were then enriched from these cultures by re-challenging 
with the peptides and magnetically sorting IFN-g secreting these cells.  These were then 
subjected to limiting dilution cloning and after further expansion the specificity, restriction 
and functional avidity of the clones determined. 
Figures 5.4 and 5.5 show how this characterisation process was undertaken. Figure 5.4 shows 
data from analysis of clone 98 (c98) from healthy donor 14496 which when stimulated with 
the pools of the T-antigen peptides recognised a peptide from within the CT 1-70 pool as 
determined by secretion of IFNɣ in ELISA assay (Fig 5.4A). Repeating recognition assays 
using the individual peptides that made up pool CT 1-70 indicated this clone was specific to 
peptide, NIP (Fig 5.4B).  Clones were confirmed to be either CD4 or CD8 by staining with 
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antibodies specific for these markers and analysing by flow cytometry, with c98 being CD4 
(Fig5.4D). To determine the MHC Class II molecule which presents this peptide, the ability 
of antibodies specific to MHC-DR or MHC-DQ to prevent recognition of EBV transformed B 
cells (LCL) sensitised with this peptide was initially assessed. Here, autologous LCLs were 
loaded with peptide, washed and then incubated with either anti-DR, anti-DQ antibody or 
without antibody. Peptide-specific T cells were then added and recognition assessed by 
measuring IFNɣ from the T cells by ELISA. In the example using NIP peptide, it was 
confirmed that T cell c98 peptide recognition was reduced when presentation was blocked 
using anti-DR antibody but unaffected with anti-DQ antibody, indicating the peptide is likely 
presented by MHC-DR molecules (Fig 5.4E). To identify which DR type presented the NIP 
peptide, c98 T cells were challenged with peptide loaded, partially DR-matched LCLs and 
recognition assessed by IFNɣ ELISA assays. Recognition, as demonstrated by secretion of 
IFNɣ was only seen in HLA-DR13 matched LCLs, indicating the NIP peptide is presented by 
HLA-DR13 molecule (Fig 5.4F).  The functional avidity of c98 was then determined by 
repeating IFNɣ ELISAs assessing the clone’s response to target cells sensitised with 10-fold 
dilutions of peptide (Fig 5.4C). In the case of c98, functional avidity as measured as the 
concentration which gives 50% maximal IFN-g production was 10-8M of peptide. 
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Figure 5.4. Identification of a CD4 T cell clone specific for HLA-DR13 MCV LT epitope, NIP.  T cell clone 
c98 isolated from healthy donor 14496 was screened for IFNγ secretion by ELISA after stimulation with T-
antigen peptide pools (A), followed by individual peptides from the reactive pool (B). The functional avidity 
(peptide conc. required for 50% max IFNγ production) was calculated by incubating T cells with autologous 
LCL sensitised with 10-fold dilutions of NIP peptide. (C). Using flow cytometry, the clone was assessed for 
surface CD4 or CD8 expression (D). MHC Class II subtype presenting NIP peptide was assessed by ability of T 
cell clone to recognise peptide-sensitised autologous LCL in the presence or absence of anti-DR and anti-DQ 
antibodies (E). MHC restriction of clone was assessed by sensitising partially HLA-DR matched LCLs with NIP 
peptide, incubating with T cell clone and measuring IFNγ release (F). 
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Figure 5.5 shows the characterisation of T cell clone, c190, isolated from healthy donor 14464 
PBMCs. This clone was able to recognise peptide FKG within pool LT 541-610 (Fig 5.5A 
and B).  Flow cytometric analysis showed this clone was CD8 (Figure 5.5C). Using FKG 
peptide loaded partially HLA-matched LCLs, recognition only occurred with LCLs matched 
for HLA-B7, indicating that the peptide FKG is presented through the HLA-B7 molecule. 
(Figure 5.5D). Unlike Class II epitopes, MHC Class I peptides generally have a defined 
length of 8-10 amino acids. As such, the 15mer FKG peptide (FKGPINSGKTSFAAA) likely 
contains the minimal HLA-B7 epitope sequence. It is well recognised that HLA-B7 epitopes 
share common features including proline at position two and a hydrophobic or aromatic 
residue at the C-terminal anchor position [393].  This aided the prediction of a likely minimal 
epitope GPINSGKTSF, with a proline at position two and phenylalanine (a large aromatic, 
hydrophobic amino acid) at position 10. A series of overlapping peptides encompassing this 
region was synthesised and used to sensitise MHC-B7 matched LCLs at ten-fold 
concentrations ranging from 10-6M to 10-9M.  The recognition of c190 T cells at these varying 
peptide concentrations was assessed in IFNɣ ELISA (Fig 5.6). From this experiment, it could 
be seen that the sequence GPINSGKTSF was recognised by the T cell clone even at low 
concentrations (functional avidity 10-8-10-9M) and this recognition was greater than that of the 
15mer FKG peptide. The other candidate minimal epitopes were comparatively poorly 
recognised by the T cell clone. Therefore, the minimal HLA-B7 epitope was concluded as 
being the GPINSGKTSF sequence and will henceforth be referred to as GPI.  
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Figure 5.5. Identification of a CD8 T cell clone specific for HLA-B7 MCV LT epitope, FKG. T cell clone 
c190 isolated from peripheral blood of healthy donor 14464was screened for IFNγ secretion by ELISA after 
stimulation with T-antigen peptide pools (A), followed by individual peptides from the reactive pool (B).  Using 
flow cytometry, the clone was assessed for surface CD4 or CD8 expression (C). MHC restriction of clone was 
assessed by sensitising partially MHC Class I matched LCLs with FKG peptide, incubating with T cell clone and 
measuring IFNγ release (D). 
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Figure 5.6. Identification of minimal HLA-B7 CD8 T cell epitope, GPI. Using the original 15mer FKG 
peptide, four candidate 10mer peptides were synthesised and all were used at used to sensitise autologous LCL at 
10-fold serial dilutions to stimulate T cell clone c190 in IFNγ ELISA. The functional avidity (peptide 
concentration required for production of 50% maximal IFNγ production) was calculated for each candidate 
peptide. 
 
Overall, successful T cell cloning experiments using four donors resulted in the identification 
of eight novel Class II restricted and one novel Class I restricted MCV T-antigen-epitopes 
(summarised in Table 5.1).  Of the Class II epitopes, 2 (LLE and NIP) were found in the CT 
region and the remainder found in the LT region. MCC specific LT mutations are individual 
and result in truncated proteins varying in length between 258 amino acids in tumour 
MCC350 (GenBank: JN038583.1) to 469 amino acids in tumour MCC339 (GenBank: 
EU375804.1). Therefore, two Class II epitopes (ALD, QSE) are found outside this region and 
are only likely to be retained in the full length T-antigen. The frequency of T cell clones 
isolated against the majority of Class II targets was low, with the exception of ALD (LT 631-
646) specific response against which 85 clones were generated from blood of an MCV-
seronegative donor 14461. This correlates with the significant ELISpot response seen using 
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cells from the same donor in response to peptide pool LT 601-670 (Fig 5.3B), suggesting this 
response was likely to be specific for the ALD peptide. There were 2 donors (14457 and 
14464) who made low frequency responses against the same HLA-DR15 epitope PID. The 
HLA-B7 Class I epitope was discovered after peripheral blood from donor 14464 was found 
by ELISpot to contain a high frequency of CD8 T cells  directed against a pool of peptides, 
subsequently identified as being specific for the GPI epitope, found outside the truncated 
region of LT. 
             Table 5.1. Identified CD4 and CD8 MCV Large T-antigen epitopes.  
 
 
 
 
 
 
 
 
 
 
 
 
CD4 
CD8 
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5.2.4 Recognition of antigen presenting cells fed MCC tumour cell lysate by MCV specific 
CD4 T cell clones  
The previous set of experiments provided a number of CD4 clones capable of recognising 
15mer peptides corresponding with the MCV T-antigen. To validate that these clones could 
recognise processed and presented antigen, a series of experiments was undertaken where 
MCV proteins were loaded on cells and these assessed for their ability to process and present 
peptide-epitopes from these proteins to the T cell clones.  Here autologous LCLs were fed 
different concentrations of lysates from either the MCC line MKL-1, which expresses a 
truncated form of LT (amino acids 1-330) or lysates from the MCV negative tumour line 
MCC13, and these incubated with the T-antigen-specific CD4 T cells. The ability of the T cell 
clones to recognise the lysate fed LCLs was assessed by IFNɣ ELISA.  As shown in Figure 
5.7, this experiment showed that T cell clones specific for epitopes LLE, NIP, KEW, TPP and 
PID were all able to recognise antigen presenting cells fed with the MKL-1 (MCV+) lysate 
and recognition decreased as lysate concentration reduced. These epitopes are all retained by 
the truncated T-antigen expressed by the MKL-1 cell line. However the T cell clone specific 
for the LT-antigen epitope, ALD, which is lost by the MKL-1 truncation, did not recognise 
LCLs fed with MKL-1 lysate. None of the T cell clones recognised LCLs fed with MCV 
negative MCC13 lysate. These studies indicate that peptides identified within the truncated T-
antigen are valid epitopes. 
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Figure 5.7. CD4 T cell clone recognition of autologous LCL fed with MCC tumour cell line lysates, MKL-1 
(MCV+) and MCC13 (MCV negative).  CD4 T cell clones specific for MCV T-antigen peptides were 
incubated independently with autologous LCLs fed either MKL-1 lysate, MCC13 lysate or loaded with cognate 
peptide (positive control) or DMSO (negative control).  IFNγ secretion was measured by ELISA. The position of 
each epitope on the T-antigen is represented schematically along with position of truncation of T-antigen in 
MKL-1 cell line.  
 
 
 
0
2000
4000
6000
10000
15000
20000
IF
N
  (
pg
/m
l)
Lysate 400  
Lysate 200  
Lysate 100  
Peptide  
DMSO 
x 
MKL-1  
Lysate 
MCC13  
Lysate 
x 
c27(LLE)  T cell  
clon
e 
c6(NIP)  c8(KEW)  c16(TPP)  c278(PID)  c16(ALD)  
              LT antigen 
MKL-1 LT      
truncation mutation 
MKL-1  
Lysate 
MCC13  
Lysate 
x MKL-1  
Lysate 
MCC13  
Lysate 
x MKL-1  
Lysate 
MCC13  
Lysate 
x MKL-1  
Lysate 
MCC13  
Lysate 
x MKL-1  
Lysate 
MCC13  
Lysate 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Cell line 
  Chapter 5: Results 
164 
 
It is conceivable that through the lysate production process, short fragments of the T-antigen 
could be created through degradation of the protein and that these are able to bind directly to 
surface MHC Class II.  To confirm whether the lysate was being processed and presented 
through the MHC Class II pathway LCLs were either fixed immediately upon feeding to with 
lysate to preventing processing but not presentation, or fixed after 18 hours of processing with 
1% paraformaldehyde. Positive and negative controls were LCLs loaded with peptide or 
DMSO respectively. These LCLs were then used in recognition assays with clones 
corresponding to two of the MCV T-antigen-epitopes, PID and KEW. As shown in Figure 
5.8, the ability for the LCL to bind peptide to the surface MHC Class II molecules is not 
affected by the fixation process for either of the two clones.  T cell recognition did not occur 
if cell fixation took place at time of feeding, indicating that presence of fragments 
corresponding to the epitope peptide within the lysate preparation was unlikely. Overall, this 
work confirms that the CD4 MCV T-antigen-epitopes discovered through T cell cloning are 
processed and presented by cells with functional antigen presenting machinery. Due to our 
finding, discussed in chapter 6, that MCC tumours and cell lines do not express surface MHC 
Class II, the role of these CD4 T cells was not likely to be as cytotoxic effectors and so further 
analysis of these clones was not conducted as part of this project.  
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Figure 5.8. Impact of cell fixation on CD4 T cell clones recognition of autologous LCLs fed MKL-1 lysate. 
CD4 T cell clones, c8 (specific for KEW) and c278 (specific for PID), were incubated with autologous LCLs 
fixed in 1% paraformaldehyde either immediately or 18 hours after feeding with MKL-1 lysate. LCLs sensitised 
with cognate peptide or DMSO were used as positive and negative controls respectively. 
 
5.2.5 Ex-vivo phenotypic analysis of MCV specific CD8 response using tetramer flow-
cytometric analysis.  
Very little is known about the characteristics of MCV-specific T cells. The majority of work 
that has been done is limited by the low frequency of circulating MCV specific T cells and so 
have often relied on cultured expansion of these cells which is likely to alter their phenotype. 
The purpose of this next portion of work was to use the identified HLA-B7 epitope, GPI, to 
create an MHC class I tetramer for use in flow cytometric phenotyping analysis of ex-vivo 
PBMC samples to better understand how these cells may behave in vivo. 
As a first step, it was essential to validate that the GPI epitope was capable of being processed 
and presented on the cell surface. To confirm this, the HLA-B7 melanoma cell line MelJuSo 
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(MJS), was transfected with the pCDNA3-IRES-nls-GFP plasmid expressing MCV wild type 
LT (WTLT) or the control pCDNA3-IRES-nls-GFP empty vector. Using IFNɣ ELISA, we 
could show that the MCV GPI-specific T cell clone, c190, was able to recognise WTLT 
expressing MJS cells but not MJS cells expressing the control empty vector (Figure 5.9). This 
experiment did confirm that the MCV GPI LT epitope is capable of being processed and 
presented by a model cell line.   
 
 
 
 
 
 
 
Figure 5.9. Recognition of WTLT MCV GPI epitope by T cell clone c190 following processing and 
presentation by MJS cells. MJS cells (HLA-B7+) were transfected with pCDNA3-IRES-nls-GFP plasmid expressing  
wild type LT (WTLT) or the plasmid backbone alone (pCDNA3 only). MJS cells loaded with 5µg/ml GPI peptide or DMSO 
were used as positive and negative controls respectively. After 24 hours, GPI-specific T cells were added and recognition 
assessed by IFNɣ ELISA. 
 
From initial ELISpot screening, donor 14464, from whom GPI specific CD8 T cells had been 
cloned, showed a readily detectable frequency of GPI-specific T cells in the peripheral blood. 
PBMCs from this donor where therefore used as a positive control to test the tetramer was 
able to stain GPI-specific CD8 T cells. As shown in Figure 5.10A, using blood from donor 
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14464, a population of CD8 cells stained with tetramer with a frequency measuring 0.204%.  
No detectable CD8 tetramer staining was seen in PBMCs from an HLA-B7 MCV 
seronegative healthy donor, 14495 (Figure 5.10B) showing the specificity of this reagent. 
In order to understand whether the detectable tetramer response seen in donor 14464 was 
generalizable to other HLA-B7 MCV seropositive donors, PBMCs from relevant donors were 
stained with tetramer and sizes of responses are shown in Figure 5.10C. Alongside healthy 
donors, PBMCs from a single HLA-B7 MCC patient, P84, were also used in the tetramer 
staining assay. The frequency of tetramer positive cells in all screened donors was very low, 
ranging from 0.002-0.019% of CD8 cells. Interestingly, the tetramer staining cells in these 
donors did not stain to the same intensity as seen in donor 14464. However, the fact that there 
are MCV seropositive donors who do not have any detectable tetramer binding cells (e.g 
14498, 14501), suggests that this is may not be simply due to non-specific binding.  
Additionally, donor 14463, in whom tetramer binding CD8 cells were seen at a frequency of 
0.017%, did make a small but reproducible response to the pool containing GPI peptide in the 
ELISpot screening experiments described in Figure 5.3A. The discordant results between 
tetramer and ELISpot assays are further discussed in section 5.2.6. The MCV patient, P84, 
included in these assays also had a similar low frequency of CD8 tetramer binding cells in the 
peripheral blood (0.019%). However, in this case, no detectable IFNɣ response was detected 
in ELISpot screening, possibly suggesting these cells do not secrete IFNɣ. Overall, these 
tetramer assays showed that although a significant MCV GPI-specific tetramer response was 
detectable in one healthy donor, the majority of healthy donors and one MCC patient had very 
low frequencies of tetramer binding CD8 T cells.  
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Figure 5.10. Screening of HLA-B7 healthy donors for populations of MCV GPI-specific T cells. PBMCs 
from HLA-B7+ healthy donor 14464, from whom GPI specific CD8 T cells were isolated, were stained with 
GPI-tetramer and CD8 (A). PBMCs from healthy donor 14495 who was HLA-B7 but MCV seronegative were 
also stained with tetramer and CD8 to act as negative control (B). PBMCs from a panel of HLA-B7 healthy 
donors alongside one MCC patient (P84) were stained with GPI tetramer and CD8. 
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The GPI tetramer was next used to characterise the cognate T cells in PBMC from donor 
14464. We were interested in in the differentiation status of these cells (using CD45RA and 
CCR7 surface expression), as well as whether they exhibit a skin homing phenotype (using 
CLA, CCR4 and CCR6 surface expression) as may be expected by cells specific for the skin-
associated MCV. This CD8 T cell response could then be compared with that of CD8 T cells 
specific for other viruses, namely the skin-tropic Herpes Simplex Virus (HSV) and 
lymphotropic Epstein-Barr Virus (EBV).  In donor 14464, the majority of MCV GPI-tetramer 
positive cells displayed an effector memory type phenotype being CCR7-CD45RA-. There 
were some apparent CCR7+ CD45RA+ tetramer positive cells; a phenotype that has been 
seen in other polyomavirus LT specific CD8 T cells (Ester Remmerswaal, Personal 
communication).  With regard to expression of skin homing markers, there was only a slight 
increase in the frequency of tetramer positive cells expressing CLA (10%) when compared 
with tetramer negative CD8 cells (4%) (Figure 5.11A).  
Although the GPI-tetramer response was very small in HLA-B7 MCC patient P84, an attempt 
was made to perform some characterisation of tetramer positive cells however the low 
frequency of tetramer binding cells means these results must be interpreted with much caution 
(Figure 5.11B). Again the majority of cells were CCR7-CD45RA-, however in this case, 
although cell numbers were small, an increased frequency of expression of skin homing 
markers was seen in tetramer positive cells as compared with tetramer negative cells. Of the 
tetramer positive cells, 50% expressed CLA and 92.9% expressed CCR4. This was in 
comparison to tetramer negative cells, of which 4.2% were CLA positive and 1.25% were 
CCR4+. There was negligible CCR6 expression seen in either tetramer binding or tetramer 
non-binding CD8 T cells. 
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As a comparator viral response with expected skin-tropism, the Herpes Simplex Virus 1 (HSV 
1) glycoprotein gD HLA-A2 specific response against the VLL epitope (gD70-78) was used. 
Following tetramer screening of multiple donors HLA-A2 healthy donors (data not shown), 
donor 14457 was shown to have the most detectable tetramer response and so was used in 
further characterisation assays. In these, VLL tetramer binding CD8 T cells did show an 
increased frequency of expression of skin homing markers (CLA: 45%, CCR6:51.5%, CCR4: 
98.5%) when compared with tetramer negative CD8 cells (Figure 5.11C).  
As a control response from a virus not thought to be skin-associated and against which virus-
specific CD8 T cells do not express high levels of CLA [289, 321], responses against EBV 
lytic and latent HLA A2 and HLA B7 epitopes were measured and characterised using 
healthy donors 14464, 14463 and 14457 (Figure 5.12). In our assays, using tetramers specific 
for HLA-A2 BMLF1 epitope GLC, and HLA-B7 EBNA 3A epitope RPP, it was seen that, as 
expected, tetramer binding cells showed a low frequency of expression of skin homing 
markers (4-10% CLA expressing) as compared with tetramer negative cells.  
Overall, characterisation of MCV-specific response in healthy donor 14464 shows that the 
majority of these cells are of effector memory type (CCR7-CD45RA-) and do not show any 
evidence for increased expression of markers of skin-homing in comparison to EBV specific 
T cells. This is in contrast to the MCV-specific response seen in MCC patient P84 in whom, 
although the size of response is small, there is an increased frequency of MCV-tetramer 
binding cells expressing skin homing markers to a similar level seen in the skin tropic HSV 
response.  
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Figure 5.11. Characterisation of MCV GPI specific CD8 T cell response and comparison with HSV VLL 
CD8 response. PBMCs from healthy donor 14464 (A) and P84 (B) were stained with MCV GPI HLA-B7 
tetramer. PBMCs from healthy donor 14457 were stained with HSV VLL HLA-A2 tetramer. Tet+ and Tet- CD8 
T cells from were analysed for expression of CCR7, CD45RA, CLA, CCR6 and CCR4.  
 
  Chapter 5: Results 
172 
 
 
Figure 5.12. Characterisation of EBV specific CD8 T cell responses against GLC and RPP epitopes. 
PBMCs from HLA-A2+ donors 14457 (A) and 14464 (B) were stained with GLC tetramer. PBMCS from donor 
14463 was stained with RPP tetramer (C). Tet+ and Tet- staining CD8+ T cells  were analysed for expression of 
CCR7, CD45RA, CLA, CCR6 and CCR4.  
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5.2.6 Investigating cross reactivity of CD8+ T cell clones specific for MCV GPI epitope 
As stated earlier, ELISpot screening assays had suggested that alongside donor 14464, donor 
14463 would also be expected to have a detectable response in MCV GPI tetramer assays. 
Both donors 14464 and 14463 show serological evidence of infection by multiple 
polyomaviruses with 14464 having serum antibody VP-1 responses against BKV, KI, WU, 
HPyV6, HPyV7, TSV and HPyV10. Donor 14463 has serum antibody responses against 
BKV, JCV, KI, WU, HPyV6, HPyV7, TSV, HPyV9 and HPyV10. Given the homology of the 
MCV T cell epitope, GPI (see Table 5.2), amongst the other members of the polyomavirus 
family we were interested to know whether the IFNɣ secreting PBMCs from donor 14463, 
detected by ELISpot assay but not through tetramer staining, were specific for one of the 
homologous epitopes. In addition to this, we wanted to see whether T cells specific for the 
other polyomavirus homologs could be detected alongside MCV specific tetramer binding 
cells in PBMCs from donor 14464.  In order to do this, polyclonal cultures using PBMCs 
from both donors were set up by stimulating with a mix of five synthetic peptides, each 
corresponding to a GPI epitope homolog from the known human polyomaviruses (MCV and 
HPyV12: GPINSGKTSF,  JCV and BKV: GPIDSGKTTL, KI, HPyV6,7,9: GPINSGKTTL, 
WUV, HPyV10: GPINSGKTTV, TSV: GPINSGKTTF). T cell clones were established as 
before and an aliquot of each proliferating clonal culture was screened in IFNɣ secretion 
ELISA following stimulation with the mix of five peptides at micromolar concentration. 
Specific clones were then expanded in culture and then re-screened with IFNɣ ELISA as 
before. Of nine expanded CD8 clones initially identified from donor 14464, six were 
confirmed to be specific for the peptides following repeat ELISA. From donor 14463, of 64 
CD8 clones selected for bulk expansion, 55 had confirmed specificity for the peptides. Ten 
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randomly selected clones from donor 14463 and all from donor 14463 were then used in 
experiments to allow further characterisation.  
 
 
 
 
Firstly, the CD8 clones identified from donors 14463 and 14464 were stained with the GPI-
tetramer. All six clones from donor 14464 bound with high intensity to the tetramer (see 
example in Figure 5.13A, clone 19), with no difference in strength of binding seen between 
the clones. Of the ten clones from donor 14463, nine bound to tetramer with lower MFI, 
suggesting a lower avidity (see example in Figure 5.13A, clone 111) and one, clone 44 did not 
bind to tetramer at all (see Figure 5.13C). These results appear to replicate those of the 
tetramer staining of PBMCs from these two donors in which a population of strongly tetramer 
binding CD8 T cells was seen in donor 14464 but not with donor 14463. 
Table 5.2 Amino acid sequence homology of selected MCV CD4 and CD8 epitopes amongst other 
members of the human polyomavirus family. Letters highlighted in red represent amino acids changes 
compared with MCV sequence. 
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We were next interested to assess which GPI homolog peptide was responsible for inducing 
IFNɣ secretion from the T cell clones. This was done through IFNɣ ELISA using titrating 
concentrations of individual peptides in parallel. It was clear that no clones from either donor 
were stimulated to secrete IFNɣ by the BK/JC and WUV/HPyv10 peptides (data not shown). 
All six clones from donor 14464 recognised the three remaining peptides, most strongly to the 
MCV peptide with a functional avidity of 10-8-10-9M of peptide and this being around ten-fold 
more sensitive than the TSV or KI/HPyV6/HPyV7/HPyV9 peptides (see Figure 5.13, c19). Of 
the clones from donor 14463, the nine that exhibited intermediate tetramer binding showed 
broadly similar recognition of the three peptides with a functional avidity of approximately 
10-8M (see Figure 5.13, c84).The clone from donor 14463 that did not bind tetramer showed 
specific recognition of the KI/HPyV6/HPyV7/HPyV9 peptide, with a functional avidity of 10-
7-10-8M (see figure 5.13, c44). There was no recognition of either MCV or TSV peptides seen. 
This data suggests that the strongly tetramer-binding clones from donor 14464 are able to 
recognise MCV peptide more strongly than the KI/HPyV6/HPyV7/HPyV9 and TSV peptides, 
although recognition of these peptides does still occur. Intermediate tetramer-binding clones 
from donor 14463 recognise MCV, KI/HPyV6/HPyV7/HPyV9 and TSV peptides to a broadly 
similar level with no obvious specificity for any single peptide. The non-tetramer binding 
clone from donor 14463 is specific for the KI/HPyV6/HPyV7/HPyV9 peptide. 
Lastly, we wanted to see whether these T cell clones were capable of recognising the GPI 
epitope following processing and presentation from protein in cells. Here, HLA-B7 
expressing cell line, MelJuSo (MJS), was transfected with plasmids expressing either wild-
type Large T-antigen (WTLT) or truncated MCC350 Large T-antigen (MCC350LT); The 
WTLT construct contains the GPI epitope while the MCC350LT does not. MJS cells 
sensitised with MCV peptide or DMSO were used as positive and negative controls 
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respectively and these cells were then used in IFNɣ recognition assay with the T cell clones. 
All six clones from donor 14464 recognised MJS cells expressing WTLT but not MCC350LT 
(see Figure 5.13C, c19). Nine of the ten clones from donor 14463 were also able to recognise 
WTLT expressing cells (see figure 5.13C, c84), albeit to a lesser extent. The tenth clone, 
clone 44, did not recognise WTLT expressing MJS cells at all (see Figure 5.13C, c44). This 
experiment shows that T cell clones from donor 14464 which bind tetramer and have high 
avidity for MCV peptide are able to recognise MJS cells expressing the WTLT. Alongside 
this, T cell clones from donor 14463 which bind to tetramer less well and show less avidity 
for the MCV peptide are still able to recognise WTLT expressing cells. The T cell clone, c44, 
that does not bind tetramer and does not recognise MCV peptide, also does not recognise 
WTLT expressing MJS cells.  
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Figure 5.13. Assessment of GPI tetramer staining, recognition of GPI-peptide homologs and recognition of 
MCV LT expressing MJS cells using GPI-specific T cell clones from healthy donors 14463 and 14464. T 
cell cloning was conducted using PBMCs from healthy donors 14463 and 14464 following stimulation with GPI 
peptide homologs. Isolated T cell clones specific for GPI peptide(s) were then further characterised by 
assessment of MCV GPI-tetramer staining by flow cytometry. Data from three representative clones is shown 
(A). The functional avidity of T cell clones was assessed by IFNγ ELISA upon stimulation with autologous 
LCLs stimulated with 10-fold dilutions of individual peptides (B). The recognition of MJS cell transfected with 
plasmid expressing wild type MCV LT-antigen (WTLT), truncated MKL-1 LT-antigen (MKL-1 LT) and 
plasmid vector backbone only by T cell clones was assessed by IFNγ ELISA. Peptide and DMSO sensitised MJS 
cells were used as positive and negative controls respectively. 
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5.3 Discussion 
The first part of this chapter showed the results of IFNɣ ELISpot assays looking at the 
frequency of circulating PBMCs specific for peptides spanning the length of the MCV Large 
T (LT) and Small T (sT) antigen proteins. It compared the frequencies of IFNɣ secreting cells 
between donor cohorts of healthy volunteers, non-immunocompromised patients with non-
melanoma skin cancer (NMSC) and non-immunocompromised Merkel cell cancer (MCC) 
patients. A previous study assessing frequency of MCV specific PBMCs in healthy donors 
and MCC patients using peptides corresponding with truncated LT and sT-antigens showed 
that the frequency of these cells was low in both groups but there was a trend towards 
increased numbers of IFNɣ producing T cells in the MCC cohort [385]. In our study, we also 
found that the frequency of MCV specific T cells was low and broadly similar between 
healthy donors, NMSC patients and MCC patients.  This suggests that as measured in the 
periphery, a low frequency of circulating cells is sufficient to control MCV infection in health 
and that there does not appear to be a significant decline of total circulating IFNɣ secreting 
MCV specific T cells in older NMSC or MCC patients. Our work extended that of the 
previous study by assessing frequency of MCV specific T cells for the entire LT and not just 
the tumour-associated truncated form but found no differences amongst the donor groups 
tested. We were also able to identify MCV seropositive and seronegative donors based on the 
presence or absence of MCV VP-1 antibodies in the serum. There was no significant 
difference between the frequency of MCV specific T cells in any of the donor groups when 
MCV seropositive and seronegative donors are compared separately. This work has 
concentrated on IFNɣ secreting T cells that has been shown to be integral to the control of 
polyomavirus control in vivo [394]. However, it is possible that variations in frequency of 
CD8 and CD4 cells producing stimulatory cytokines such as IL-2, or other effector molecules 
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such as perforin and granzyme differ between the groups investigated and this may be an 
avenue for further work. 
During the ELISpot screening experiments mostly weak responses to the MCV peptides were 
observed except for when two healthy donors exhibited high frequency responses to particular 
pools of peptides which were then mapped to specific LT epitopes using T cell cloning. 
Donor 14461 made a CD4 T cell response to peptide ALD (LT aa631-646) despite being 
MCV seronegative. It is possible that the response to the peptide may be due to cross reactive 
recognition from CD4 T cells specific for another polyomavirus to which the donor has been 
exposed. Indeed, there is a significant amount of sequence homology of the ALD peptide 
within the polyomavirus family as shown in Table 5.2. Alternatively, it is possible that this T 
cell response is MCV specific but the donor is seronegative either through primary failure to 
produce detectable levels of antibodies or the loss of detectable antibodies through the 
complete clearance of virus following a robust cellular immune response. Whether such a 
phenomenon can occur following MCV infection is not known, however the finding of T cell 
clones for the less homologous CD4 epitope LLE (CT 16-30, Table 5.2) from the same donor 
increases the likelihood that prior infection with MCV may have occurred. Interestingly, it has 
been shown for JCV that the absence of polyomavirus-specific antibodies is linked with 
certain HLA Class II alleles leading the authors to suggest that in these cases, the lack of 
detectable serum antibodies may be a result of a more robust CD4 anti-viral response [395]. 
In addition to the aforementioned two, a further six novel Class II epitopes were discovered 
through this work from three MCV seropositive healthy donors.  
Importantly, most of the CD4 epitopes identified are present in the region of LT remaining 
after the truncation mutation seen in the MKL-1 cell line, established from a primary MCC 
tumour.  In the described experiments, we show that CD4 T cells specific for five LT epitopes 
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are able to recognise and secrete IFNɣ in response to antigen presenting cells fed with lysates 
made from the MKL-1 cell line. This suggests that these discovered MCV-specific CD4 T 
cells have the potential to act directly against MHC Class II expressing virally-infected cells 
as has been shown in other viral infections [396-398]. There is no current strong evidence that 
MCV has tropism for Class II expressing cells but studies are limited.  Alternatively, CD4 
cells may act indirectly following uptake of viral antigens by professional antigen presenting 
cells resulting in anti-viral cytokine production [399], as well as having a role in the 
maintenance of CD8 memory cell populations during persistent viral infections [287]. As the 
LT Class II epitopes are shared and potentially expressed by MCC tumour cells as well as 
virally infected cells, it is also possible that MCV specific CD4 T cells may be able to 
similarly exert immune control over tumour cells as has been shown with SV40 polyomavirus 
mediated tumourigenesis in vivo [309].  
The second large ELISpot response, seen in MCV seropositive donor 14464, was attributable 
to CD8+ T cells specific for the novel class I epitope, GPI (LT 593-603). This epitope is 
found in the full length T-antigen but not the truncated tumour associated T-antigen and was 
the only Class I epitope discovered during this study. This pattern is similar to the previous 
published study assessing MCV VP-1 and truncated LT-antigen specific responses in 
peripheral blood that also found only one CD8 T cell epitope as compared with numerous 
CD4 responses [385]. Together, these results may suggest that CD4 mediated cellular 
immunity against MCV may be more dominant than CD8.  Indeed, the majority of IFNɣ 
secretion in response to MCV VP-1 virus like particles is attributable to the CD4 subset [302]. 
The high frequency of CD4 responses in comparison to CD8 has also been noted in cellular 
immunity against other members of the polyomavirus family, BKV and JCV, suggesting this 
may not be a feature exclusive to MCV [288-290, 400].  
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Using the newly-identified HLA-B7, CD8 epitope, GPI, we investigated the phenotypic 
characterisation of MCV specific CD8 T cells ex vivo. Although MCV DNA has been 
isolated from many tissues at low frequency, it has been by far most commonly found on the 
skin, leading to the assumption that it is a skin-tropic virus. Alongside this, 
immunohistochemical analysis of MCC tumours has found that the majority of CD8 T cells 
found within tumours express Cutaneous Lymphocyte Antigen (CLA) [321], a marker found 
on the majority of T cells recovered from the skin (alongside the chemokine receptors CCR4, 
CCR6 and CCR10) as compared to 5-10% of circulating PBMCs [259, 401, 402]. Whether 
this up regulation of CLA expression occurs in the blood or in the skin is not completely 
clear. Koelle et al assessed circulating CD8 lymphocytes specific for the HLA B7 epitope 
VP22 from the HSV-2 UL49 open reading frame, finding that 50-80% expressed CLA in 
comparison to 2-10% of EBV and CMV specific CD8 T cells [403]. This suggests that 
specialisation towards skin-homing occurs within the circulation. In a small number of MCC 
patients, using the defined HLA-A24 MCV LT-antigen epitope, 20-80% of tetramer binding 
cells were CLA expressing, again an increased proportion when compared to CD8 
lymphocytes specific for other non-skin tropic viruses CMV and EBV [321].  
In our study, one healthy HLA-B7+ donor, 14464, had a sizable GPI-specific CD8 T cell 
population suitable for phenotypic assessment using tetramer assay. These cells had an 
effector memory phenotype but, in contrast to HSV-specific cells, did not exhibit the 
phenotype of skin-homing lymphocytes based on expression levels of CLA. In comparison 
we saw that in the MCC patient, P84, the tetramer-binding CD8  response exhibited more skin 
homing characteristics in keeping with that seen in MCC patients in a previous study [321]. It 
must be noted that the frequency of cells in this donor was very small and so results must be 
interpreted with caution. As MCC patients tend to have high levels of viral DNA in the skin it 
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is likely that MCV antigens would have been presented at this site and so memory 
lymphocytes may continue to maintain this skin-tropic phenotype. As the GPI epitope is not 
one found in LT-expressing MCC cancers, the CD8 response could not have developed as a 
result of an anti-tumour immune response. In the healthy donor, the mechanism and site of 
antigen presentation to CD8 T cells is less certain and may not have occurred via the skin, 
possibly explaining the lack of skin-homing phenotype seen.  It is also possible that the 
majority of skin-homing lymphocytes are sequestered within the skin and so are not found in 
examinations of the peripheral blood. This could be further assessed by looking at the 
phenotype of MCV specific skin infiltrating lymphocytes, however, it is likely that this 
process would be very complicated by low cell frequency and difficulty obtaining appropriate 
samples. The examination of virus-specific T cells has been conducted using skin infiltrating 
lymphocytes, however, this has been preceded by antigenic stimulation in the form of 
vaccination in order to maximise and localise the numbers of T cells present to enable detailed 
analysis [269]. 
Lastly, we saw that PBMCs from two MCV seropositive healthy donors, 14463 and 14464, 
both made IFNɣ secreting T cell responses following stimulation with GPI peptide in ELISpot 
assays. However, unlike PBMCs from donor 14464, PBMCs from donor 14463 displayed no 
detectable tetramer binding.  Similar findings of non-tetramer binding, virus specific CD8 T 
cells have been seen in mice with influenza infections [404] and human donors with chronic 
hepatitis B [405]. It has been suggested that this occurs through alterations in lipid raft 
integrity that affects the arrangement of the TCR on the lymphocyte surface [406]. Rather 
than reflecting low avidity to peptide, this “partial tolerance” to viral antigen may act as a 
protective mechanism to prevent T cell exhaustion and subsequent deletion in the face of high 
prolonged antigen exposure as seen in chronic infections. It is therefore possible that a similar 
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situation is present in donor 14463. Importantly, these virus-specific, non-tetramer binding 
cells have been shown to remain functional with regard to cytokine production. A second 
explanation for the lack of tetramer binding is that the response seen in donor 14463 is   cross 
reactive response, particularly as there is such close homology between polyomaviruses at the 
GPI epitope (Table 5.2). We further investigated this possibility by isolating GPI specific T 
cell clones from donor 14463 and 14464. CD8 T cell clones from donor 14464 clearly showed 
increased specificity for the MCV GPI peptide and a single clone from donor 14463 showed 
specificity for the novel KI/HPyV6/HPyV7/HPyV9 GPI epitope. However, the majority of 
clones from donor 14463 showed broadly similar responses to the MCV, TSV and 
KI/HPyV6/HPyV7/HPyV9 peptides. These clones were also able to recognise antigen 
presenting cells expressing MCV LT. This indicates that these CD8+ T cells do appear to 
have the ability to respond to homologous GPI epitopes from a number of the polyomavirus 
family. Cross reactive CD8 T cells against polyomavirus epitopes have been widely 
described, particularly for shared BK and JC epitopes [291, 294, 299-301] and this work 
extends this and highlights what may be an important mechanism of cellular immune control 
of this closely related and growing family of viruses.
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Chapter 6  
Investigation of immune evasion properties of MCV LT and sT-antigens 
6.1 Introduction 
The data presented in the previous chapter, confirms and extends our knowledge that there are 
epitopes on the MCV LT and sT-antigens that can be recognised by CD4 and CD8 T cells. 
This suggests that, as MCV LT (truncated) and sT are expressed by the majority of MCC 
cells, tumours can be potentially recognised and killed through T cell mediated mechanisms.  
Indeed, this is supported by clinical data that positively correlates CD8 T cell infiltration into 
MCC tumours with improved survival [311]. However, the avoidance of destruction by the 
immune system is a recognised hallmark of cancer, as defined by Hanahan and Weinberg 
[407]. In virus-associated cancers, viral proteins may be involved in this process of immune 
evasion through a number of mechanisms involving both innate and cellular immune 
pathways. The impact of immune evasion in MCC and the role of viral proteins integrated 
within the cancer cell genome is not well understood.  
All nucleated cells express MHC Class I on the cell surface enabling T cell recognition. The 
down-regulation of MHC Class I alongside other molecules involved in Class I antigen 
processing such as TAP-1 and -2 has been described and associated with poorer prognosis in 
numerous cancers, such as melanoma [408, 409]. In MCC tumours, surface MHC Class I 
expression assessed by immunohistochemistry is low or undetectable in over 50% of cases 
and this is seen significantly more frequently in MCV+ as compared with MCV negative 
tumours. Alongside this, in MCV+ MCC tumour cell lines (MKL-1and WaGa), the 
expression of MHC Class I is also reduced when compared with MCV negative MCC tumour 
cell lines (MCC13, MCC26) [320]. The surface expression of MHC Class I in MCV+ cell 
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lines can be up-regulated through the use of treatment modalities included IFN-β, etoposide 
chemotherapy and ionizing radiation [320]. Conducting mRNA analysis of a subgroup of 
MCC tumours showed that reduced expression of MHC Class I was strongly correlated with 
the reduced expression of β2 microglobulin and TAP -1 and TAP-2, suggesting dysregulation 
of multiple molecules from the Class I antigen processing pathway. The role, if any, that the 
tumour expressed MCV LT and sT play in regulation of MHC Class I expression of infected 
cells is not known and may represent an important mechanism of virally mediated immune 
evasion, similar to other immune evasion proteins expressed by viruses such as EBV [410, 
411]. It is also not known whether the up regulation of MHC Class I is by itself sufficient to 
allow recognition by CD8 T cells or if other co-existing mechanisms of evasion will prevent 
this. 
CD4 T cell recognition is mediated though interaction with MHC Class II molecules. Unlike 
Class I, constitutive Class II expression is classically limited to a small number of cell types, 
namely professional antigen presenting cells; dendritic cells, macrophages and B cells. Other 
cell types, such as fibroblasts, endothelial and epithelial cells can be induced to express Class 
II under certain conditions, through activation of the Class II transactivator (CIITA) gene 
(reviewed in [412]). As a number of CD4 epitopes have been defined for MCV LT and sT, it 
is important to know whether Merkel cells fall into either of these categories. There is no 
published data to our knowledge that describes the level of Class II expression on Merkel 
cells and given the low frequency of these cells in the skin, this may be difficult to 
characterise. The expression of Class II in MCC primary tumours and cell lines has also not 
been described to our knowledge. Immune evasion through modulation of Class II has been 
seen with other viral proteins such as the KSHV latent protein vIRF3 [413] but any similar 
function of MCV T-antigens are not clearly defined. 
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The aims of this chapter are initially to confirm using primary tumour cells and MCC cell 
lines, that MHC Class I expression on the cell surface is down-regulated as well as 
determining MHC Class II surface expression status on these same cell types. 
Secondly, using MCC cell lines, we will assess the effect of IFNɣ and ionising radiation on 
MHC Class I and Class II expression in addition to the effect ionising radiation has on the 
ability of CD8 T cells to recognise MCC cell lines. 
Lastly, we will use a model antigen presenting system to see whether the MCV LT and ST-
antigens have any role in MHC Class I and II regulation and/or the ability of LT/ST 
expressing cells to be recognised by CD4 and CD8 T cells. 
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6.2 Results 
6.2.1 MHC Class I and II expression on primary MCC tumour cells 
A wide range of tumours, including MCC, down-regulate expression of MHC Class I in order 
to evade detection by CD8 T cells. There is little known of the expression of MHC Class II on 
MCC tumours. Therefore we evaluated MHC Class I and II expression on surface of MCC 
tumour cells. Due to the scarce availability of MCV+ clinical samples, this was only possible 
on a single tumour specimen from patient P164 (MCV+). A small portion of tumour was 
minced into a cell suspension, filtered and stained with CD3, CD56, CD45, MHC Class I and 
Class II fluorochrome-conjugated antibodies and analysed on flow cytometer. Figure 6.1 
shows that tumour associated lymphocytes (CD45+) cells expressed Class I and Class II, 
however, both Class I and Class II expression is low on tumour cells (CD56+, CD45-). 
Although limited to a single tumour specimen, this experiment confirms previous work that 
shows MCC tumours express little surface MHC Class I. It also suggests that MCC tumours 
do not express high levels of surface MHC Class II. 
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Figure 6.1. Surface MHC Class 1 and Class 2 expression on P164 MCC tumour cells and tumour 
associated lymphocytes. Tumour was minced and stained with fluorochrome-conjugated markers to 
differentiate lymphocytes (CD45+) from tumour cells (CD56+, CD45). Surface MHC Class 1 and 2 levels were 
compared between the two populations. 
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6.2.2 MHC Class I levels on MCC tumour cell lines and the impact of IFNɣ 
A previous study has shown that, like the majority of primary tumours, MCV+ MCC cell 
lines express very low levels of MHC Class I compared when compared with MCV negative 
cell lines but that this could be up-regulated through stimulation with IFNs.  We sought to 
confirm this using the MKL-1 (MCV+) and MCC13 (MCV negative) cell lines and figure 2 
shows staining both cell types for MHC Class I cell surface expression. This confirms that 
MKL-1 cells had barely detectable levels of MHC Class I, while there was clear expression of 
in MCC13 cells. Incubation in the presence of IFNγ for 72 hours, led to surface MHC Class I 
up-regulation on both cell types. This confirms that the MCV+ cell line, MKL-1 expresses 
low levels of MHC Class I when compared to the MCV negative cell line, MCC13. In both 
cell types, Class I levels can be up-regulated through incubation with IFNɣ. 
 
6.2.3 MHC Class II levels on MCC tumour cell lines and the impact of IFNɣ  
Although only a subset of cells express MHC Class II on the surface, other cell types, such as 
fibroblasts, can be induced to express this through different mechanisms including stimulation 
with IFNs. We were interested to see if MCC tumour cell lines express MHC Class II and 
whether expression was altered by IFNɣ. We assessed surface MHC Class II expression on 
MKL-1 and MCC13 cell lines as well as fibroblasts, finding that MHC Class II expression 
was not seen (Figure 6.2). Following exposure to IFNɣ for 72 hours this was not altered in 
MKL-1 or MCC13 cell types, however, up-regulation was seen in the fibroblast cells.  This 
suggests that both MCV+ and MCV negative MCC cell lines do not natively express MHC 
Class II, nor can they be induced to do so with IFNɣ. 
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Figure 6.2. Surface Class I and Class II expression on MCC cell lines and fibroblasts with and without 
stimulation by IFNγ. MCC cell lines, MKL-1 (MCV+) and MCC13 (MCV-) were assessed for expression of 
Surface MHC Class I and Class II by flow cytometry after 72 hours incubation with 50IU/ml IFNγ (red line) or 
media alone (blue line). Fibroblast cells, known to up-regulate Class I and Class II upon stimulation with IFNγ 
were assayed in parallel to act as experimental control. Isotype controls are shown as shaded regions.   
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6.2.4 Effect of ionising radiation on MHC Class I and Class II on MCC cell lines 
Ionising radiation is a well-recognised mode of anti-cancer therapy. Alongside direct tumour 
cell killing, it has also been shown to have immunogenic properties such as up-regulation of 
MHC Class I and II in some cancer cell lines [414, 415]. Using our MCC cancer cell lines, we 
investigated the effect of different doses of ionizing radiation on MHC Class I and II surface 
expression levels (Figure 6.3). Cells were treated with varying doses of radiation (0 Gy, 4 Gy 
or 10Gy). We also analysed the impact of radiation on MelJuSo (MJS) cells that 
constitutively express Class I and Class II as a control cell line. In MJS cells, there was minor 
up-regulation with Class I and Class II following exposure to 4 and 10Gy. The MCV negative 
MCC13 cell line showed MHC Class I expression level similar at baseline to that seen with 
MJS cells and there was no obvious increase upon exposure to radiation. In MCC13 cells, 
MHC Class II was seen neither at baseline nor following radiation. The low baseline levels of 
MHC Class I expression on the MCV+ MKL-1 cell line could be up-regulated with exposure 
to ionising radiation, although there was no obvious difference between the two radiation 
doses. As with MCC13, there was no appreciable expression of MHC Class II at baseline and 
no change with exposure to ionising radiation. In summary, these experiments show that in 
MCC cell lines, MKL-1 cells can be induced to up-regulate MHC Class I upon exposure to 
relatively low doses of radiation. However, irradiation of MCC13 and MJS cell lines that 
already express Class I on their surface does not significantly alter expression. With regard to 
MHC Class II expression, in natively expressing Class II MJS cells there is some increase in 
levels associated with radiation exposure. Irradiating MCC cell lines that do not natively 
express Class II, has no impact on Class II levels.  
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Figure 6.3. The impact of radiation on surface MHC class I and II levels on MCC cell lines. MKL-1 and 
MCC13 cell lines were exposed to 0 (red), 4 (blue) or 10 (orange) Gy doses of radiation and surface MHC class I and II 
levels were assessed by flow cytometry.  MelJuSo (MJS) cells known to express both Class I and Class II naturally were also 
exposed to the same radiation doses and acted as positive control in experiment. 
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6.2.5 Impact of ionising radiation on recognition of MCC Cell lines by CD8 T cells  
The previous set of experiments showed that the MCV+ MKL-1 cell line expresses very low 
levels of MHC Class I, but that this can be up-regulated with exposure to irradiation. The 
MCV negative MCC13 cell line, does express MHC Class I and this is maintained with 
exposure to ionising radiation. We were next interested to see whether MKL-1 and MCC13 
cells were capable of processing and presenting antigen on the cell surface and the effect 
ionising radiation had on this. HLA typing analysis showed that both cell lines expressed the 
Class I HLA-A11 allele. Using a modified vaccinia virus Ankara construct expressing the 
EBV EBNA3B gene (MVA-EBNA3B, kind gift from Dr G Taylor) we infected these cell 
lines to induce expression of this reporter antigen. This antigen contains the HLA-A11 CD8 
epitope, IVT, for which specific T cell clones were available to be used in T cell recognition 
experiments. MKL-1 and MCC13 cells were irradiated (0, 4 and 10Gy) and these were then 
infected for two hours at a multiplicity of infection (MOI) of 10 by either the MVA-
EBNA3B, a control MVA-PSC11 (MVA-PSC) that did not express EBNA3B, or loaded with 
5µg/ml IVT peptide. In parallel, HLA-A11 expressing EBV transformed LCL cells, known to 
be capable of antigen processing and presenting were also similarly treated to act as a positive 
control for the experiment. After infection/peptide loading, cells were washed thoroughly and 
then 1x105 cells/well were added, in duplicate, to a 96 well plate with 5x103 cells/well of 
IVT-specific T cell clone. T cell recognition was then assessed after 18 hours using IFNɣ 
ELISA assay and these results are summarised in Figure 6.4.  
As expected LCL cells, both when infected with MVA-EBNA3B or when peptide loaded, 
elicited high levels of IFNɣ release from T cells. It was noted that there was low level 
recognition of LCL infected with the control MVA due to the presence of endogenous 
EBNA3B in these cells. The MCC13 cells not exposed to radiation elicited similar levels of T 
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cell recognition after both MVA-EBNA3B infection and peptide loading (~15000pg/ml). The 
amount of IFNɣ produced following MVA-EBNA3B infection was similar to that seen with 
the LCL. Exposure of MCC13 cells to 4 or 10Gy radiation did not appear to affect IFNɣ 
production compared with non-irradiated cells. MKL-1 cells loaded with peptide or infected 
with EBNA-3B MVA did provoke low level IFNɣ secretion from IVT specific T cells 
(~300pg/ml). This was not seen after infection with the control MVA. There was no change in 
IFNɣ secretion from T cells after irradiation of peptide loaded MKL-13 cells at either 4 or 
10Gy doses. There was also no dramatic change in IFNɣ secretion after irradiation of EBNA-
3B MVA infected MKL-1 cells, although there was a suggestion of an increased production 
of IFNɣ at the 4Gy dose which was not maintained at the 10Gy dose.  
Overall, this experiment shows that MCC13 cells are capable of processing and presenting 
EBNA-3B to IVT specific T cells. Although MKL-1 cells are also able to process and present 
antigen, the amount of IFNɣ secreted by T cells following peptide loading or EBNA-3B 
MVA infection is approximately 100 fold less than seen with MCC13 cells. In this assay, 
irradiation does not appear to alter the ability of either MCC13 or MKL-1 cells to process and 
present antigen. 
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Figure 6.4. CD8 T cell recognition pre and post radiation using MCC cell lines infected with MVA 
expressing reporter antigen EBNA3B. MKL-1 (black bars) and MCC13 cells (blue bars) were irradiated with 
0, 4 or 10Gy and were then either loaded with 5μg/ml IVT peptide or infected with the EBNA3B MVA or empty 
pSC11 (control) MVA at an MOI of 10. To act as positive control, non-irradiated HLA-A11 LCL cells with 
functional antigen processing and presentation machinery  were also infected with peptide or MVA (red bars). 
2.5x104 of each antigen presenting cells were then plated in duplicate with 5x103IVT specific CD8+ T cells in 96 
well plates and T cell recognition quantified by IFNγ ELISA after 24 hours. 
 
6.2.6 The impact of MCV LT and sT on Surface MHC Class I expression 
We, and others, have shown that the MCV+ MCC cell line, MKL-1 expresses lower levels of 
MHC Class I at the cell surface when compared with MCV negative cell line, MCC13. We 
were, therefore, interested to see whether the MCV tumour associated proteins, LT or sT, are 
involved in the down regulation of surface Class I levels. To test this, DNA constructs 
corresponding with wild-type LT, two tumour-derived truncated LT (MCC350 and MKL-1) 
and sT were cloned into the pCDNA3-IRES-NLS-GFP plasmid. This is a bicistronic vector 
that allows simultaneous expression of both protein of interest alongside GFP using an 
Internal Ribosomal Entry Site (IRES) from the same RNA transcript (see Figure 6.5). These 
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constructs were then individually transfected into MJS cells and then surface MHC Class I 
expression was analysed after 24 and 48 hours by flow cytometry through comparison of live, 
transfected (GFP+) and non-transfected (GFP-) cell subsets.  The EBV genes BNLF2a and 
BDLF3 which are both known to down-regulate MHC Class I were also cloned into the same 
vector and used as positive controls (kind gifts from Dr A Hislop and Dr L Quinn 
respectively). The empty pCDNA3-IRES-NLS-GFP plasmid (henceforth called pCDNA3) 
was used as a negative control.     
                          
Figure 6.5. Schematic diagram of MCV T-antigen expression constructs. Expression of wild-type Large T 
(WTLT), two tumour-associated truncated Large T (MCV350, MKL-1) and Small T (sT) was achieved through 
individual insertion of genes into the pCDNA3-IRES-GFP vector using a CMV promoter (PCMV). The construct 
also contained an internal ribosomal site (IRES) GFP allowing for identification of transfected cells by flow 
cytometry. 
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As shown in Figure 6.6, cells transfected with the pCDNA3 showed no change in Class I 
expression compared with non-transfected cells. As expected, there was a down-regulation of 
Class I expression in both BNLF2a and BDLF3 transfected cells compared with non-
transfected cells at 24 hours, but this became less pronounced at 48 hours. Transfection with 
any of the MCV genes (WT LT, MCV 350 LT, MKL-1 LT and sT) had no impact on surface 
Class I levels at either 24 or 48 hours.  Overall, this experiment suggests that transient 
transfection with MCV LT, truncated LT or sT is not capable of down-regulating surface 
Class I levels on MJS cells. 
6.2.7 The impact of MCV LT and sT on Surface MHC Class II expression 
As our earlier experiments had found that surface MHC Class II expression was low in both 
MCC primary tumour cells and MCC tumour cell lines, we were interested in uncovering 
whether MCV T-antigens had any role to play in this. Using the same model system as 
described in the above section, GFP-tagged plasmids containing MCV LT, truncated LT and 
sT genes were transfected into MJS cells. Again, the empty pCDNA3 vector was used as a 
negative control. Transfection with genes known to down-regulate surface Class II, the EBV 
gene BDLF3 and the KSHV gene vIRF3, were used as experimental positive controls. In 
Figure 6.7, it is shown that transfection with the empty control pCDNA3 vector has no impact 
on the Class II level. Transfection with BDLF3 shows down-regulation of Class II at 24 hours 
but this is lost at 48 hours. In contrast, transfection with vIRF3, shows no change in Class II 
levels at 24 hours, but some slight reduction at 48 hours. MCV WT LT, truncated LT and sT 
show no impact on surface class II expression at either 24 or 48 hours. These experiments 
suggest that transient transfection with MCV T-antigens are not capable of affecting surface 
Class II levels. 
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Figure 6.6. Effect of MCV T-antigen genes on surface Class I expression of MJS cells. MelJuSo (MJS) cells 
were transfected with GFP-tagged pcdna3 plasmid constructs containing genes of interest. Surface Class I was 
assessed at both 24 and 48 hours post transfection comparing transfected, GFP+ cells (red) with non-transfected 
GFP- cells (blue). Plasmid containing no gene (pcdna3) was used as negative control. EBV genes BNLF2a and 
BDLF3 known to down-regulate Class I were used as positive controls.  
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Figure 6.7. Effect of MCV T-antigen genes on surface Class II expression of MJS cells. MelJuSo (MJS) 
cells were transfected with GFP-tagged pCDNA3-IRES-nls-GFP plasmid constructs containing genes of interest. 
Surface Class II was assessed at both 24 and 48 hours post transfection comparing transfected, GFP+ cells (red) 
with non-transfected GFP- cells (blue). Plasmid containing no gene (pcdna3) was used as negative control. 
KSHV gene vIRF3 and EBV gene BDLF3 known to down-regulate Class II were used as positive controls.  
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6.2.8 The effect of MCV T-antigens on recognition of reporter antigens by CD8 and CD4 T 
cells 
The previous experiments suggested that MCV T-antigen proteins did not appear to have a 
role in immune evasion through direct down-regulation of surface Class I or II in the model 
system used. However, it remains possible that MCV proteins may affect the recognition of 
virally-infected or MCC tumour cells by either CD8 or CD4 T cells through other 
mechanisms. In order to assess the impact of MCV LT and sT proteins on epitope recognition 
by T cells, a model system utilising EBV reporter antigens and appropriate CD4 and CD8 T 
cell clones was used. For the CD8 T cell recognition work, MJS cells were co-transfected 
with individual plasmids encoding the MCV T-antigen genes described above (Figure 5) 
together with a plasmid encoding the EBV gene BZLF1 which encodes the HLA-B8 
restricted CD8 peptide, RAK, as a target reporter antigen (kind gift from Mr Calum Forrest). 
For the CD4 T cell recognition assays, plasmid encoding EBNA1, which encodes the HLA-
DR51 restricted CD4 peptide, SNP (kind gift from Dr Graham Taylor) were co-transfected 
with the MCV T-antigen gene constructs.  As MJS cells do not naturally express the DR-51 
allele, MJS cells engineered to stably express this allele though retroviral transduction were 
used (kind gift from Dr Jianmin Zuo [416]). After 24 hours, co-transfected cells were 
harvested and percentage of live, transfected cells (as defined using flow cytometry staining 
gating on propidium iodide negative and GFP positive cells ) were quantified. Duplicate wells 
of a 96 well plate were then filled with 1x104 live transfected cells and equalised with the 
addition of non-transfected MJS cells, such that the total number of cells in each well was the 
same. Finally, 5x103 T cell clones specific for either RAK epitope (CD8 assay) or SNP 
epitope (CD4 assay) were added to each well and T cell recognition measured the following 
day using IFNɣ ELISA.  
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Figure 6.8. CD4 and CD8 T cell recognition of transfected MJS cells co-expressing MCV LT, truncated 
LT or sT alongside an EBV reporter antigen.  (A) MJS cells were transfected with pCDNA3-IRES-nls-GFP 
plasmids expressing individual MCV T-antigens, wild type LT (WTLT), two tumour-associated truncated LT 
(350LT and MKL1LT) and Small T (sT).  The known EBV CD8 immune evasion protein, BNLF2a expressed in 
the same vector acted as positive control. Plasmid expressing EBV BZLF1 gene was co-transfected as reporter 
antigen. 24 hours post transfection, IFNγ secretion measured by ELISA following stimulation of transfected MJS 
cells with RAK specific CD8 T cells. (B) MJS cells were transfected with the same pCDNA3-IRES-nls-GFP 
plasmids expressing individual MCV T-antigens as mentioned above.  The known KSHV CD4 immune evasion 
protein, vIRF3 expressed within the same vector as a positive control. Plasmid expressing the EBV gene with a 
deletion of nuclear localisation signal, EBNA1 (ΔNLS) was co-transfected to act as reporter antigen. 24 hours 
post transfection, IFNγ secretion measured by ELISA following stimulation of transfected MJS cells with SNP 
specific CD4 T cells. 
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Figure 6.8A shows results from duplicate experiments assessing the effect of viral gene 
transfection on the recognition of MJS cell expressing the EBV BZLF1 epitope by RAK-
specific T cells. In one assay, there appeared to be a reduction in T cell recognition with MCV 
sT to a similar extent to that seen with the known CD8 immune evasion EBV gene, BNLF2a, 
used as a positive control. However, in the duplicate experiment, although the reduction of 
recognition by sT expressing cells was maintained, there was no change in recognition of the 
BNLF2a expressing cells. In both experiments, the WT and the MKL-1 truncated LT 
appeared to have a positive effect on T cell recognition with increased IFNɣ secretion seen 
when compared with the transfection of the control pCDNA3 vector. Unfortunately due to 
time constraints, it was not possible to perform further replicate experiments to confirm these 
findings. 
Figure 6.8B shows duplicate experiments assessing the effect of viral gene transfection on the 
recognition of MJS cells expressing the EBV EBNA1 gene by a SNP epitope-specific CD4 T 
cell clone. In these assays, both MCV WT LT and MCV sT appeared to impair recognition by 
CD4 T cells to a similar level seen with the known KSHV immune evasion gene, vIRF3. 
However, there were inconsistent results with the truncated forms of MCV LT, MCV350 and 
MKL-1 which in one assay appeared to have an effect on reducing CD4 T cell recognition 
though not to the same extent as the WT LT or sT while in the other appearing to have no 
effect compared with transfection with the control pCDNA3 vector. Again, unfortunately it 
was not possible to perform further replicates of this experiment to confirm the findings. 
These experiments suggest that MCV T-antigens may have an impact on recognition by both 
CD8 and CD4 T cells. The MCV sT gene appears to impair recognition of both CD4 and CD8 
T cells, whilst MCV WT LT has a negative impact on CD4 recognition only. Both WT and 
truncated forms of MCV LT seem to increase recognition by CD8 T cells while the effect of 
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truncated LT on CD4 recognition remains uncertain. It must be noted that there were some 
inconsistencies demonstrated in these assay replicates and so further work is needed to 
confirm findings before definitive conclusions can be made.  
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6.3 Discussion 
In the work described, we have investigated the Class I and Class II expression of MCC 
tumour cells and cell lines as well as the antigen processing and presentation ability of MCC 
cell lines. We have also assessed whether the MCV LT or sT-antigens have properties that 
may affect recognition of cells expressing these antigens by T cells.   
All nucleated cells can express MHC Class I and thus virally infected cells should present 
antigen directly to CD8 T cells which can then go on to kill the cell. In order to avoid 
recognition, viruses have evolved mechanisms to minimise their impact, such as inhibiting 
surface MHC Class I expression and this feature is retained in many virally-induced cancers 
[417]. Recently, it was shown that MHC Class I down-regulation is prevalent in MCV+ MCC 
tumours but not as common in MCV negative tumours. [320]. We have confirmed that MCV+ 
MCC tumour cells and the MCV+ MCC cell line, MKL-1, express low levels of MHC Class I 
compared with the MCV negative MCC13 cell line. The exact mechanism for the down-
regulation of Class I is unknown and likely to be multi-factorial. In the previously mentioned 
study, the Class I-low MCC tumours all commonly down-regulated mRNA levels for the 
class I heavy chain, β2 microglobulin and TAP suggesting multiple proteins of the Class I 
pathway are being simultaneously affected [320]. Given the finding that MHC Class I levels 
are lower in MCV+ MCC compared with MCV negative, potentially the MCV genes 
expressed by MCC, namely LT and sT, may play a role in Class I down-regulation. In our 
assays the transient transfection of LT (both the WT and truncated forms) or sT had no impact 
on surface Class I levels at 24 or 48 hours, suggesting that these MCV proteins are not solely 
responsible for changes in Class I expression. It is also possible the effects on Class I take 
longer than 48 hours to become apparent or that the high-level, short-term expression of these 
proteins in our experiment does not replicate the effects of longer-term, low-level expression 
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that may be seen in an MCV infected or MCC tumour cell. Developing stably-transfected LT 
and sT expressing cell lines in which levels of expression can be regulated through inducible 
gene promoters could further address this question. 
As tumours that have down-regulated Class I will likely have reduced susceptibility to CD8 T 
cell mediated cytotoxicity, interventions aimed at reversing this process may be useful to re-
instate a anti-tumour cell immune response.  Interferons are able to induce MHC Class I up-
regulation through the stimulation of Interferon Regulatory Factors (IRFs) which can directly 
activate Class I genes [418-420].  Radiation is also able to up-regulate Class I by causing 
degradation of cellular proteins resulting in the production of increased peptides which leads 
to higher levels of TAP activity [421].  Both IFNɣ and irradiation led to an increase in MHC 
Class I levels in MCV+ MCC cell lines in our experiments, in agreement with results from a 
previous study [320].  This change in Class I levels may have been expected to also lead to an 
improvement in recognition of the MCC MKL-1  cell line by CD8 T cells. In our assay using 
an EBV reporter antigen, radiation appeared to have little impact on the ability of T cells to 
recognise the MKL-1 cells as measured by IFNɣ secretion.  Previously published work, using 
chromium release assays have shown that CD8 T cell mediated cytotoxicity increases 
following radiation of cancer cell lines [422].  However, rather than being IFN-mediated, it 
appears that this increased cytotoxicity is driven by Fas-Fas ligand interaction between T cell 
and tumour cell [423]. This may explain why we did not see an increase in IFNɣ secretion 
from CD8 T cells following irradiation of MCC cell lines. Additionally, our assay measured 
the recognition of one specific T cell clone and its cognate peptide epitope. As radiation 
driven Class I up-regulation is thought to occur through the creation of novel peptides, it is 
possible that although in our assay recognition of a single epitope remains unchanged, the 
same stimulation in vivo would increase the overall breadth of T cell response and lead to an 
  Chapter 6: Results 
206 
 
overall increased amount of T cell recognition. Interestingly, Chapuis et al, performed an in 
vivo experiment using a patient with metastatic MCC treated with a combination of 
irradiation or intralesional interferon-β as well as infusion of polyclonal MCV T-antigen 
specific T cells [424].  This resulted in an up-regulation of MHC Class I on the surface of 
tumour cells, an accumulation of tumour-specific T cells within metastatic deposits and 
tumour regression. It is unlikely that changes in Class I levels is solely responsible for causing 
T cell infiltration into MCC tumours as when such tumours have been examined 
histologically, there is no direct correlation between Class I levels and T cell infiltration 
[320]. Overall, the use of radiotherapy or IFN treatments is likely to provide clinical benefit in 
MCC through modulating tumour immunogenicity. However, the underlying mechanism 
behind this is likely to be multi-factorial and not just governed by changes in MHC Class I 
levels. 
Evasion of the immune system by viruses and virally-induced tumours can also affect the 
MHC Class II pathway. To our knowledge, investigation of the Class II surface expression on 
Merkel cells or MCC has not been conducted and so the potential importance of Class II in 
the context of MCV and MCC has been thus far undefined. As Merkel cells are thought to 
have a sensory rather than professional antigen presenting function, native surface Class II 
expression would not be expected. However, given these cells are found only in the skin and 
also at low frequency, to confirm this experimentally would be very difficult. The use of 
MCC tumours and cell lines provides an opportunity to investigate Class II expression in cells 
that are more readily available. In our assays, primary tumour cells and MCC cell lines did 
not appear to express detectable levels of MHC Class II on the cell surface. As with our Class 
I results, the transient transfection of MCV LT or sT did not appear to have any impact on 
Class II surface levels suggesting these proteins are not responsible for the   failure to express 
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Class II. However, the same cautions must be taken when interpreting these results as 
documented above with our Class I data. 
Some non- professional antigen presenting cells such as fibroblasts and endothelial cells that 
do not ordinarily express Class II can be induced to express it commonly as a response to 
IFNɣ stimulation.  This activates downstream signalling pathways such as JAK/STAT and 
activates the pIV promoter of the CIITA gene leading to the up-regulation of Class II 
associated antigen presentation machinery [412, 425].  Although less clearly defined, 
irradiation has also been shown to increase Class II expression in some tumour cell lines 
[414]. In our described assays, IFNɣ or irradiation could not induce Class II expression on 
MCV+ or MCV negative MCC cell lines. The reasons for this are unknown but may be 
related to these cells having  reduced responsiveness to IFNɣ stimulation through a block in 
the JAK/STAT pathway preventing activation of the CIITA promoter [426]. Whether the 
MCV T-antigen has a any role in this process is not known, although there is evidence that 
murine polyomavirus LT can block activity of this pathway through direct binding to and 
inactivation of JAK1 [427].  It has also been shown that TGF-β is able to inhibit Class II up-
regulation by IFNɣ [428] and this is potentially a further pathway that may be important as 
TGF-β can be up-regulated within tumours [429]. The potential benefit of MCV inhibiting 
Class II expression is not clear, due to a lack of knowledge of the wider cellular tropism of the 
virus.  There is some recent evidence that dermal fibroblasts are a candidate host cell for 
MCV infection and as mentioned above, such cells can express Class II under certain 
conditions [126]. Additionally, MCV DNA has also been previously isolated from peripheral 
blood monocytes [132] and the gene expression signature of MCC tumour cells bears greater 
similarity to a pro-B cell than the epidermal Merkel cell [430] suggesting that MCV may have 
a tropism for MHC Class II expressing cells and consequently may require mechanisms to 
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evade detection. Overall, the effect of MCV on the Class II pathway remains unclear but our 
results do suggest that MCC tumour cells are incapable of presenting antigen through the 
Class II pathway and so cannot be directly targeted by CD4 T cells.  
Although they did not have any obvious impact on Class I and Class II surface expression, 
our preliminary experiments showed both MCV LT and sT independently appeared to affect 
the ability of antigen-specific CD4 and CD8 T cells to recognise cells expressing their 
cognate antigen.  To our knowledge, no immune evasion function of the MCV T-antigen has 
previously been identified. MCV sT appeared to reduce CD8 T cell recognition of a reporter 
antigen; an effect not seen with either the WTLT or the MCC derived truncated LT (MCC350 
and MKL-1) which surprisingly appear to increase recognition. The potential mechanism of 
action for this is not known but a number of other viral proteins have been shown to reduce 
CD8 T cell recognition through a variety of means. The EBV protein BNLF2a blocks both 
ATP and peptide binding to the TAP transporter protein, inhibiting the formation of MHC 
Class I complexes bound to peptide and limiting antigen display on the surface [410]. The 
KSHV proteins, K3 and K5, are E3 ubiquitin ligases that promote the endocytosis of Class I 
chains from the cell surface leading to their subsequent degradation within an intracellular 
endolysosomal compartment [431]. These mechanisms of action are usually associated with a 
reduction of surface Class I, which was not seen with the transfection of MCV sT suggesting 
that it may not operate in this fashion. Further work to confirm these early results and 
investigate possible mechanisms of action are required. Given the opposite effects on CD8 T 
cell recognition caused by expression of LT and sT when expressed individually, the effect of 
co-expressing both genes as occurs in infected or MCC tumour cells is not clear. Interestingly, 
exposure to UV light has been shown to increase mRNA expression of sT while not affecting 
LT levels [108]. As MCC is more commonly found in areas of sun exposed skin, it is possible 
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that this increased sT transcription may favour a reduction in CD8 T cell recognition and 
provide a mechanism of immune evasion for the developing tumour.  
In our preliminary experiments, WT LT and sT both appear to impair CD4 T cell recognition 
of a reporter antigen while truncated forms of LT do not.  The mechanism through which this 
may occur is unclear as with CD8 recognition. Again, other viral proteins have been shown to 
have effects on recognition by affecting the Class II pathway. Viral proteins from EBV 
(BZLF1) and KSHV (vIRF3) have been shown to reduce CD4 recognition by inhibiting 
transcription of CIITA resulting in reduced synthesis of Class II molecules [413, 432]. This is 
associated with reduction in surface Class II expression, which we did not see with MCV WT 
LT or sT. However, as the kinetics of this down-regulation can be very slow, as exemplified 
by vIRF3, it is possible that such changes were simply not identified by our assay. Another 
immune evasion protein from EBV, BZLF2, is able to sterically hinder the interaction 
between Class II and the TCR, consequently reducing CD4 T cell recognition [433]. This 
does not alter surface expression of MHC Class II and so provides a potential alternative 
mechanism through which MCV LT and sT may affect recognition of CD4 T cells. 
Although preliminary, our results suggest that both MCV LT and sT may exhibit some 
immune evasion function by reducing T cell recognition. MCV sT in particular appears to 
affect both CD4 and CD8 T cell recognition although how this occurs is not known. Further 
confirmatory work must follow as well as investigation to assess if this property of sT is 
specific to MCV or shared more generally by other polyomaviruses.
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Chapter 7  
Final Discussion 
It has long been known that the rare and aggressive cutaneous malignancy, Merkel cell cancer 
(MCC), is associated with risk factors such as ageing, UV light exposure and 
immunosuppression [7]. A more recent finding is that an important causal factor in the 
majority of cases of MCC is the integration of DNA from the Merkel cell polyomavirus 
(MCV) into the cellular genome [42]. This viral DNA encodes truncated Large T (LT) and 
Small T (sT) antigens, proteins that that are able to dysregulate cell cycle control through a 
number of mechanisms and lead to uncontrolled cellular proliferation and tumour formation. 
It has subsequently been hypothesised that the link between immunosuppression and this 
virally-associated cancer stems from a loss of anti-viral immunity against MCV.  However, 
unlike other polyomavirus-mediated diseases such as BKV-associated nephropathy (BKVAN) 
or JCV-associated progressive multifocal leukoencephalopathy (PML), in which affected 
patients are almost universally immunosuppressed, the majority of MCC patients have no 
history of clinical immunosuppression [39]. This meant that a detailed investigation into both 
the general immune function and specific anti-MCV viral immunity in MCC patients in 
comparison with other control groups was warranted in order to further our understanding of 
the link in this context. 
Multiple studies have shown that MCC patients have higher MCV VP-1 serum antibody 
levels in comparison to healthy controls and that this appears to correlate with higher levels of 
MCV DNA isolated from skin swabs [125, 137]. This suggests that there has been a loss of 
MCV-specific viral control in these patients and this may have contributed to the development 
of MCC, particularly as the increase in serum VP-1 antibodies can predate the onset of cancer 
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by a period of years [337]. However, studies assessing antibody levels of the other members 
of the polyomavirus family as well as directly comparing MCV VP-1 serum responses of 
MCC patients with other donor populations has not been previously conducted. We aimed to 
improve our knowledge in this area through collaboration with Dr Tim Waterboer 
(Heidelberg, Germany), who had developed a multiplexed-bead binding luminex assay 
capable of identifying and quantifying VP-1 seroresponses against ten of the twelve known 
human polyomaviruses [181]. Serum from a cohort of patients either with an active or past 
history of MCC attending clinic at Queen Elizabeth Hospital Birmingham was collected 
alongside serum from young and elderly healthy controls as well as other patient cohorts. This 
included non-melanoma skin cancer (NMSC) patients, chosen due to shared risk factors with 
MCC such as ageing and UV light exposure but no known link with viral infection, and a 
cohort of chronic lymphocytic leukaemia (CLL) patients who are known to be at increased 
risk of MCC development and are commonly immunosuppressed. Comparative analysis 
between these cohorts assessing for total numbers of polyomavirus-specific seroresponses 
showed that evidence of multiple infections was commonly seen in all groups and median 
numbers of responses did not differ suggesting that none of the studied groups are more at 
risk of acquiring polyomavirus infections than the others. It was clear, in agreement with the 
published literature, that MCV VP-1 seroresponses were more commonly seen in the MCC 
patients [75], however, this finding was not replicated for any of the other viruses tested and 
leads us to suggest that any loss of immune control in MCC patients may be specific for MCV 
rather than being a generalised polyomavirus-wide phenomenon. This is in agreement with 
previous studies that have assessed for responses against BKV, JC, KI and WU in MCC 
patients [74, 152].  
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Our work importantly extends this through the inclusion of responses for the skin-associated 
polyomaviruses such as HPyV6, HPyV7 and TSV. As responses against these viruses also 
appear unchanged in MCC patients compared with the control groups, this suggests that the 
underlying cause for a loss of MCV control is not mediated simply by dysfunctional 
cutaneous immunity occurring in MCC patients. We were also able to make an assessment of 
serum T-antigen antibody responses against the same panel of polyomaviruses utilising the 
same methodology. Here, we saw that MCV T-antigen seroresponses were seen specifically 
in MCC patients with active or recently treated disease, the majority of whom had no history 
of immunosuppression. This mirrors a previous report that described MCV T antigen 
responses are found extremely rarely in the serum of non-MCC patients, become elevated in 
active disease and then fall following treatment, thus having potential utility as a biomarker of 
tumour burden in MCC [354]. The assessment of the other polyomavirus T-antigen responses 
has been much more limited and from our data, detectable responses are generally rare. 
However, of MCC patients in whom MCV T-antigen seroresponses were detectable, a large 
proportion also had detectable responses for multiple other viral T-antigens, particularly the 
skin-associated HPyV6, HPy7 and TSV.  Unlike MCV T-antigen antibody responses, which 
can be driven by tumour-associated antigen load, other polyomavirus T-antigen responses 
may only be expected at times of active viral replication. An interpretation of these results 
could be that multiple skin-associated polyomaviruses may be actively replicating at the same 
time as a result of cutaneous immunosuppression. This is inconsistent with the VP-1 
seroresponse data discussed above and may mean that T-antigen antibody measurement is the 
more sensitive serological marker for detecting viral replication. An alternative possibility 
that cannot be excluded based on this data alone is that, given the high degree of homology 
seen between T-antigens of the polyomavirus family, these results are a product of cross-
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reactivity between the seroresponses for the different antigens. In order to clarify this, further 
work could include the recovery of DNA from skin swabs from MCC patients and use of real-
time quantitative PCR using multiple primers specific for distinct sequences from each 
individual polyomavirus in order to see whether there are sequences from just one or many 
viruses present. 
Although this serology data provides some evidence suggesting that the anti-viral control of 
MCV may be dysfunctional in MCC patients including those with no history of 
immunosuppression, it provides no underlying mechanism for why this may be the case. In 
order to further understand this we performed a detailed analysis assessing general immune 
markers of peripheral blood samples in non-immunosuppressed MCC patients and compared 
this with the same markers in a group of NMSC patients of a similar age profile. No such 
similar investigation has been completed previously although some indication as to the 
potential importance of cellular subsets in MCC have been intimated through the recent 
findings that non-immunosuppressed MCC patients with lower absolute lymphocyte counts 
and higher neutrophil:lymphocyte ratio at diagnosis have a poor prognosis [41, 390].  
In our dataset, MCC patients did have lower median lymphocyte counts (although not 
statistically significant) compared with NMSC patients, with the B cell subset being most 
significantly affected. Potentially related to this was the finding that numbers of T cell-
independent antibody responses against 12 vaccination polysaccharide antigens from different 
serotypes of pneumococcus were significantly reduced in MCC patients compared with 
NMSC patients while T cell-dependent antibody responses such as those against tetanus 
toxoid and diphtheria were retained. Although an interesting finding, the functional relevance 
of this in the context of MCV directed immunity is uncertain as MCC patients are known to 
have high levels of MCV-antibodies compared to healthy individuals and although not 
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demonstrated clearly with MCV itself, other polyomavirus-specific antibody responses appear 
to be T-cell dependent [121, 336, 434].  
In the elderly, anti-viral cellular immune responses may be affected by the accumulation of 
large populations of terminally differentiated effector memory CD45RA+ (TEMRA) CD8 T 
cells directed against a small number of epitopes taking up immunological space infection and 
preventing adequate cellular responses against other viral infections [246, 387]. This process 
is most commonly driven by co-infection by cytomegalovirus (CMV) infection and may be a 
potential mechanism contributing to the loss of control of MCV infection seen in MCC 
patients. Our data did not support this as evidence of CMV infection and the prevalence of 
expanded TEMRA populations are both split relatively equally between MCC and NMSC 
patients. A further cause for loss of viral control may relate to impaired functionality of 
responding lymphocytes and so this was assessed by measuring proliferative response of 
lymphocytes following mitogenic stimulation. This showed there was no difference in 
proliferative response between MCC patients currently in remission with NMSC patients. 
However, MCC patients with active disease did have a significantly lower functional response 
when compared with other MCC patients indicating the likely presence of cancer-induced 
immunosuppression that has been widely documented in the context of other cancers [435]. 
Overall, our assessment of peripheral immunity of MCC patients did not uncover any clearly 
definable differences that would account for a loss of MCV-directed immune response 
leading us to believe that this occurs as part of a multi-factorial process. Further work could 
include the assessment of other immune cell subsets such as myeloid derived suppressor cells 
(MDSCs) in MCC patients compared with other patient groups to assess their importance in 
immunosuppression in this context. 
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In general, cellular immunity is integral to the control of viral infections and in the context of 
MCC, increased infiltration by CD8 T cells into tumours is associated with a good prognosis 
and when examined these infiltrating T cells can be specific for MCV T-antigen epitopes that 
can be utilised therapeutically [311, 385, 424]. Taken together this suggests that MCV-
directed T cell immunity may be important not only for the control of MCV, but also have a 
role in determining clinical outcomes of MCC and thus we began to focus attention on the 
investigating the T cell response to MCV in greater detail. 
We aimed to assess whether there were differences in MCV-specific T cell immunity in MCC 
patients in comparison with a similarly aged cohort of NMSC patients through the 
quantification of circulating IFNɣ secreting T cells in response to stimulation with peptides 
spanning the length of the LT and sT proteins in ELISpot assays. These experiments showed 
that in general, the total numbers of responding T cells was low, a pattern that has been 
demonstrated previously in MCV as well as the other well-studied polyomaviruses, BKV and 
JCV [288, 294, 385].  In our study, the sizes of responses were not significantly different 
when MCC patients and NMSC patients were compared even after stratification on the basis 
of MCV seropositivity.  In a previous study using similar assays to quantify numbers of 
responding T cells against MCV VP-1, truncated LT and sT proteins, MCC patients were 
shown to have (non-significantly) higher numbers of MCV-specific T cells compared with 
healthy donors [385]. This would appear to broadly agree with our findings and certainly 
suggest that MCC patients do not have a peripheral deficiency of MCV-specific T cells when 
compared to control groups. Although not directly compared with the MCC and NMSC 
patients due to differences in assay design, the majority of younger healthy volunteer donors 
recruited as part of this study also showed low numbers of responding cells suggesting that 
even in healthy individuals, the number of circulating T cells required to control MCV 
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infection is low. What remains unknown and is an interesting avenue for further research lies 
in understanding whether the peripheral MCV-specific T cell response is representative of the 
MCV-specific response in the skin. It is possible that in MCC patients, although circulating 
MCV-specific T cells are present at normal frequency, these are not able to infiltrate the skin 
due to abnormal functional or homing phenotype. This may be possible by performing 
biopsies from normal skin of MCC patients, NMSC patients and healthy donors to see if there 
are differences in the frequency of  MCV-specific T cells. However, as biopsy samples are 
small, this type of characterisation will be extremely difficult unless we have a greater 
understanding of what viral epitopes the T cells are targeting. This led on to the next part of 
this investigation in which we focused on trying to address this question. 
Defining the epitopes of T cell response against MCV LT and sT will help in our 
understanding of how such an anti-viral response is directed as well as potentially providing 
therapeutic targets for intervention against MCC. Due to the low numbers of detectable 
circulating virus-specific T cells this was attempted through limiting dilution T cell cloning 
from healthy donors rather than with direct ex vivo assessment of peripheral blood. Using this 
method, we identified a number of T cell clones from donors of different HLA types that were 
specific for novel epitopes on the T-antigen. The majority of these were CD4 T cells 
recognising MHC Class II targets along the length of the LT protein. This is consistent with 
previous studies which have shown that most detectable MCV-specific responses in healthy 
donors are due to CD4 T cells [302, 304]. This is also a similar scenario to that seen in 
responses against both BKV and JCV and suggests that a diverse range of CD4 T cell 
responses is seen in polyomavirus infections [289-291]. Whether the diversity of CD4 T cell 
responses diminishes in MCC patients and this contributes to the loss of viral control is not 
known and would be an avenue for further work. 
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We were able to isolate one CD8 T cell response specific for a HLA-B7 restricted epitope 
contained within the portion of MCV LT usually lost by truncation mutation during 
tumourigenesis.   To our knowledge, this is the first described CD8 response to the MCV T-
antigen in an individual not suffering with MCC. Although, the response was readily 
detectable using tetramer analysis in one healthy donor, responses in a panel of further HLA-
B7 donors were not easily seen ex vivo. This corresponds with existing data in which the 
majority of CD8 T cell responses against MCV T-antigen have been identified only after 
extended culture in the presence of the relevant peptide rather than directly ex vivo [306]. It 
would be interesting to perform such extended culture using peripheral blood lymphocytes 
from the panel of HLA-B7 healthy donors used in this study in order to better confirm the 
wider frequency of this response. In the donor with a detectable ex-vivo response, the MCV-
specific CD8 T cells did not appear to express markers typical of a skin-homing phenotype, 
particularly with regard to a lack of CLA expression. This is in contrast to what is seen with T 
cells specific for the skin-associated virus, HSV as well as a previous study looking at CD8 T 
cells from MCC patients specific for a single MCV LT epitope [321, 403]. Ex vivo CD8 T 
cells were available from a single HLA-B7 MCC and were stained with our tetramer and 
although response was very small, making interpretation difficult, those cells that did bind 
tetramer appeared to show increased expression of skin-homing markers such as CLA. The 
reason that the MCV-specific T cells isolated from our healthy donor do not have a classical 
skin-homing phenotype is unclear. It may be that in health, such cells are usually retained 
within the skin and those that are recirculating within the peripheral blood do not share this 
phenotype.  In our healthy donor, it would be very interesting to perform comparative studies 
of the phenotype of the circulating MCV-specific T cell with those that are found in the skin. 
Such experiments have been conducted to investigate responses to the VZV virus through 
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skin biopsy after delivery of the VZV vaccination in order to concentrate specific cells to the 
area to be examined [269]. In the case of MCV, the lack of an available vaccination in order 
to stimulate congregation of virus specific T cells to one area in the skin will mean it is 
unlikely a biopsy would contain significant numbers of MCV-specific T cells and so be 
difficult to interpret. It is also possible that, in this donor, the site of MCV infection is in a 
tissue other than the skin as although most commonly detected from cutaneous swabs, MCV 
DNA has also been found at low frequency in a number of other tissues [127, 129]. 
Although, epitope-specific CD8 T cells were only readily detectable in a single donor using 
tetramer analysis, we did find evidence in another healthy donor of the presence of CD8 T cell 
clones that despite not binding tetramer with a high avidity were able to recognise the same 
MCV LT peptide as well as cells transfected with the MCV LT. These CD8 T cells appeared 
to be equally sensitive to peptides corresponding the homologs of this epitope seen in other 
polyomaviruses, KI, HPyV6, HPyV7, TSV and HPyV9 as shown by similar functional 
avidities. This leads to the suggestion that there may be some cross-reactivity between 
polyomavirus-specific CD8 T cells where there is a degree of homology of the epitope. In 
order to confirm this, it would be necessary to assess if the CD8 T cell clones recognise cells 
expressing the other candidate polyomavirus LT protein as well as MCV.  Cross-reactivity of 
CD8 T cells in the context of BK and JC polyomavirus infection have been the subject of 
previous studies and a number of cells that can recognise homologous epitopes between these 
two viruses have been identified, although to our knowledge such studies with any of the 
other members of the human polyomavirus family have not taken place [299, 301]. Given the 
high degree of homology seen between  VP-1, LT and sT of the different polyomaviruses, it is 
possible that so–called “heterologous immunity”, in which memory T cells raised following 
infection with a certain pathogen can be re-activated following infection with a separate 
  Chapter 7: Final Discussion 
219 
 
pathogen sharing a homologous epitope, may be an important protective mechanism of the 
anti-polyomavirus immune response [436].  It is also possible that cross-reactivity could be 
detrimental to a viral response if such cross-reactive T cells have a lower avidity for the newly 
infecting pathogen than would ordinarily have been produced in the absence of pre-existing 
cells. This concept, known as “original antigenic sin” is thought to be important in delaying 
effective CD8 responses to Dengue virus, in which during acute haemorrhagic infection, the 
majority of virus-specific CD8 T cells show higher affinity for other, probably previously 
encountered, viral serotypes [437].  Investigating the order in which polyomavirus infections 
are acquired in MCC patients compared with other elderly donors may be useful to help 
understand whether such a process is important to the development of MCC, however, as 
MCC is so rare and polyomavirus infections tend to be asymptomatic, conducting such a 
project would be extremely difficult. 
The MCV peptides capable of inducing IFNɣ T cell responses identified through T cell 
cloning were all capable of being processed and presented as Class I and Class II epitopes by 
model antigen presenting cells. This is particularly important as although all these newly 
discovered epitopes are likely to be expressed by virally-infected cells, the majority of the 
CD4 T cell epitopes reside in the portion of the T-antigen that becomes integrated within the 
MCC tumour genome and so would also be expressed by MCV+ MCC tumour cells. 
Although our data suggests that MCC tumour cells do not themselves express MHC Class II, 
there is potential for tumour cell debris to be taken up by professional antigen presenting 
cells. This would lead to the presentation of tumour-associated epitopes displayed and 
consequently cause activation of CD4 T cells that could stimulate other effector immune cells 
including CD8 T cells leading to further tumour cell killing. This “indirect” mechanism of 
anti-tumour immune response has been described previously in models of cancer that do not 
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express MHC Class II [438-440]. As little is known regarding the anti-tumour effect of CD4 
T cells in MCC, this may be an interesting avenue to explore in future work, particularly 
focusing on whether such responses can be therapeutically manipulated to improve clinical 
outcomes. 
Our finding and that of other groups, of multiple T cell epitopes on the MCV T-antigen means 
that there is potential for T cell recognition and killing of both virally-infected cells and 
tumour cells. To protect from such attacks, both virus-infected cells and tumour cells can 
evolve mechanisms of immune evasion and in cases of virally-associated cancers, such 
mechanisms can be shared. In the case of MCV, the best candidate viral proteins to have an 
immune evasion function would be LT and sT proteins as these are at least partially expressed 
by MCV+ MCC tumour cells. No such function affecting cellular immunity has been 
previously described although both LT and sT can negatively impact on the innate immune 
response through TLR9 down-regulation and inhibition of NF-κB pathway activation [275, 
279]. We saw, as has been previously described [320], that in MCC primary tumour cells and 
MCV+ MCC cell lines, MHC Class I was low and that this was reversible with either 
exposure to IFNɣ or irradiation. In our in vitro assays, up-regulation of Class I did not result 
in a significant alteration in the ability of T cells to recognise tumour cells and so it is difficult 
to know how much effect such a treatment may have.  It is possible that an effect may be 
more readily detectable in vivo as in a single patient with metastatic MCC treated with a 
combination of IFN, radiation and infusions of an expanded population of CD8 T cells 
specific for a MCV LT epitope, there was a clinical response to treatment with an increase in 
both tumour-infiltrating lymphocytes and MHC Class I expression [424]. Although, MHC 
Class I is down-regulated in MCV+ MCC, the mechanism behind this remains unknown with 
our studies showing no obvious reduction in surface expression levels seen in cells transiently 
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transfected with either MCV LT or sT.  In a previously published paper in which MHC Class 
I down-regulation was found to be commonly prevalent in MCV+ MCC, there were changes 
in expression of multiple proteins within the MHC Class I pathway leading the authors to 
suggest that a multi-factorial process was occurring [320]. How expression levels of these 
proteins, such as TAP-1 and -2, change following transfection of MCV T-antigen proteins 
would be useful to assess what role, if any, is played by LT and/or sT in this process. 
Additionally, in a provisional set of experiments assessing the recognition of T cells specific 
for a reporter antigen in cells co-expressing MCV LT or sT, sT appeared to reduce the ability 
of CD8 T cells to recognise the antigen presenting cell. This finding requires further 
confirmatory experiments that should then lead onto investigations into the potential 
mechanisms underpinning these changes in T cell recognition. 
Our data suggests that MHC Class II is not expressed by MCC primary tumour cells or MCC 
tumour cell lines and expression of Class II cannot be induced with exposure to IFNɣ or 
irradiation. As previously mentioned, this means that direct cytotoxicity against tumour cells 
by CD4 T cells is unlikely. However, as recent evidence suggests that dermal fibroblasts may 
be the preferential host cell for MCV infection within the skin, manipulation of the MHC 
Class II pathway by MCV may be important to evade immune detection [126]. As was seen 
with Class I, the transfection of MCV LT or sT into model antigen presenting cells did not 
appear to affect Class II expression levels. However, in provisional experiments, cells 
transfected with a reporter antigen alongside either MCV LT or sT were poorly recognised by 
CD4 T cells when compared with cells not expressing either T-antigen. These results also 
require further confirmation but may uncover a potential viral immune evasion for the T-
antigens. Whether this attribute is specific to MCV or shared with the homologous T-antigen 
proteins from other members of the human polyomavirus family is not known and would be a 
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good direction of further study. If fibroblasts are potentially the primary host cell for MCV 
infection, the impact of expression of MCV T-antigens on Class I and Class II regulation 
would be very interesting. In particular, being a cell type in which Class II expression is not 
constitutive but can be up-regulated in response to stimuli such as IFNɣ, one would want to 
assess whether LT or sT proteins are capable of preventing up-regulation of Class II upon 
stimulation with IFNɣ to give an indication of how such a potential immune evasion function 
may help protect the virus during infection.  
In a period where cancer immunotherapy is undergoing huge expansion, understanding how 
this may be best delivered in the context of MCV+ MCC is important. Although, clinical 
studies with immunotherapeutic agents such as anti-PD-1 antibodies have begun with 
encouraging early results, it is clear that some patients will not respond for unknown reasons 
[327]. The role of T cell control, particularly by CD4 T cells, in MCC has not been well 
studied and the discovery of a number of CD4 T cell clones specific for novel MCV T-antigen 
epitopes provides tools with which this can be further probed.  The finding that both MCV LT 
and sT may have T cell immune evasion properties needs confirmation but may occur through 
a mechanism which if reversible may improve responses to immunotherapy. The 
characterisation of peripheral immunity in MCC patients suggests there are a number of subtle 
but significant differences seen when compared with an age-similar cohort of NMSC patients. 
Whether such differences could be used as biomarkers to predict the likelihood of response or 
resistance to immunotherapy is a further avenue of investigation aimed at improving the 
future effective management of MCC patients.   
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